424B5
Filed
Pursuant to Rule 424(b)(5)
Registration Statement
No. 333-147180
Prospectus Supplement
(To Prospectus Dated November 6, 2007)
$1,034,999,000
MetLife, Inc.
7.717% Senior Debt
Securities, Series B, Due 2019
This prospectus supplement relates to the remarketing of
$1,034,999,000 aggregate principal amount of 7.717% Senior
Debt Securities, Series B, due 2019 (the
Debentures). This prospectus supplement also
relates to the remarketing of Senior Debt Securities,
Series B, due 2014, none of which were sold. MetLife, Inc.
issued the Debentures originally as 4.91% Junior Subordinated
Debt Securities, Series B, due 2040, to MetLife Capital
Trust III, a Delaware statutory trust (the
Trust), in connection with the offering of
our 6.375% Common Equity Units (the Units) in
June 2005. Each Unit initially consisted of a contract to
purchase shares of MetLife, Inc.s common stock in
accordance with the terms of the Unit, as well as a
1/80th or 1.25% undivided beneficial ownership interest in
a Series A trust preferred security of MetLife Capital
Trust II (the Series A Trust Preferred
Securities) and a 1/80th or 1.25% undivided
beneficial ownership interest in a Series B trust preferred
security of the Trust (the Series B
Trust Preferred Securities). In August 2008,
MetLife Capital Trust II was dissolved and the underlying
debt securities distributed to holders of Series A
Trust Preferred Securities were remarketed. MetLife, Inc.
dissolved the Trust on February 5, 2009 and distributed
4.91% Junior Subordinated Debt Securities, Series B, due
2040 to the holders of the Series B Trust Preferred
Securities. MetLife, Inc. solicited and obtained the consent of
a sufficient number of holders of Units in their capacity as
beneficial owners of the Series B Trust Preferred
Securities of the Trust to effect amendments to the Indenture
(as defined below) to allow for a remarketing of the Debentures
in two or more tranches. On February 6, 2009, MetLife, Inc.
and The Bank of New York Mellon Trust Company, N.A. entered
into the Seventh Supplemental Indenture (as defined below)
implementing those and certain additional amendments to the
Indenture. The Debentures are unsecured obligations of MetLife,
Inc. and rank equally in right of payment with all of our
existing and future senior unsecured and unsubordinated
indebtedness. We do not have the right to defer payment of
interest on the Debentures. The Debentures will be issued only
in registered form in denominations of $1,000 and integral
multiples thereof.
Interest on the Debentures will accrue at 7.717% per annum from
February 15, 2009. We will pay interest on the Debentures
in cash semi-annually on February 15 and August 15 of each year.
The first such interest payment on the Debentures will be made
on August 15, 2009.
The stated maturity of the Debentures will be February 15,
2019. The Debentures will be redeemable at MetLife, Inc.s
option in whole or in part, at any time, on or after
February 15, 2011, at a redemption price equal to the
greater of 100% of the principal amount to be redeemed plus
accrued and unpaid interest to the date of redemption and the
Make-Whole Redemption Amount calculated as
described in this prospectus supplement.
The Debentures are being remarketed through Citigroup Global
Markets Inc., Morgan Stanley & Co. Incorporated, Barclays
Capital Inc., and the other remarketing agents named herein
(each, a Remarketing Agent and together, the
Remarketing Agents) pursuant to a remarketing
agreement dated January 12, 2009 (the Remarketing
Agreement) among the Remarketing Agents, MetLife, Inc.
and The Bank of New York Mellon Trust Company, N.A., not
individually, but solely as Purchase Contract Agent (as defined
in the Remarketing Agreement) and as attorney-in-fact of the
holders of Purchase Contracts (as defined in the Remarketing
Agreement). We will not receive any of the proceeds from the
remarketing, except as described under Use of
Proceeds and Relationship of the Common Equity Units
to the Remarketing in this prospectus supplement.
The Debentures are not, and are not expected to be, listed on
any national securities exchange nor included in any automated
quotation system. The Remarketing Agents expect to deliver the
Debentures, in book-entry form only, through the facilities of
the Depository Trust Company (DTC) for
the accounts of its participants, including Clearstream Banking,
société anonyme, Luxembourg (Clearstream
Luxembourg)
and/or
Euroclear Bank N.V./S.A. (Euroclear), on or
about February 17, 2009.
See Risk Factors beginning on
page S-12
and continued on
page S-18
of this prospectus supplement to read about important factors
you should consider before buying the Debentures.
Neither the Securities and Exchange Commission nor any other
regulatory body has approved or disapproved of these securities
or passed upon the adequacy of this prospectus supplement or the
accompanying prospectus. Any representation to the contrary is a
criminal offense.
The Debentures are not bank deposits and are not insured by
the Federal Deposit Insurance Corporation or any other
governmental agency, nor are they obligations of, or guaranteed
by, a bank. In addition, the Debentures will not be guaranteed
under the Federal Deposit Insurance Corporations Temporary
Liquidity Guarantee Program.
|
|
|
|
|
|
|
|
|
|
|
Per Debenture
|
|
|
Total
|
|
|
Price to the Public (1)
|
|
|
100.35%
|
|
|
$
|
1,038,621,497
|
|
Remarketing Fee to Remarketing Agents
|
|
|
0.35%
|
|
|
$
|
3,622,497
|
|
Net Proceeds (2)
|
|
|
100.00%
|
|
|
$
|
1,034,999,000
|
|
|
|
|
(1)
|
|
Plus accrued interest from and
including February 15, 2009, but excluding the date of
settlement, which is expected to be February 17, 2009.
|
(2)
|
|
We will not receive any proceeds
from the remarketing. See Use of Proceeds and
Relationship of the Common Equity Units to the
Remarketing.
|
Joint Bookrunners
Barclays Capital
|
|
|
|
|
ANZ
Securities |
BNP
PARIBAS |
CALYON |
Daiwa
Securities America Inc. |
HSBC |
|
|
|
|
RBS
Greenwich Capital |
ING
Wholesale |
Raymond
James |
Standard
Chartered |
|
|
|
|
|
Blaylock
& Company, Inc. |
Cabrera
Capital Markets, LLC |
Guzman
& Company |
Ramirez
& Co., Inc. |
The
Williams Capital Group, L.P. |
The date of this prospectus
supplement is February 11, 2009
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
|
Prospectus Supplement
|
|
|
|
S-3
|
|
|
|
|
S-3
|
|
|
|
|
S-5
|
|
|
|
|
S-6
|
|
|
|
|
S-7
|
|
|
|
|
S-18
|
|
|
|
|
S-20
|
|
|
|
|
S-25
|
|
|
|
|
S-26
|
|
|
|
|
S-27
|
|
|
|
|
S-28
|
|
|
|
|
S-29
|
|
|
|
|
S-36
|
|
|
|
|
S-39
|
|
|
|
|
S-39
|
|
|
|
|
S-42
|
|
|
|
|
S-42
|
|
|
Prospectus
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
5
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
15
|
|
|
|
|
21
|
|
|
|
|
23
|
|
|
|
|
24
|
|
|
|
|
25
|
|
|
|
|
26
|
|
|
|
|
28
|
|
|
|
|
31
|
|
|
|
|
32
|
|
|
|
|
32
|
|
You should rely only on the information contained or
incorporated by reference in this prospectus supplement and the
accompanying prospectus. Neither we nor the Remarketing Agents
have authorized anyone to provide you with additional or
different information. If anyone provided you with additional or
different information, you should not rely on it. Neither we nor
the Remarketing Agents are making an offer to sell these
securities in any jurisdiction where the offer or sale is not
permitted. You should assume that the information contained in
this prospectus supplement, the accompanying prospectus and the
documents incorporated by reference, is accurate only as of
their respective dates. Our business, financial condition,
results of operations and prospects may have changed since those
dates.
S-2
The Debentures are offered for sale in those jurisdictions in
the United States, Europe, Asia and elsewhere where it is lawful
to make such offers. The distribution of this prospectus
supplement and the accompanying prospectus and the offering or
sale of the Debentures in some jurisdictions may be restricted
by law. Persons into whose possession this prospectus supplement
and the accompanying prospectus come are required by us and the
Remarketing Agents to inform themselves about and to observe any
applicable restrictions. This prospectus supplement and the
accompanying prospectus may not be used for or in connection
with an offer or solicitation by any person in any jurisdiction
in which that offer or solicitation is not authorized or to any
person to whom it is unlawful to make that offer or
solicitation. See Offering Restrictions in this
prospectus supplement.
ABOUT
THIS PROSPECTUS SUPPLEMENT
You should read this prospectus supplement along with the
accompanying prospectus carefully before investing in the
Debentures. This prospectus supplement contains the terms of
this remarketing of Debentures. This prospectus supplement may
add, update or change information in the accompanying
prospectus. In addition, the information incorporated by
reference in the accompanying prospectus may have added, updated
or changed information in the accompanying prospectus. If
information in this prospectus supplement is inconsistent with
any information in the accompanying prospectus (or any
information incorporated therein by reference), this prospectus
supplement will apply and will supersede such information.
It is important for you to read and consider all information
contained in this prospectus supplement and the accompanying
prospectus in making your investment decision. You should also
read and consider the additional information under the caption
Where You Can Find More Information in the
accompanying prospectus.
Unless otherwise stated or the context otherwise requires,
references in this prospectus supplement and the accompanying
prospectus to MetLife, we,
our, or us refer to
MetLife, Inc., together with its direct and indirect
subsidiaries, while references to MetLife,
Inc. refer only to the holding company on an
unconsolidated basis.
WHERE YOU
CAN FIND MORE INFORMATION
MetLife, Inc. files reports, proxy statements and other
information with the Securities and Exchange Commission
(SEC). These reports, proxy statements and
other information can be read and copied at the SECs
public reference room at 100 F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330
for further information on the operation of the public reference
room. The SEC maintains an internet site at www.sec.gov that
contains reports, proxy and information statements and other
information regarding companies that file electronically with
the SEC, including MetLife, Inc. MetLife, Inc.s common
stock is listed and trading on the New York Stock Exchange under
the symbol MET. These reports, proxy statements and
other information can also be read at the offices of the New
York Stock Exchange, 11 Wall Street, New York, New York 10005.
The SEC allows incorporation by reference into this
prospectus supplement and the accompanying prospectus of
information that MetLife, Inc. files with the SEC. This permits
MetLife, Inc. to disclose important information to you by
referencing these filed documents. Any information referenced
this way is considered part of this prospectus supplement and
accompanying prospectus, and any information filed with the SEC
subsequent to the date of this prospectus will automatically be
deemed to update and supersede this information. Information
furnished under Item 2.02 and Item 7.01 of MetLife,
Inc.s Current Reports on
Form 8-K
is not incorporated by reference in this prospectus supplement
and accompanying prospectus. MetLife, Inc. incorporates by
reference the following documents which have been filed with the
SEC:
|
|
|
|
|
Annual Report on
Form 10-K
for the year ended December 31, 2007 (the 2007
MetLife
Form 10-K);
|
|
|
|
Quarterly Reports on
Form 10-Q
for the quarters ended March 31, 2008, June 30, 2008
and September 30, 2008; and
|
|
|
|
Current Reports on
Form 8-K
filed January 16, 2008, February 19, 2008,
March 5, 2008, April 8, 2008, April 22, 2008,
April 28, 2008, May 15, 2008, June 2, 2008,
July 15, 2008, July 25, 2008, August 11, 2008,
August 15, 2008, September 12, 2008,
September 17, 2008, October 2, 2008, October 7,
2008, October 8, 2008, October 9, 2008,
October 14, 2008, October 16, 2008, October 29,
2008 (only with respect to the
|
S-3
|
|
|
|
|
Item 8.01 information), November 14, 2008,
November 17, 2008, November 19, 2008,
December 18, 2008, December 31, 2008, January 14,
2009, January 30, 2009, February 9, 2009 (only with
respect to the Item 3.03 information) and February 10, 2009.
|
MetLife, Inc. incorporates by reference the documents listed
above and any future filings made with the SEC in accordance
with Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934, as amended (the Exchange
Act), until MetLife, Inc. files a post-effective
amendment which indicates the termination of the offering of the
securities made by this prospectus supplement and accompanying
prospectus. Any reports filed by us with the SEC after the date
of this prospectus supplement and before the date that the
offering of securities by means of this prospectus supplement
and accompanying prospectus is terminated will automatically
update and, where applicable, supersede any information
contained in this prospectus supplement and accompanying
prospectus or incorporated by reference in this prospectus
supplement and accompanying prospectus.
MetLife, Inc. will provide without charge upon written or oral
request, a copy of any or all of the documents that are
incorporated by reference into this prospectus supplement and
accompanying prospectus, other than exhibits to those documents,
unless those exhibits are specifically incorporated by reference
into those documents. Requests should be directed to Investor
Relations, 1095 Avenue of the Americas, New York, New York
10036, by electronic mail (metir@metlife.com), or by telephone
(212-578-2211).
You may also obtain some of the documents incorporated by
reference into this document at MetLifes website,
www.metlife.com. All other information contained on
MetLifes website is not a part of this document.
S-4
FORWARD-LOOKING
STATEMENTS
This prospectus supplement may contain or incorporate by
reference information that includes or is based upon
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements give expectations or forecasts of future events.
These statements can be identified by the fact that they do not
relate strictly to historical or current facts. They use words
such as anticipate, estimate,
expect, project, intend,
plan, believe and other words and terms
of similar meaning in connection with a discussion of future
operating or financial performance. In particular, these include
statements relating to future actions, prospective services or
products, future performance or results of current and
anticipated services or products, sales efforts, expenses, the
outcome of contingencies such as legal proceedings, trends in
operations and financial results.
Any or all forward-looking statements may turn out to be wrong.
They can be affected by inaccurate assumptions or by known or
unknown risks and uncertainties. Many such factors will be
important in determining MetLifes actual future results.
These statements are based on current expectations and the
current economic environment. They involve a number of risks and
uncertainties that are difficult to predict. These statements
are not guarantees of future performance. Actual results could
differ materially from those expressed or implied in the
forward-looking statements. Risks, uncertainties, and other
factors that might cause such differences include the risks,
uncertainties and other factors identified in MetLife,
Inc.s filings with the SEC. These factors include:
(i) difficult and adverse conditions in the global and
domestic capital and credit markets; (ii) continued
volatility and further deterioration of the capital and credit
markets; (iii) uncertainty about the effectiveness of the
U.S. governments plan to stabilize the financial
system by injecting capital into financial institutions,
purchasing large amounts of illiquid, mortgage-backed and other
securities from financial institutions, or otherwise;
(iv) the impairment of other financial institutions;
(v) potential liquidity and other risks resulting from
MetLifes participation in a securities lending program and
other transactions; (vi) exposure to financial and capital
market risk; (vii) changes in general economic conditions,
including the performance of financial markets and interest
rates, which may affect MetLifes ability to raise capital
and generate fee income and market-related revenue;
(viii) defaults on MetLifes mortgage and consumer
loans; (ix) investment losses and defaults, and changes to
investment valuations; (x) market value impairments to
illiquid assets; (xi) unanticipated changes in industry
trends; (xii) heightened competition, including with
respect to pricing, entry of new competitors, the development of
new products by new and existing competitors and for personnel;
(xiii) discrepancies between actual claims experience and
assumptions used in setting prices for MetLifes products
and establishing the liabilities for MetLifes obligations
for future policy benefits and claims; (xiv) discrepancies
between actual experience and assumptions used in establishing
liabilities related to other contingencies or obligations;
(xv) ineffectiveness of risk management policies and
procedures; (xvi) catastrophe losses; (xvii) changes
in assumptions related to deferred policy acquisition costs,
value of business acquired or goodwill; (xviii) downgrades
in MetLifes and its affiliates claims paying
ability, financial strength or credit ratings;
(xix) economic, political, currency and other risks
relating to MetLifes international operations;
(xx) regulatory, legislative or tax changes that may affect
the cost of, or demand for, MetLifes products or services;
(xxi) changes in accounting standards, practices
and/or
policies; (xxii) adverse results or other consequences from
litigation, arbitration or regulatory investigations;
(xxiii) deterioration in the experience of the closed
block established in connection with the reorganization of
Metropolitan Life Insurance Company; (xxiv) the effects of
business disruption or economic contraction due to terrorism or
other hostilities; (xxv) MetLifes ability to identify
and consummate on successful terms any future acquisitions, and
to successfully integrate acquired businesses with minimal
disruption; (xxvi) MetLife, Inc.s primary reliance,
as a holding company, on dividends from its subsidiaries to meet
debt payment obligations and the applicable regulatory
restrictions on the ability of the subsidiaries to pay such
dividends; and (xxvii) other risks and uncertainties
described from time to time in MetLife, Inc.s filings with
the SEC.
MetLife, Inc. does not undertake any obligation to publicly
correct or update any forward-looking statement if MetLife, Inc.
later becomes aware that such statement is not likely to be
achieved. Please consult any further disclosures MetLife, Inc.
makes on related subjects in reports to the SEC.
S-5
NOTE REGARDING
RELIANCE ON STATEMENTS IN OUR CONTRACTS
In reviewing the agreements included as exhibits to any of the
documents incorporated by reference into this prospectus
supplement, please remember that they are incorporated to
provide you with information regarding their terms and are not
intended to provide any other factual or disclosure information
about MetLife, Inc., its subsidiaries or the other parties to
the agreements. The agreements contain representations and
warranties by each of the parties to the applicable agreement.
These representations and warranties have been made solely for
the benefit of the other parties to the applicable agreement and:
|
|
|
|
|
should not in all instances be treated as categorical statements
of fact, but rather as a way of allocating the risk to one of
the parties to the agreement if those statements prove to be
inaccurate;
|
|
|
|
have been qualified by disclosures that were made to the other
party in connection with the negotiation of the applicable
agreement, which disclosures are not necessarily reflected in
the agreement;
|
|
|
|
may apply standards of materiality in a way that is different
from what may be viewed as material to investors; and
|
|
|
|
were made only as of the date of the applicable agreement or
such other date or dates as may be specified in the agreement
and are subject to more recent developments.
|
Accordingly, these representations and warranties may not
describe the actual state of affairs as of the date they were
made or at any other time.
S-6
SUMMARY
This summary contains basic information about us and this
remarketing. Because it is a summary, it does not contain all of
the information that you should consider before purchasing any
securities in the remarketing. You should read this entire
prospectus supplement and the accompanying prospectus carefully,
including the section entitled Risk Factors, our
financial statements and the notes thereto incorporated by
reference into the prospectus supplement and the accompanying
prospectus, before making an investment decision.
MetLife
MetLife, Inc. is a leading provider of individual insurance,
employee benefits and financial services with operations
throughout the United States and the Latin America, Europe and
Asia Pacific regions. Through its subsidiaries and affiliates,
MetLife, Inc. reaches more than 70 million customers around
the world and MetLife is the largest life insurer in the United
States (based on life insurance in-force). The MetLife companies
offer life insurance, annuities, auto and home insurance, retail
banking and other financial services to individuals, as well as
group insurance and retirement & savings products and
services to corporations and other institutions. MetLife is one
of the largest insurance and financial services companies in the
United States. MetLife believes that its franchises and brand
names uniquely position it to be the preeminent provider of
protection and savings and investment products in the United
States. In addition, its international operations are focused on
markets where the demand for insurance and savings and
investment products is expected to grow rapidly in the future.
MetLife divides its business into four operating segments:
|
|
|
|
|
Institutional. The Institutional segment
offers a broad range of group insurance and
retirement & savings products and services to
corporations and other institutions and their respective
employees.
|
Group insurance products and services include group life
insurance, non-medical health insurance products and related
administrative services, as well as other benefits and services,
such as employer-sponsored auto and homeowners insurance
provided through the Auto & Home segment and prepaid
legal services plans. MetLife offers group insurance products as
employer-paid benefits or as voluntary benefits where all or a
portion of the premiums are paid by the employee. MetLife has
built a leading position in the U.S. group insurance market
through long-standing relationships with many of the largest
corporate employers in the United States. MetLife distributes
its group insurance products and services through a sales force
that is segmented by the size of the target customer. Voluntary
products are sold through the same sales channels, as well as by
specialists for these products.
Institutionals retirement & savings products and
services include an array of annuity and investment products,
including guaranteed interest products and other stable value
products, accumulation and income annuities, and separate
account contracts for the investment management of defined
benefit and defined contribution plan assets. MetLife
distributes retirement & savings products and services
through dedicated sales teams and relationship managers. In
addition, the retirement & savings organization works
with the distribution channels in the Individual segment and in
the group insurance area, to better reach and service customers,
brokers, consultants and other intermediaries.
|
|
|
|
|
Individual. The Individual segment offers a
wide variety of protection and asset accumulation products aimed
at serving the financial needs of our customers throughout their
entire life cycle. Individual segment products include insurance
products, such as traditional, variable and universal life
insurance and variable and fixed annuities. In addition,
Individual sales representatives distribute disability insurance
and long-term care insurance products offered through the
Institutional segment, investment products such as mutual funds,
as well as other products offered by MetLifes other
businesses.
|
Individual products are distributed nationwide through multiple
channels, with the primary distribution systems being the
individual distribution group and the third party distribution
group.
|
|
|
|
|
International. The International segment
provides life insurance, accident and health insurance, credit
insurance, annuities and retirement & savings products
to both individuals and groups. MetLife focuses on emerging
markets primarily within the Latin America, Europe and Asia
Pacific regions. MetLife operates in
|
S-7
|
|
|
|
|
Latin America in Mexico, Chile, Argentina, Brazil and Uruguay.
In Europe, MetLife operates in the United Kingdom, Belgium,
Poland and Ireland. The results of our operations in India are
also included in this region. In the Asia Pacific region,
MetLife operates in South Korea, Taiwan, Australia, Japan, Hong
Kong and China.
|
|
|
|
|
|
Auto & Home. The Auto &
Home segment offers personal lines property and casualty
insurance directly to employees at their employers
worksite, as well as to individuals through a variety of retail
distribution channels, including independent agents, property
and casualty specialists, direct response marketing and the
agency distribution group.
|
Corporate & Other contains the excess capital not
allocated to the business segments, various
start-up
entities, including MetLife Bank, N.A., a national bank, and
run-off entities, as well as interest expense related to the
majority of MetLifes outstanding debt and expenses
associated with certain legal proceedings and income tax audit
issues. Corporate & Other also includes the
elimination of all intersegment amounts.
On September 12, 2008, MetLife completed a tax-free
split-off of its majority-owned subsidiary, Reinsurance Group of
America, Incorporated (RGA). The disposition
of RGA resulted in the elimination of MetLifes Reinsurance
segment.
On October 15, 2008, MetLife, Inc. issued
86,250,000 shares of its common stock at a price of
$26.50 per share for gross proceeds of $2.3 billion.
Of the shares issued, 75,000,000 shares were issued from
treasury stock.
For the year ended December 31, 2007, MetLife had total
revenue of $47.3 billion and net income of
$4.3 billion. At December 31, 2007, MetLife had cash
and invested assets of $328.6 billion, total assets of
$559.1 billion and stockholders equity of
$35.2 billion.
MetLife, Inc. is incorporated under the laws of the State of
Delaware. MetLife, Inc.s principal executive offices are
located at 200 Park Avenue, New York, New York
10166-0188
and its telephone number is
(212) 578-2211.
S-8
The
Remarketing
|
|
|
Issuer |
|
MetLife, Inc. |
|
Securities Remarketed |
|
$1,034,999,000 aggregate principal amount of 7.717% Senior
Debt Securities, Series B, due 2019 (the
Debentures). This prospectus supplement
also relates to the remarketing of Senior Debt Securities,
Series B, due 2014, none of which were sold. |
|
Aggregate Principal Amount |
|
$1,035,000,000 |
|
Maturity Date |
|
February 15, 2019. |
|
Interest Rate |
|
Interest on the Debentures will accrue at 7.717% per annum from
February 15, 2009. The Debentures will pay interest in cash. |
|
Interest Payment Dates |
|
February 15 and August 15 of each year. August 15, 2009
will be the first interest payment date on which interest is
paid at the above referenced Interest Rate. |
|
The Remarketing |
|
We issued the Debentures originally as 4.91% Junior Subordinated
Debt Securities, Series B, due 2040 to MetLife Capital
Trust III (the Trust) in connection with
the offering of our 6.375% Common Equity Units (the
Units) in June 2005. Each Unit initially
consisted of a contract to purchase shares (the
Purchase Contract) of MetLife, Inc.s
common stock (the Common Stock) in accordance
with the terms of the Unit, as well as a 1/80th or 1.25%
undivided beneficial interest in a Series A trust preferred
security of the Trust (the Series A
Trust Preferred Securities) and a 1/80th or 1.25%
undivided beneficial ownership interest in a 4.91% Series B
trust preferred security of MetLife Capital Trust III (the
Series B Trust Preferred
Securities, and together with the Series A
Trust Preferred Securities, the
Trust Preferred Securities). To secure
their obligations under the Purchase Contract, investors in the
Units pledged their Trust Preferred Securities to a
collateral agent. In August 2008, MetLife Capital Trust II
was dissolved and the underlying debt securities distributed to
holders of Series A Trust Preferred Securities were
remarketed. On February 5, 2009, in accordance with the
terms of the Declaration, we dissolved the Trust and distributed
4.91% Junior Subordinated Debt Securities, Series B, due
2040 to the holders of the Series B Trust Preferred
Securities. MetLife, Inc. solicited and obtained the consent of
a sufficient number of holders of Units in their capacity as
beneficial owners of the Series B Trust Preferred
Securities of the Trust to effect amendments to the Indenture to
allow for a remarketing of the Debentures in two or more
tranches. On February 6, 2009, MetLife, Inc. and The Bank
of New York Mellon Trust Company, N.A. entered into the
Seventh Supplemental Indenture implementing those and certain
additional amendments to the Indenture. |
|
|
|
Under the terms of the Units, we were obligated to engage one or
more nationally recognized investment banks to remarket the
Debentures on behalf of holders (other than those holders who
have elected not to participate in the remarketing) pursuant to
the Remarketing Agreement. |
|
Remarketing Agents |
|
Appointed Remarketing Agents are: |
S-9
|
|
|
|
|
Citigroup Global Markets Inc., Morgan Stanley & Co.
Incorporated, Barclays Capital Inc., ANZ Securities, Inc., BNP
Paribas Securities Corp., Calyon Securities (USA) Inc., Daiwa
Securities America Inc., HSBC Securities (USA) Inc., Greenwich
Capital Markets, Inc., ING Financial Markets LLC, Raymond
James & Associates, Inc., Standard Chartered Bank,
Blaylock Robert Van, LLC, Cabrera Capital Markets, LLC,
Guzman & Company, Samuel A. Ramirez &
Company, Inc. and The Williams Capital Group, L.P. |
|
Redemption |
|
The Debentures will be redeemable at MetLife, Inc.s option
in whole or in part, at any time on or after February 15,
2011 at a redemption price equal to the greater of 100% of the
principal amount to be redeemed plus accrued and unpaid interest
to the date of redemption and the Make-Whole
Redemption Amount calculated as described under
Description of the Remarketed Debentures
Redemption. |
|
|
|
|
|
Anticipated Ratings
|
|
Standard & Poors Ratings Services, a division of
the McGraw-Hill Companies Inc.
(S&P):
|
|
A
|
|
|
Moodys Investors Service, Inc.
(Moodys):
|
|
A2
|
|
|
Fitch Ratings, Inc. (Fitch):
|
|
A
|
|
|
|
|
|
An explanation of the significance of ratings may be obtained
from the rating agencies. Generally, rating agencies base their
rating on such material and information, and such of their own
investigations, studies and assumptions, as they deem
appropriate. The rating of the Debentures should be evaluated
independently from similar ratings of other securities. A credit
rating of a security is not a recommendation to buy, sell or
hold securities and may be subject to review, revision,
suspension, reduction or withdrawal at any time by the assigning
rating agency. |
|
Ranking |
|
The Debentures are unsecured obligations of MetLife, Inc. and
rank equally in right of payment with all of our existing and
future senior unsecured and unsubordinated indebtedness. We do
not have the right to defer payment of interest on the
Debentures. |
|
Denomination |
|
$1,000 and integral multiples thereof. |
|
Use of Proceeds |
|
We will not receive any of the proceeds from the remarketing.
Proceeds from the remarketing attributable to the Debentures
that are part of normal Units (i.e., Units
consisting, prior to the settlement of the remarketing, of a
1/80th interest in the Debentures and a stock purchase
contract), that participated in the remarketing will be used as
follows: |
|
|
|
to pay the Remarketing Agents a remarketing fee not
exceeding 0.35% of the total principal attributable to the
Debentures that are part of normal Units that participated in
the remarketing;
|
|
|
|
to satisfy the obligation of holders of normal Units
to purchase newly-issued common stock of MetLife, Inc. under the
stock purchase contract on the date of settlement of the
remarketing; and
|
|
|
|
any remaining portion, if any, of the proceeds will
be remitted for the benefit of holders of normal Units
participating in the remarketing.
|
S-10
|
|
|
|
|
See Relationship of the Common Equity Units to the
Remarketing. |
|
Clearance and Settlement |
|
The Debentures will be cleared through DTC, Clearstream,
Luxembourg and the Euroclear System. |
|
Listing |
|
The Debentures are not, and are not expected to be, listed on
any national securities exchange nor included in any automated
quotation system. |
|
Governing Law |
|
New York. |
|
|
|
Recent Developments |
On February 3, 2009, MetLife announced its results for the
fourth quarter of 2008 and for the year ended December 31,
2008. Net income available to common shareholders for the
quarter ended December 31, 2008 is $1.0 billion, or
$1.20 per share, compared with $1.1 billion, or $1.44 per
share, for the fourth quarter of 2007. Net income available to
common shareholders for 2008 is $3.1 billion, or $4.14 per
share, compared with $4.2 billion, or $5.48 per share, for
2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months
|
|
|
For The Year
|
|
|
|
Ended December 31,
|
|
|
Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(In millions, except per common share data)
|
|
|
Net income available to common shareholders
|
|
$
|
954
|
|
|
$
|
1,083
|
|
|
$
|
3,084
|
|
|
$
|
4,180
|
|
Net income available to common shareholders per diluted common
share
|
|
$
|
1.20
|
|
|
$
|
1.44
|
|
|
$
|
4.14
|
|
|
$
|
5.48
|
|
Book value per diluted common share
|
|
$
|
27.33
|
|
|
$
|
43.94
|
|
|
|
|
|
|
|
|
|
Premiums, fees and other revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Institutional
|
|
$
|
4,157
|
|
|
$
|
3,517
|
|
|
$
|
16,625
|
|
|
$
|
13,920
|
|
Individual
|
|
|
2,147
|
|
|
|
2,261
|
|
|
|
8,452
|
|
|
|
8,522
|
|
International
|
|
|
1,006
|
|
|
|
1,106
|
|
|
|
4,583
|
|
|
|
4,115
|
|
Auto & Home
|
|
|
747
|
|
|
|
776
|
|
|
|
3,009
|
|
|
|
3,009
|
|
Corporate & Other
|
|
|
122
|
|
|
|
22
|
|
|
|
212
|
|
|
|
107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total premiums, fees and other revenues:
|
|
$
|
8,179
|
|
|
$
|
7,682
|
|
|
$
|
32,881
|
|
|
$
|
29,673
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2008, MetLife had net
investment gains of $1,812 million versus a loss of
$578 million for the year ended December 31, 2007. The
change to net investment gains was due to an increase in gains
on derivatives, partially offset by losses primarily on fixed
maturity and equity securities. Net investment income decreased
by $1.8 billion, or 10%, to $16.3 billion for the year
ended December 31, 2008 from $18.1 billion for the
comparable 2007 period. Gross unrealized losses on fixed
maturity and equity securities at December 31, 2008 were
$29.8 billion, compared with $4.7 billion at
December 31, 2007. The portion of the $29.8 billion of
gross unrealized losses for fixed maturity and equity securities
(i) where the estimated fair value has declined and
remained below amortized cost or cost by 20% or more was
$21.7 billion at December 31, 2008, and
(ii) where the estimated fair value has declined and
remained below amortized cost or cost by less than 20% was
$8.1 billion at December 31, 2008.
Securities with a cost or amortized cost of $20.8 billion
and $41.1 billion and an estimated fair value of
$22.9 billion and $42.1 billion were on loan under
MetLifes securities lending program at December 31,
2008 and 2007, respectively. MetLife was liable for cash
collateral under its control in connection with securities
lending activities of $23.3 billion and $43.3 billion
at December 31, 2008 and 2007, respectively. Of this
$23.3 billion of cash collateral at December 31, 2008,
$5.1 billion was on open terms, meaning that the related
loaned security could be returned to MetLife on the next
business day requiring return of cash collateral and the
following amounts are due within 30 days and
60 days - $14.7 billion and $3.5 billion,
respectively. The fair value of the securities on loan related
to such cash collateral which could be required to be returned
the next business day was $5.0 billion at December 31,
2008. The fair value of the reinvestment portfolio acquired with
the cash collateral was $19.5 billion at December 31,
2008.
S-11
Supplemental
Risk Factors
The following should be read to supplement the factors that
may affect MetLifes business or operations, as described
under Risk Factors in Part II, Item 1A of
MetLifes Quarterly Report on
Form 10-Q
for the quarter ended September 30, 2008.
Our
Participation in a Securities Lending Program Subjects Us to
Potential Liquidity and Other Risks
We participate in a securities lending program whereby blocks of
securities, which are included in fixed maturity securities and
short-term investments, are loaned to third parties, primarily
major brokerage firms and commercial banks. We require
collateral equal to 102% of the current market value of the
loaned securities to be obtained at the inception of a loan, and
maintained at a level greater than or equal to 100% for the
duration of the loan. During the extraordinary market events
occurring in the fourth quarter of 2008, we, in limited
instances, accepted collateral less than 102% at the inception
of certain loans, but never less than 100%, of the market value
of such loaned securities. These loans involved
U.S. Government Treasury Bills which we considered to have
limited variation in their market value during the term of the
loan. Securities with a cost or amortized cost of
$20.8 billion and $41.1 billion and an estimated fair
value of $22.9 billion and $42.1 billion were on loan
under the program at December 31, 2008 and
December 31, 2007, respectively. Securities loaned under
such transactions may be sold or repledged by the transferee. We
were liable for cash collateral under our control of
$23.3 billion and $43.3 billion at December 31,
2008 and December 31, 2007, respectively.
Returns of loaned securities by the third parties would require
us to return the cash collateral associated with such loaned
securities. In addition, in some cases, the maturity of the
securities held as invested collateral (i.e., securities that we
have purchased with cash received from the third parties) may
exceed the term of the related securities on loan and the market
value may fall below the amount of cash received as collateral
and invested. If we are required to return significant amounts
of cash collateral on short notice and we are forced to sell
securities to meet the return obligation, we may have difficulty
selling such collateral that is invested in securities in a
timely manner, be forced to sell securities in a volatile or
illiquid market for less than we otherwise would have been able
to realize under normal market conditions, or both. In addition,
under stressful capital market and economic conditions, such as
those conditions we have experienced recently, liquidity broadly
deteriorates, which may further restrict our ability to sell
securities.
Of this $23.3 billion of cash collateral at
December 31, 2008, approximately $5.1 billion was on
open terms, meaning that the related loaned security could be
returned to us on the next business day requiring return of cash
collateral and the following amounts are due within
30 days, and 60 days - $14.7 billion and
$3.5 billion, respectively. The estimated fair value of the
securities related to the cash collateral on open at
December 31, 2008 has been reduced to $5.0 billion
from $15.8 billion as of November 30, 2008. Of the
$5.0 billion of estimated fair value of the securities
related to the cash collateral on open at December 31,
2008, $4.4 billion were U.S. Treasury and agency
securities which, if put to us, can be immediately sold to
satisfy the cash requirements. The remainder of the securities
on loan are primarily U.S. Treasury and agency securities,
and very liquid residential mortgage-backed securities. Within
the U.S. Treasury securities on loan, they are primarily
holdings of
on-the-run
U.S. Treasury securities, the most liquid
U.S. Treasury securities available. If these high quality
securities that are on loan are put back to us, the proceeds
from immediately selling these securities can be used to satisfy
the related cash requirements. The estimated fair value of the
reinvestment portfolio acquired with the cash collateral was
$19.5 billion at December 31, 2008, and consisted
principally of fixed maturity securities (including residential
mortgage-backed, asset-backed, U.S. corporate and foreign
corporate securities). If the on loan securities or the
reinvestment portfolio become less liquid, we have the liquidity
resources of most of our general account available to meet any
potential cash demand when securities are put back to us.
If we decrease the amount of our securities lending activities
over time, the amount of income generated by these activities
will also likely decline.
S-12
We Are
Exposed to Significant Financial and Capital Markets Risk which
May Adversely Affect Our Results of Operations, Financial
Condition and Liquidity, and Our Net Investment Income Can Vary
from Period to Period
We are exposed to significant financial and capital markets
risk, including changes in interest rates, credit spreads,
equity prices, real estate markets, foreign currency exchange
rates, market volatility, the performance of the economy in
general, the performance of the specific obligors included in
our portfolio and other factors outside our control. Our
exposure to interest rate risk relates primarily to the market
price and cash flow variability associated with changes in
interest rates. A rise in interest rates will increase the net
unrealized loss position of our fixed income investment
portfolio and, if long-term interest rates rise dramatically
within a six to twelve month time period, certain of our life
insurance businesses may be exposed to disintermediation risk.
Disintermediation risk refers to the risk that our policyholders
may surrender their contracts in a rising interest rate
environment, requiring us to liquidate fixed income investments
in an unrealized loss position. Due to the long-term nature of
the liabilities associated with certain of our life insurance
businesses, guaranteed benefits on variable annuities, and
structured settlements, sustained declines in long-term interest
rates may subject us to reinvestment risks and increased hedging
costs. In other situations, declines in interest rates may
result in increasing the duration of certain life insurance
liabilities, creating asset liability duration mismatches. Our
investment portfolio also contains interest rate sensitive
instruments, such as fixed income securities, which may be
adversely affected by changes in interest rates from
governmental monetary policies, domestic and international
economic and political conditions and other factors beyond our
control. A rise in interest rates would increase the net
unrealized loss position of our fixed income investment
portfolio, offset by our ability to earn higher rates of return
on funds reinvested. Conversely, a decline in interest rates
would decrease the net unrealized loss position of our fixed
income investment portfolio, offset by lower rates of return on
funds reinvested. Our mitigation efforts with respect to
interest rate risk are primarily focused towards maintaining an
investment portfolio with diversified maturities that has a
weighted average duration that is approximately equal to the
duration of our estimated liability cash flow profile. However,
our estimate of the liability cash flow profile may be
inaccurate and we may be forced to liquidate fixed income
investments prior to maturity at a loss in order to cover the
liability. Although we take measures to manage the economic
risks of investing in a changing interest rate environment, we
may not be able to mitigate the interest rate risk of our fixed
income investments relative to our liabilities.
Our exposure to credit spreads primarily relates to market price
and cash flow variability associated with changes in credit
spreads. A widening of credit spreads will increase the net
unrealized loss position of the fixed income investment
portfolio, will increase losses associated with credit based
non-qualifying derivatives where we assume credit exposure, and,
if issuer credit spreads increase significantly or for an
extended period of time, would likely result in higher
other-than-temporary
impairments. Credit spread tightening will reduce net investment
income associated with new purchases of fixed maturity
securities. In addition, market volatility can make it difficult
to value certain of our securities if trading becomes less
frequent. As such, valuations may include assumptions or
estimates that may have significant period to period changes
which could have a material adverse effect on our consolidated
results of operations or financial condition. Credit spreads on
both corporate and structured securities widened during 2008,
resulting in continuing depressed pricing. Continuing challenges
include continued weakness in the U.S. real estate market
and increased mortgage delinquencies, investor anxiety over the
U.S. economy, rating agency downgrades of various
structured products and financial issuers, unresolved issues
with structured investment vehicles and monoline financial
guarantee insurers, deleveraging of financial institutions and
hedge funds and a serious dislocation in the inter-bank market.
If significant, continued volatility, changes in interest rates,
changes in credit spreads and defaults, a lack of pricing
transparency, market liquidity, declines in equity prices, and
the strengthening or weakening of foreign currencies against the
U.S. dollar, individually or in tandem, could have a
material adverse effect on our consolidated results of
operations, financial condition or cash flows through realized
losses, impairments, and changes in unrealized positions.
Our primary exposure to equity risk relates to the potential for
lower earnings associated with certain of our insurance
businesses, such as variable annuities, where fee income is
earned based upon the fair value of the assets under management.
In addition, certain of our annuity products offer guaranteed
benefits which increase our potential benefit exposure should
equity markets decline. We are also exposed to interest rate and
equity risk based upon the discount rate and expected long-term
rate of return assumptions associated with our pension and other
S-13
post-retirement benefit obligations. Sustained declines in
long-term interest rates or equity returns likely would have a
negative effect on the funded status of these plans.
Our exposure to real estate risk relates to market price and
cash flow variability associated with changes in real estate
markets, default and bankruptcy rates, geographic and sector
concentration as well as illiquidity of real estate investments.
The current economic environment has led to significant
weakening of the residential and commercial real estate markets,
increases in foreclosures, bankruptcies and unsuccessful
development projects as well as limited access to credit. Our
real estate investments, including those held by joint ventures
and real estate funds, may be negatively impacted by weakened
local real estate conditions, such as oversupply, reduced demand
and the availability and creditworthiness of current and
prospective tenants and borrowers. In addition, real estate
investments are relatively illiquid, and could limit our
ability, and that of our joint ventures partners and real estate
fund managers, to sell assets to respond to changing economic,
financial and investment conditions. Also, these factors could
impact mortgage and consumer loan fundamentals. These factors
and others beyond our control could have a material adverse
effect on our consolidated results of operations, financial
condition or cash flows through net investment income, realized
losses and impairments.
Significant declines in equity prices, changes in
U.S. interest rates, changes in credit spreads, and changes
in foreign currency exchange rates could have a material adverse
effect on our consolidated results of operations, financial
condition or liquidity. Changes in these factors, which are
significant risks to us, can affect our net investment income in
any period, and such changes can be substantial.
We invest a portion of our invested assets in leveraged buy-out
funds, hedge funds and other private equity funds reported
within Other Limited Partnerships, many of which make private
equity investments. The amount and timing of net investment
income from such investment funds tends to be uneven as a result
of the performance of the underlying investments, including
private equity investments. The timing of distributions from the
funds, which depends on particular events relating to the
underlying investments, as well as the funds schedules for
making distributions and their needs for cash, can be difficult
to predict. As a result, the amount of net investment income
that we record from these investments can vary substantially
from quarter to quarter. Recent equity, real estate and credit
market volatility have further reduced net investment income and
related yields for these types of investments and we may
continue to experience reduced net investment income due to
continued volatility in the equity, real estate and credit
markets in 2009. In addition, due to the normal lag in the
preparation of and then receipt of periodic financial statements
from other limited partnership interests and real estate joint
ventures and funds, results from late 2008 during periods of
volatility will be reported to us in 2009.
Consolidation
of Distributors of Insurance Products May Adversely Affect the
Insurance Industry and the Profitability of Our
Business
The insurance industry distributes many of its individual
products through other financial institutions such as banks and
broker-dealers. As capital, credit and equity markets continue
to experience volatility, bank and broker-dealer consolidation
activity may increase and negatively impact the industrys
sales, and such consolidation could increase competition for
access to distributors, result in greater distribution expenses
and impair our ability to market insurance products to our
current customer base or to expand our customer base.
Industry
Trends Could Adversely Affect the Profitability of Our
Businesses
Our business segments continue to be influenced by a variety of
trends that affect the insurance industry, including intense
competition with respect to product features, price,
distribution capability, customer service and information
technology. The impact on our business and on the life insurance
industry generally of the volatility and instability of the
financial markets is difficult to predict, and our business
plans, financial condition and results of operations may be
negatively impacted or affected in other unexpected ways. In
addition, the life insurance industry is subject to state
regulation, and, as complex products are introduced, regulators
may refine capital requirements and introduce new reserving
standards. Furthermore, regulators have undertaken market and
sales practices reviews of several markets or products,
including equity-indexed annuities, variable annuities and group
products. The current market environment may also lead to
changes in regulation that may benefit or disadvantage us
relative to some of our competitors.
S-14
Change
in Our Discount Rate, Expected Rate of Return and Expected
Compensation Increase Assumptions for Our Pension and Other
Postretirement Benefit Plans May Result in Increased Expenses
and Reduce Our Profitability
We determine our pension and other postretirement benefit plan
costs based on our best estimates of future plan experience.
These assumptions are reviewed regularly and include discount
rates, expected rates of return on plan assets and expected
increases in compensation levels and expected medical inflation.
Changes in these assumptions may result in increased expenses
and reduce our profitability.
A
Downgrade or a Potential Downgrade in Our Financial Strength or
Credit Ratings Could Result in a Loss of Business and Materially
Adversely Affect Our Financial Condition and Results of
Operations
Financial strength ratings, which various Nationally Recognized
Statistical Rating Organizations (NRSROs)
publish as indicators of an insurance companys ability to
meet contractholder and policyholder obligations, are important
to maintaining public confidence in our products, our ability to
market our products and our competitive position.
Downgrades in our financial strength ratings could have a
material adverse effect on our financial condition and results
of operations in many ways, including:
|
|
|
|
|
reducing new sales of insurance products, annuities and other
investment products;
|
|
|
|
adversely affecting our relationships with our sales force and
independent sales intermediaries;
|
|
|
|
materially increasing the number or amount of policy surrenders
and withdrawals by contractholders and policyholders;
|
|
|
|
requiring us to reduce prices for many of our products and
services to remain competitive; and
|
|
|
|
adversely affecting our ability to obtain reinsurance at
reasonable prices or at all.
|
In addition to the financial strength ratings of our insurance
subsidiaries, various NRSROs also publish credit ratings for
MetLife, Inc. and several of its subsidiaries. Credit ratings
are indicators of a debt issuers ability to meet the terms
of debt obligations in a timely manner and are important factors
in our overall funding profile and ability to access certain
types of liquidity. Downgrades in our credit ratings could have
a material adverse effect on our financial condition and results
of operations in many ways, including adversely limiting our
access to capital markets, potentially increasing the cost of
debt, and requiring us to post collateral. A two-notch decrease
in the financial strength ratings of our insurance company
subsidiaries would require us to post less than
$200 million of collateral in connection with derivative
collateral arrangements, to which we are a party and would have
allowed holders of approximately $500 million aggregate
account value of our funding agreements to terminate such
funding agreements on 90 days notice.
On September 18, 2008, September 29, 2008,
October 2, 2008 and October 10, 2008, A.M. Best
Company, Inc., Fitch, Moodys and S&P, respectively,
each revised its outlook for the U.S. life insurance sector
to negative from stable, citing, among other things, the
significant deterioration and volatility in the credit and
equity markets, economic and political uncertainty, and the
expected impact of realized and unrealized investment losses on
life insurers capital levels and profitability. On
January 12, 2009, S&P maintained its negative outlook
on the U.S. life insurance sector.
In view of the difficulties experienced recently by many
financial institutions, including our competitors in the
insurance industry, we believe it is possible that the NRSROs
will heighten the level of scrutiny that they apply to such
institutions, will increase the frequency and scope of their
credit reviews, will request additional information from the
companies that they rate, and may adjust upward the capital and
other requirements employed in the NRSRO models for maintenance
of certain ratings levels, such as the AA (S&P) and Aa2
(Moodys) insurer financial strength ratings currently held
by our life insurance subsidiaries. In this regard, on
February 9, 2009, Moodys affirmed our credit ratings
and the insurance financial strength ratings of our insurance
subsidiaries, but changed the outlook for us and our
subsidiaries to negative from stable. On February 11, 2009,
Fitch announced in a press release that it has assigned an A
rating to this remarketing of the Debentures, and that it has
revised its outlook
S-15
on MetLife, Inc.s ratings to negative from stable, as
described in the full rating announcement provided in the
release. In its announcement, Fitch stated that it is in the
process of completing its analysis of MetLife, Inc.s
year-end 2008 financial results, and updating its views of
MetLifes Inc.s capital position, liquidity profile,
and earnings performance. According to the announcement, while
this review is not yet complete, Fitch decided to provide the
market updated commentary on MetLife, Inc.s ratings due to
MetLife, Inc.s proposed offering of the Debentures. In the
announcement, Fitch stated that it anticipates completing its
review within the next several weeks, and will reflect those
results in the ratings at that time. According to the
announcement, it is anticipated that any downgrade of MetLife,
Inc.s ratings, if there is one, would be limited to one
notch. On February 11, 2009, S&P notified MetLife,
Inc. that it assigned its A rating on this remarketing of the
Debentures. We do not believe that the actions taken by
Moodys and Fitch will have a material adverse impact on
our results of operations and financial condition. However, it
is possible that any future adverse ratings consequences,
including any downgrade, could have a material adverse effect on
our results of operations and financial condition.
We cannot predict what actions rating agencies may take, or what
actions we may take in response to the actions of rating
agencies, which could adversely affect our business. As with
other companies in the financial services industry, our ratings
could be downgraded at any time and without any notice by any
NRSRO.
An
Inability to Access Our Credit Facilities Could Result in a
Reduction in Our Liquidity and Lead to Downgrades in Our Credit
and Financial Strength Ratings
We have a $2.85 billion five-year revolving credit facility
that matures in June 2012, as well as other facilities that we
enter into in the ordinary course of business.
We rely on our credit facilities as a potential source of
liquidity. The availability of these facilities could be
critical to our credit and financial strength ratings and our
ability to meet our obligations as they come due, particularly
in the current market when alternative sources of credit are
tight. The credit facilities contain certain administrative,
reporting, legal and financial covenants. We must comply with
certain covenants under our credit facilities (including the
$2.85 billion five-year revolving credit facility) that
require us to maintain a specified minimum consolidated net
worth.
Our right to make borrowings under these facilities is subject
to the fulfillment of certain important conditions, including
our compliance with all covenants, and our ability to borrow is
also subject to the continued willingness and ability of the
lenders that are parties to the facilities to provide funds. Our
failure to comply with the covenants in the credit facilities or
fulfill the conditions to borrowings, or the failure of lenders
to fund their lending commitments (whether due to insolvency,
illiquidity or other reasons) in the amounts provided for under
the terms of the facilities, would restrict our ability to
access these credit facilities when needed and, consequently,
could have a material adverse effect on our financial condition
and results of operations.
Defaults,
Downgrades or Other Events Impairing the Value of Our Fixed
Maturity Securities Portfolio May Reduce Our
Earnings
We are subject to the risk that the issuers, or guarantors, of
fixed maturity securities we own may default on principal and
interest payments they owe us. We are also subject to the risk
that the underlying collateral within loan-backed securities,
including mortgage-backed and asset-backed securities, may
default on principal and interest payments causing an adverse
change in cash flows paid to our investment. At
December 31, 2008, the fixed maturity securities of
$188.3 billion in our investment portfolio represented
58.4% of our total cash and invested assets. The occurrence of a
major economic downturn (such as the current downturn in the
economy), acts of corporate malfeasance, widening risk spreads,
or other events that adversely affect the issuers, guarantors or
underlying collateral of these securities could cause the value
of our fixed maturity securities portfolio and our net income to
decline and the default rate of the fixed maturity securities in
our investment portfolio to increase. A ratings downgrade
affecting issuers or guarantors of particular securities, or
similar trends that could worsen the credit quality of issuers,
such as the corporate issuers of securities in our investment
portfolio, could also have a similar effect. With economic
uncertainty, credit quality of issuers or guarantors could be
adversely affected. Similarly, a ratings downgrade affecting a
loan-backed security we hold could indicate the credit quality
of that security has deteriorated. Any event reducing the value
of these securities other than on a temporary basis could
S-16
have a material adverse effect on our business, results of
operations and financial condition. Levels of write down or
impairment are impacted by our assessment of the intent and
ability to hold securities which have declined in value until
recovery. If we determine to reposition or realign portions of
the portfolio so as not to hold certain securities in an
unrealized loss position to recovery, then we will incur an
other than temporary impairment charge in the period that
the decision was made not to hold the security to
recovery. In addition, in January, 2009, Moodys revised
its loss projections for U.S. Alt-A residential
mortgage-backed securities, and it is anticipated that
Moodys will be downgrading virtually all 2006 and 2007
Alt-A securities to below investment grade, which will increase
the percentage of our portfolio that will be rated below
investment grade.
We
Face Unforeseen Liabilities or Asset Impairments Arising from
Possible Acquisitions and Dispositions of Businesses or
Difficulties Integrating Such Businesses
We have engaged in dispositions and acquisitions of businesses
in the past, and expect to continue to do so in the future.
There could be unforeseen liabilities or asset impairments,
including goodwill impairments, that arise in connection with
the businesses that we may sell or the businesses that we may
acquire in the future. In addition, there may be liabilities or
asset impairments that we fail, or are unable, to discover in
the course of performing due diligence investigations on each
business that we have acquired or may acquire. Furthermore, the
use of our own funds as consideration in any acquisition would
consume capital resources that would no longer be available for
other corporate purposes.
Our ability to achieve certain benefits we anticipate from any
acquisitions of businesses will depend in large part upon our
ability to successfully integrate such businesses in an
efficient and effective manner. We may not be able to integrate
such businesses smoothly or successfully, and the process may
take longer than expected. The integration of operations may
require the dedication of significant management resources,
which may distract managements attention from
day-to-day
business. If we are unable to successfully integrate the
operations of such acquired businesses, we may be unable to
realize the benefits we expect to achieve as a result of such
acquisitions and our business and results of operations may be
less than expected.
Guarantees
Within Certain of Our Variable Annuity Guarantee Riders that
Protect Policyholders Against Significant Downturns in Equity
Markets May Increase the Volatility of Our Results Related to
the Inclusion of an Own Credit Adjustment in the Fair Value of
the Liability for These Riders
In determining the valuation of certain variable annuity
guarantee rider liabilities that are carried at fair value, we
must consider our own credit standing, which is not hedged. A
decrease in our own credit spread could cause the value of these
liabilities to increase, resulting in a reduction to net income.
An increase in our own credit spread could cause the value of
these liabilities to decrease, resulting in an increase to net
income. Because this credit adjustment is determined, at least
in part, by taking into consideration publicly available
information relating to our publicly traded debt (including
related credit default swap spreads), the overall condition of
fixed income markets may impact this adjustment. The credit
premium implied in our publicly traded debt instruments may not
always necessarily reflect our actual credit rating or our
claims paying ability. Recently, the fixed-income markets have
experienced a period of extreme volatility which negatively
impacted market liquidity and increased credit spreads. The
increase in credit default swap spreads has at times been even
more pronounced than in the fixed income cash markets. In a
broad based market downturn, this increase in our own credit
spread could result in net income being relatively flat when a
deterioration in other market inputs required for the estimate
of fair value would otherwise result in a significant reduction
in net income. The inclusion of our own credit standing in this
case has the effect of muting the actual net income losses
recognized. In subsequent periods, if our credit spreads improve
relative to the overall market, we could have a reduction of net
income in an overall improving market.
S-17
Investment in the Debentures remarketed hereby will involve
certain risks described below. However, this prospectus
supplement and the accompanying prospectus do not describe all
of the risks involving an investment in these securities. You
should also read the Risk Factors set forth in our Quarterly
Report on
Form 10-Q
for the nine months ended September 30, 2008 (the
2008 MetLife
Form 10-Q),
which is incorporated by reference herein. Investors should
note, however, that MetLifes business, financial
condition, results of operations and prospects may have changed
since the date of the 2008 MetLife
Form 10-Q.
Therefore, you should review the information included in the
Risk Factors set forth in the 2008 MetLife
Form 10-Q
as such information has been modified and supplemented in
documents subsequently filed by MetLife, Inc. with the SEC and
incorporated by reference in this prospectus supplement and the
accompanying prospectus, including the Risk Factors in our
Current Report on
Form 8-K
filed February 10, 2009.
In consultation with your own financial and legal advisors,
you should carefully consider the information included in this
prospectus supplement and the accompanying prospectus together
with the other information incorporated by reference in this
prospectus supplement and the accompanying prospectus and pay
special attention to the following discussion of risks relating
to the Debentures, before deciding whether an investment in the
securities offered hereby is suitable for you. The securities
offered hereby will not be an appropriate investment for you if
you are not knowledgeable about significant features of the
securities offered hereby or financial matters in general. You
should not purchase any of the offered securities unless you
understand, and know that you can bear, these investment
risks.
There
Are No Financial Covenants in the Indenture.
Neither we nor any of our subsidiaries are restricted from
incurring additional debt or other liabilities, including
additional senior debt, under the Indenture (as defined under
Description of the Remarketed Debentures). If we
incur additional debt or liabilities, our ability to pay our
obligations on the Debentures could be adversely affected. We
expect that we will from time to time incur additional debt and
other liabilities. In addition, we are not restricted from
paying dividends or issuing or repurchasing our securities under
the Indenture.
There are no financial covenants in the Indenture. You are not
protected under the Indenture in the event of a highly leveraged
transaction, reorganization, change of control, restructuring,
merger or similar transaction that may adversely affect you,
except to the extent described in the accompanying prospectus
under Description of the Debt Consolidation,
Merger, Sale of Assets and Other Transactions.
The
Debentures Are Not Guaranteed by Any of Our Subsidiaries and Are
Structurally Subordinated to the Debt and Other Liabilities of
Our Subsidiaries, which Means that Creditors of Our Subsidiaries
Will be Paid from Their Assets Before Holders of the Debentures
Would Have Any Claims to Those Assets.
We are a holding company and conduct substantially all of our
operations through subsidiaries. However, the Debentures are
obligations exclusively of MetLife, Inc. and are not guaranteed
by any of our subsidiaries. As a result, the Debentures are
structurally subordinated to all debt and other liabilities of
our subsidiaries (including liabilities to policyholders and
contractholders), which means that creditors of our subsidiaries
will be paid from their assets before holders of the Debentures
would have any claims to those assets. As of September 30,
2008, our subsidiaries had outstanding $478.3 billion of
total liabilities, including $7.6 billion of total debt
(excluding, in each case, intercompany liabilities).
An
Active After-Market for the Debentures May Not
Develop.
The Debentures have no established trading market. We cannot
assure you that an active after-market for the Debentures will
develop or be sustained or that holders of the Debentures will
be able to sell their Debentures at favorable prices or at all.
Although the Remarketing Agents have indicated to us that they
intend to make a market in the Debentures, as permitted by
applicable laws and regulations, they are not obligated to do so
and may discontinue any such market-making at any time without
notice. Accordingly, no assurance can be given as to the
liquidity of, or trading markets for, the Debentures. The
Debentures are not listed and we do not plan to apply to list
the Debentures on any securities exchange or to include them in
any automated dealer quotation system. If we or our affiliates
S-18
purchase Debentures in the remarketing, the liquidity of any
trading market in the Debentures may be adversely affected.
If a
Trading Market Does Develop, Changes in Our Credit Ratings or
the Debt Markets Could Adversely Affect the Market Price of the
Debentures.
The price for the Debentures depends on many factors, including:
|
|
|
|
|
Our credit ratings with major credit rating agencies;
|
|
|
|
The prevailing interest rates being paid by other companies
similar to us;
|
|
|
|
Our financial condition, financial performance and future
prospects; and
|
|
|
|
The overall condition of the financial markets.
|
The condition of the financial markets and prevailing interest
rates have fluctuated in the past and are likely to fluctuate in
the future. Such fluctuations could have an adverse effect on
the price of the Debentures.
In addition, credit rating agencies continually review their
ratings for the companies that they follow, including us. The
credit rating agencies also evaluate the insurance industry as a
whole and may change their credit ratings for us based on their
overall view of our industry. A negative change in any of our
ratings could have an adverse effect on the price of the
Debentures.
S-19
SELECTED
HISTORICAL FINANCIAL INFORMATION
The following selected financial data has been derived from
MetLifes audited consolidated financial statements. The
statement of income data for the years ended December 31,
2007, 2006 and 2005 and the balance sheet data as of
December 31, 2007 and 2006 has been derived from
MetLifes audited financial statements included in the
MetLife Annual Report on
Form 10-K
for the year ended December 31, 2007, which have been
updated by the Current Report on
Form 8-K
filed on November 6, 2008 incorporated by reference in this
prospectus supplement. The statement of income data for the
years ended December 31, 2004 and 2003 and the balance
sheet as of December 31, 2005 and 2004 has been derived
from MetLifes audited financial statements included in the
MetLife Annual Report on
Form 10-K
for the year ended December 31, 2005 not included herein.
The selected consolidated financial information at and for the
nine months ended September 30, 2008 and 2007 have been
derived from the unaudited interim condensed consolidated
financial statements included in MetLifes Quarterly Report
on
Form 10-Q
for the nine months ended September 30, 2008 incorporated
by reference into this prospectus supplement. This selected
financial data should be read in conjunction with and is
qualified by reference to those financial statements and the
related notes.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months
|
|
|
|
|
|
|
Ended September 30,
|
|
|
Years Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
(In millions)
|
|
|
Statement of Income Data (1)(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues (3)(4):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premiums
|
|
$
|
19,428
|
|
|
$
|
17,050
|
|
|
$
|
22,985
|
|
|
$
|
22,066
|
|
|
$
|
20,990
|
|
|
$
|
18,853
|
|
|
$
|
17,928
|
|
Universal life and investment-type product policy fees
|
|
|
4,206
|
|
|
|
3,901
|
|
|
|
5,310
|
|
|
|
4,779
|
|
|
|
3,827
|
|
|
|
2,866
|
|
|
|
2,495
|
|
Net investment income
|
|
|
12,670
|
|
|
|
13,365
|
|
|
|
18,086
|
|
|
|
16,302
|
|
|
|
14,117
|
|
|
|
11,675
|
|
|
|
10,904
|
|
Other revenues
|
|
|
1,141
|
|
|
|
1,105
|
|
|
|
1,466
|
|
|
|
1,302
|
|
|
|
1,221
|
|
|
|
1,150
|
|
|
|
1,171
|
|
Net investment gains (losses)
|
|
|
(341
|
)
|
|
|
(466
|
)
|
|
|
(561
|
)
|
|
|
(1,387
|
)
|
|
|
(110
|
)
|
|
|
115
|
|
|
|
(614
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
37,104
|
|
|
|
34,955
|
|
|
|
47,286
|
|
|
|
43,062
|
|
|
|
40,045
|
|
|
|
34,659
|
|
|
|
31,884
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses (3)(4):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Policyholder benefits and claims
|
|
|
20,475
|
|
|
|
17,759
|
|
|
|
23,839
|
|
|
|
22,942
|
|
|
|
22,298
|
|
|
|
19,969
|
|
|
|
18,701
|
|
Interest credited to policyholder account balances
|
|
|
3,573
|
|
|
|
4,082
|
|
|
|
5,478
|
|
|
|
4,916
|
|
|
|
3,667
|
|
|
|
2,783
|
|
|
|
2,851
|
|
Policyholder dividends
|
|
|
1,324
|
|
|
|
1,289
|
|
|
|
1,726
|
|
|
|
1,700
|
|
|
|
1,680
|
|
|
|
1,665
|
|
|
|
1,731
|
|
Other expenses
|
|
|
8,091
|
|
|
|
7,565
|
|
|
|
10,458
|
|
|
|
9,565
|
|
|
|
8,281
|
|
|
|
6,853
|
|
|
|
6,405
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
33,463
|
|
|
|
30,695
|
|
|
|
41,501
|
|
|
|
39,123
|
|
|
|
35,926
|
|
|
|
31,270
|
|
|
|
29,688
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before provision for income tax
|
|
|
3,641
|
|
|
|
4,260
|
|
|
|
5,785
|
|
|
|
3,939
|
|
|
|
4,119
|
|
|
|
3,389
|
|
|
|
2,196
|
|
Provision for income tax (3)
|
|
|
1,078
|
|
|
|
1,223
|
|
|
|
1,668
|
|
|
|
1,018
|
|
|
|
1,161
|
|
|
|
932
|
|
|
|
529
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
2,563
|
|
|
|
3,037
|
|
|
|
4,117
|
|
|
|
2,921
|
|
|
|
2,958
|
|
|
|
2,457
|
|
|
|
1,667
|
|
Income (loss) from discontinued operations, net of income tax (3)
|
|
|
(339
|
)
|
|
|
162
|
|
|
|
200
|
|
|
|
3,372
|
|
|
|
1,756
|
|
|
|
387
|
|
|
|
576
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before cumulative effect of a change in accounting, net
of income tax
|
|
|
2,224
|
|
|
|
3,199
|
|
|
|
4,317
|
|
|
|
6,293
|
|
|
|
4,714
|
|
|
|
2,844
|
|
|
|
2,243
|
|
Cumulative effect of a change in accounting, net of income tax
(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(86
|
)
|
|
|
(26
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
2,224
|
|
|
|
3,199
|
|
|
|
4,317
|
|
|
|
6,293
|
|
|
|
4,714
|
|
|
|
2,758
|
|
|
|
2,217
|
|
Preferred stock dividends
|
|
|
94
|
|
|
|
102
|
|
|
|
137
|
|
|
|
134
|
|
|
|
63
|
|
|
|
|
|
|
|
|
|
Charge of conversion of company-obligated mandatorily redeemable
securities of a subsidiary trust
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income available to common shareholders
|
|
$
|
2,130
|
|
|
$
|
3,097
|
|
|
$
|
4,180
|
|
|
$
|
6,159
|
|
|
$
|
4,651
|
|
|
$
|
2,758
|
|
|
$
|
2,196
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S-20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
(In millions)
|
|
|
Balance Sheet Data (2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General account assets
|
|
|
$381,496
|
|
|
$
|
398,994
|
|
|
$
|
383,746
|
|
|
$
|
354,048
|
|
|
$
|
270,327
|
|
|
$
|
251,721
|
|
Separate account assets
|
|
|
139,803
|
|
|
|
160,142
|
|
|
|
144,349
|
|
|
|
127,855
|
|
|
|
86,755
|
|
|
|
75,743
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets (3)
|
|
|
$521,299
|
|
|
$
|
559,136
|
|
|
$
|
528,095
|
|
|
$
|
481,903
|
|
|
$
|
357,082
|
|
|
$
|
327,464
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Life and health policyholder liabilities (5)
|
|
|
$274,168
|
|
|
$
|
263,319
|
|
|
$
|
253,913
|
|
|
$
|
245,623
|
|
|
$
|
183,368
|
|
|
$
|
169,518
|
|
Property and casualty policyholder liabilities (5)
|
|
|
3,249
|
|
|
|
3,324
|
|
|
|
3,453
|
|
|
|
3,490
|
|
|
|
3,180
|
|
|
|
2,943
|
|
Short-term debt
|
|
|
1,106
|
|
|
|
667
|
|
|
|
1,449
|
|
|
|
1,414
|
|
|
|
1,445
|
|
|
|
3,642
|
|
Long-term debt
|
|
|
10,811
|
|
|
|
9,100
|
|
|
|
8,822
|
|
|
|
9,088
|
|
|
|
7,006
|
|
|
|
5,305
|
|
Collateral financing arrangements
|
|
|
5,132
|
|
|
|
4,882
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Junior subordinated debt securities
|
|
|
3,759
|
|
|
|
4,075
|
|
|
|
3,381
|
|
|
|
2,134
|
|
|
|
|
|
|
|
|
|
Payables for collateral under securities loaned and other
transactions
|
|
|
43,299
|
|
|
|
44,136
|
|
|
|
45,846
|
|
|
|
34,515
|
|
|
|
28,678
|
|
|
|
27,083
|
|
Other
|
|
|
12,139
|
|
|
|
34,312
|
|
|
|
33,084
|
|
|
|
28,683
|
|
|
|
23,826
|
|
|
|
22,081
|
|
Separate account liabilities
|
|
|
139,803
|
|
|
|
160,142
|
|
|
|
144,349
|
|
|
|
127,855
|
|
|
|
86,755
|
|
|
|
75,743
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities (3)
|
|
|
493,466
|
|
|
|
523,957
|
|
|
|
494,297
|
|
|
|
452,802
|
|
|
|
334,258
|
|
|
|
306,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, at par value
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
Common stock, at par value
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
Additional paid-in capital
|
|
|
17,602
|
|
|
|
17,098
|
|
|
|
17,454
|
|
|
|
17,274
|
|
|
|
15,037
|
|
|
|
14,991
|
|
Retained earnings (6)
|
|
|
22,041
|
|
|
|
19,884
|
|
|
|
16,574
|
|
|
|
10,865
|
|
|
|
6,608
|
|
|
|
4,193
|
|
Treasury stock, at cost
|
|
|
(4,279
|
)
|
|
|
(2,890
|
)
|
|
|
(1,357
|
)
|
|
|
(959
|
)
|
|
|
(1,785
|
)
|
|
|
(835
|
)
|
Accumulated other comprehensive income (loss) (7)
|
|
|
(7,540
|
)
|
|
|
1,078
|
|
|
|
1,118
|
|
|
|
1,912
|
|
|
|
2,956
|
|
|
|
2,792
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
27,833
|
|
|
|
35,179
|
|
|
|
33,798
|
|
|
|
29,101
|
|
|
|
22,824
|
|
|
|
21,149
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
|
$521,299
|
|
|
$
|
559,136
|
|
|
$
|
528,095
|
|
|
$
|
481,903
|
|
|
$
|
357,082
|
|
|
$
|
327,464
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S-21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months
|
|
|
|
|
|
|
Ended September 30,
|
|
|
Years Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
(In millions, except per share data)
|
|
|
Other Data (1)(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income available to common shareholders
|
|
$
|
2,130
|
|
|
$
|
3,097
|
|
|
$
|
4,180
|
|
|
$
|
6,159
|
|
|
$
|
4,651
|
|
|
$
|
2,758
|
|
|
$
|
2,196
|
|
Return on common equity (8)
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
13.0
|
%
|
|
|
21.9
|
%
|
|
|
18.5
|
%
|
|
|
12.5
|
%
|
|
|
11.4
|
%
|
Return on common equity, excluding accumulated other
comprehensive income
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
13.2
|
%
|
|
|
22.6
|
%
|
|
|
20.4
|
%
|
|
|
14.4
|
%
|
|
|
13.0
|
%
|
Earnings Per Share Data (1)(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from Continuing Operations Available to Common
Shareholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
3.44
|
|
|
$
|
3.93
|
|
|
$
|
5.35
|
|
|
$
|
3.66
|
|
|
$
|
3.87
|
|
|
$
|
3.27
|
|
|
$
|
2.23
|
|
Diluted
|
|
$
|
3.39
|
|
|
$
|
3.84
|
|
|
$
|
5.22
|
|
|
$
|
3.62
|
|
|
$
|
3.83
|
|
|
$
|
3.25
|
|
|
$
|
2.20
|
|
Income from Discontinued Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.47
|
)
|
|
$
|
0.22
|
|
|
$
|
0.27
|
|
|
$
|
4.43
|
|
|
$
|
2.34
|
|
|
$
|
0.52
|
|
|
$
|
0.78
|
|
Diluted
|
|
$
|
(0.47
|
)
|
|
$
|
0.21
|
|
|
$
|
0.26
|
|
|
$
|
4.38
|
|
|
$
|
2.32
|
|
|
$
|
0.50
|
|
|
$
|
0.77
|
|
Cumulative Effect of a Change in Accounting (4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
(0.11
|
)
|
|
$
|
(0.04
|
)
|
Diluted
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
(0.11
|
)
|
|
$
|
(0.04
|
)
|
Net Income Available to Common Shareholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
2.97
|
|
|
$
|
4.15
|
|
|
$
|
5.62
|
|
|
$
|
8.09
|
|
|
$
|
6.21
|
|
|
$
|
3.67
|
|
|
$
|
2.97
|
|
Diluted
|
|
$
|
2.92
|
|
|
$
|
4.05
|
|
|
$
|
5.48
|
|
|
$
|
7.99
|
|
|
$
|
6.16
|
|
|
$
|
3.65
|
|
|
$
|
2.94
|
|
Dividends Declared Per Common Share
|
|
|
N/A
|
|
|
|
N/A
|
|
|
$
|
0.74
|
|
|
$
|
0.59
|
|
|
$
|
0.52
|
|
|
$
|
0.46
|
|
|
$
|
0.23
|
|
|
|
|
(1) |
|
During the fourth quarter of 2008, MetLife, Inc. recorded a
cumulative out-of-period adjustment in connection with the
exclusion of certain derivatives gains from the estimation of
cumulative gross profits used in the determination of DAC
amortization. The adjustment decreased deferred policy
acquisition costs and increased DAC amortization by $124 million
and decreased net income by $80 million in the fourth quarter of
2008. Had the amounts been reflected during the nine months
ended September 30, 2008 in the periods in
which they arose DAC amortization would have
increased by $124 million resulting in a decrease of net
income by $80 million. Net income available to common
shareholders per diluted common share would have been lower by
$0.11 during the nine months ended September 30, 2008 had
the amounts been reflected in the periods in which they arose.
Based upon an evaluation of all relevant quantitative and
qualitative factors, and after considering the provisions of APB
28, paragraph 29, and SAB Nos. 99 and 108, MetLife, Inc.
believes this correcting adjustment was not material to the full
year results for 2008 or the trends of earnings. |
|
(2) |
|
On July 1, 2005, MetLife, Inc. acquired The Travelers
Insurance Company, excluding certain assets, most significantly,
Primerica, from Citigroup Inc., and substantially all of
Citigroup Inc.s international insurance businesses. The
2005 selected financial data includes total revenues and total
expenses of $966 million and $577 million,
respectively, from the date of the acquisition. |
|
(3) |
|
Discontinued Operations: |
Real
Estate
In accordance with Statement of Financial Accounting Standards
(SFAS) No. 144, Accounting for the
Impairment or Disposal of Long-Lived Assets
(SFAS 144), income related to real estate
sold or classified as
S-22
held-for-sale for transactions initiated on or after
January 1, 2002 is presented as discontinued operations.
The following information presents the components of income from
discontinued real estate operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months
|
|
|
|
|
|
|
Ended September 30,
|
|
|
Years Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
(In millions)
|
|
|
Investment income
|
|
$
|
45
|
|
|
$
|
38
|
|
|
$
|
61
|
|
|
$
|
267
|
|
|
$
|
431
|
|
|
$
|
686
|
|
|
$
|
756
|
|
Investment expense
|
|
|
(19
|
)
|
|
|
(23
|
)
|
|
|
(32
|
)
|
|
|
(175
|
)
|
|
|
(269
|
)
|
|
|
(411
|
)
|
|
|
(444
|
)
|
Net investment gains (losses)
|
|
|
|
|
|
|
5
|
|
|
|
13
|
|
|
|
4,795
|
|
|
|
2,125
|
|
|
|
146
|
|
|
|
420
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
26
|
|
|
|
20
|
|
|
|
42
|
|
|
|
4,887
|
|
|
|
2,287
|
|
|
|
421
|
|
|
|
732
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13
|
|
|
|
4
|
|
Provision for income tax
|
|
|
9
|
|
|
|
7
|
|
|
|
18
|
|
|
|
1,725
|
|
|
|
814
|
|
|
|
143
|
|
|
|
265
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations, net of income tax
|
|
$
|
17
|
|
|
$
|
13
|
|
|
$
|
24
|
|
|
$
|
3,162
|
|
|
$
|
1,473
|
|
|
$
|
265
|
|
|
$
|
463
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operations
In September 2007, September 2005 and January 2005, MetLife sold
its MetLife Insurance Limited (MetLife
Australia) annuities and pension businesses,
P.T. Sejabtera (MetLife Indonesia) and
SSRM Holdings, Inc. (SSRM), respectively. In
accordance with SFAS 144, the assets, liabilities and
operations of MetLife Indonesia, MetLife Australia and SSRM have
been reclassified into discontinued operations for all years
presented. The following tables present these discontinued
operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
(In millions)
|
|
|
Revenues
|
|
$
|
71
|
|
|
$
|
100
|
|
|
$
|
74
|
|
|
$
|
333
|
|
|
$
|
235
|
|
Expenses
|
|
|
58
|
|
|
|
89
|
|
|
|
89
|
|
|
|
310
|
|
|
|
206
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income tax
|
|
|
13
|
|
|
|
11
|
|
|
|
(15
|
)
|
|
|
23
|
|
|
|
29
|
|
Provision for income tax
|
|
|
4
|
|
|
|
3
|
|
|
|
(2
|
)
|
|
|
13
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations, net of income tax
|
|
|
9
|
|
|
|
8
|
|
|
|
(13
|
)
|
|
|
10
|
|
|
|
16
|
|
Net investment gains (losses), net of income tax
|
|
|
10
|
|
|
|
52
|
|
|
|
182
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discounted operations, net of income tax
|
|
$
|
19
|
|
|
$
|
60
|
|
|
$
|
169
|
|
|
$
|
10
|
|
|
$
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
(In millions)
|
|
|
General account assets
|
|
$
|
1,563
|
|
|
$
|
1,621
|
|
|
$
|
410
|
|
|
$
|
210
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
1,563
|
|
|
$
|
1,621
|
|
|
$
|
410
|
|
|
$
|
210
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Life and health policyholder liabilities (5)
|
|
$
|
1,595
|
|
|
$
|
1,622
|
|
|
$
|
24
|
|
|
$
|
17
|
|
Short-term debt
|
|
|
|
|
|
|
|
|
|
|
19
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
225
|
|
|
|
73
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
$
|
1,595
|
|
|
$
|
1,622
|
|
|
$
|
268
|
|
|
$
|
90
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On September 12, 2008, MetLife completed a tax-free
split-off of its majority-owned subsidiary, Reinsurance Group of
America, Incorporated (RGA), as described in
Item 8.01 of the Current Report on
Form 8-K
filed on November 14, 2008. In accordance with
SFAS 144, the assets, liabilities and operations of RGA
have
S-23
been reclassified into discontinued operations for all years
presented. The following tables present these discontinued
operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
(In millions)
|
|
|
Revenues
|
|
$
|
5,895
|
|
|
$
|
5,195
|
|
|
$
|
4,567
|
|
|
$
|
3,984
|
|
|
$
|
3,163
|
|
Expenses
|
|
|
5,477
|
|
|
|
4,971
|
|
|
|
4,417
|
|
|
|
3,876
|
|
|
|
3,077
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income tax
|
|
|
418
|
|
|
|
224
|
|
|
|
150
|
|
|
|
108
|
|
|
|
86
|
|
Provision for income tax
|
|
|
146
|
|
|
|
79
|
|
|
|
50
|
|
|
|
35
|
|
|
|
29
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations, net of income tax
|
|
|
272
|
|
|
|
145
|
|
|
|
100
|
|
|
|
73
|
|
|
|
57
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net investment (losses) gains, net of income tax
|
|
|
(115
|
)
|
|
|
5
|
|
|
|
14
|
|
|
|
39
|
|
|
|
40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations, net of income tax
|
|
$
|
157
|
|
|
$
|
150
|
|
|
$
|
114
|
|
|
$
|
112
|
|
|
$
|
97
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
|
(In millions)
|
|
|
General account assets
|
|
$
|
22,020
|
|
|
$
|
19,435
|
|
|
$
|
16,617
|
|
|
$
|
14,552
|
|
|
$
|
12,622
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
22,037
|
|
|
$
|
19,451
|
|
|
$
|
16,631
|
|
|
$
|
14,566
|
|
|
$
|
12,635
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Life and health policyholder liabilities (5)
|
|
|
15,113
|
|
|
|
13,332
|
|
|
|
11,751
|
|
|
|
10,464
|
|
|
|
8,983
|
|
Long-term debt
|
|
|
528
|
|
|
|
307
|
|
|
|
401
|
|
|
|
406
|
|
|
|
399
|
|
Other
|
|
|
4,317
|
|
|
|
3,929
|
|
|
|
2,729
|
|
|
|
2,084
|
|
|
|
1,798
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
$
|
19,958
|
|
|
$
|
17,568
|
|
|
$
|
14,881
|
|
|
$
|
12,954
|
|
|
$
|
11,180
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4) |
|
The cumulative effect of a change in accounting, net of income
tax, of $86 million for the year ended December 31,
2004, resulted from the adoption of
SOP 03-1,
Accounting and Reporting by Insurance Enterprises for Certain
Nontraditional Long-Duration Contracts and for Separate
Accounts. The cumulative effect of a change in accounting, net
of income tax, of $26 million for the year ended
December 31, 2003, resulted from the adoption of
SFAS No. 133 Implementation Issue No. B36,
Embedded Derivatives: Modified Coinsurance Arrangements and Debt
Instruments That Incorporate Credit Risk Exposures That Are
Unrelated or Only Partially Related to the Creditworthiness of
the Obligor under Those Instruments. |
|
(5) |
|
Policyholder liabilities include future policy benefits, other
policyholder funds and bank deposits. The life and health
policyholder liabilities also include policyholder account
balances, policyholder dividends payable and the policyholder
dividend obligation. |
|
(6) |
|
The cumulative effect of changes in accounting, net of income
tax, of $329 million, which decreased retained earnings at
January 1, 2007, resulted from $292 million related to
the adoption of Statement of Position (SOP)
05-1,
Accounting by Insurance Enterprises for Deferred Acquisition
Costs in Connection with Modifications or Exchanges of Insurance
Contracts
(SOP 05-1)
and $37 million related to the adoption of Financial
Accounting Standards Board (FASB)
Interpretation (FIN) No. 48, Accounting
for Uncertainty in Income Taxes An Interpretation of
FASB Statement No. 109 (FIN 48). |
|
(7) |
|
The cumulative effect of a change in accounting, net of income
tax, of $744 million resulted from the adoption of
SFAS No. 158, Employers Accounting for Defined
Benefit Pension and Other Postretirement Plans, and decreased
accumulated other comprehensive income at December 31, 2006. |
|
(8) |
|
Return on common equity is defined as net income available to
common shareholders divided by average common stockholders
equity. |
S-24
RATIO OF
EARNINGS TO FIXED CHARGES AND
PREFERRED STOCK DIVIDENDS
The following table sets forth MetLifes historical ratio
of earnings to fixed charges for the:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months
|
|
|
|
|
|
|
Ended September 30,
|
|
|
Years Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
Ratio of Earnings to Fixed Charges (1)
|
|
|
1.85
|
|
|
|
1.78
|
|
|
|
1.78
|
|
|
|
1.63
|
|
|
|
1.90
|
|
|
|
2.01
|
|
|
|
1.69
|
|
Ratio of Earnings to Fixed Charges
and Preferred Stock Dividends (1)
|
|
|
1.83
|
|
|
|
1.76
|
|
|
|
1.75
|
|
|
|
1.61
|
|
|
|
1.88
|
|
|
|
2.01
|
|
|
|
1.69
|
|
|
|
|
(1) |
|
For purposes of this computation, earnings are defined as income
before provision for income tax and discontinued operations and
excluding undistributed income and losses from equity method
investments, minority interest and fixed charges, excluding
capitalized interest. Fixed charges are the sum of interest and
debt issue costs, interest credited to policyholder account
balances, and an estimated interest component of rent expense.
MetLife, Inc. did not have any preferred stock outstanding prior
to the initial issuances of the (i) Floating Rate Note
Cumulative Preferred Stock, Series A, issued on
June 13, 2005; and (ii) 6.5% Non-Cumulative Preferred
Stock, Series B, issued on June 16, 2005. The
preferred stock dividends are included within the total fixed
charges to calculate the ratio of earnings to fixed charges and
preferred stock dividends. |
S-25
USE OF
PROCEEDS
We will not receive any of the proceeds from the remarketing.
Proceeds from the remarketing attributable to the Debentures
that are part of normal Units (i.e., Units
consisting, prior to the settlement of the remarketing, of a
1/80th interest in the Debentures and a stock purchase
contract), that participated in the remarketing will be used as
follows:
|
|
|
|
|
to pay the Remarketing Agents a remarketing fee not exceeding
0.35% of the principal attributable to the Debentures that are
part of normal Units that participated in the remarketing;
|
|
|
|
to satisfy the obligation of holders of normal Units to purchase
common stock of MetLife, Inc. under the stock purchase contract
on the date of settlement of the remarketing; and
|
|
|
|
any remaining portion, if any, of the proceeds will be remitted
for the benefit of holders of normal Units participating in the
remarketing.
|
See Relationship of the Common Equity Units to the
Remarketing.
S-26
CAPITALIZATION
The following table sets forth MetLifes historical and
unaudited pro forma capitalization (i) at
September 30, 2008, and (ii) as adjusted to give
effect to this remarketing of the Debentures and the settlement
of the related stock purchase contracts. The following data
should be read in connection with our consolidated financial
statements and notes, which are incorporated by reference.
|
|
|
|
|
|
|
|
|
|
|
September 30, 2008
|
|
|
|
Actual
|
|
|
As Adjusted
|
|
|
|
(In millions)
|
|
|
Short-term debt
|
|
$
|
1,106
|
|
|
$
|
1,106
|
|
Long-term debt (1)
|
|
|
10,811
|
|
|
|
11,846
|
|
Collateral financing arrangements
|
|
|
5,132
|
|
|
|
5,132
|
|
Junior subordinated debt securities
|
|
|
3,759
|
|
|
|
2,692
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
20,808
|
|
|
|
20,776
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity:
|
|
|
|
|
|
|
|
|
Preferred stock, at par value
|
|
|
1
|
|
|
|
1
|
|
Common stock, at par value (2)(3)
|
|
|
8
|
|
|
|
8
|
|
Additional paid-in capital (2)(3)
|
|
|
17,602
|
|
|
|
18,637
|
|
Retained earnings
|
|
|
22,041
|
|
|
|
22,041
|
|
Treasury stock, at cost (3)
|
|
|
(4,279
|
)
|
|
|
(4,279
|
)
|
Accumulated other comprehensive loss
|
|
|
(7,540
|
)
|
|
|
(7,540
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
27,833
|
|
|
|
28,868
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
48,641
|
|
|
$
|
49,644
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Reflects $1,035 million of Debentures. Related debt
remarketing costs of $4.1 million will be capitalized and
amortized until February 15, 2019. |
|
(2) |
|
Reflects 24,343,200 newly-issued shares of common stock to be
issued on February 17, 2009 to settle the stock purchase
contracts associated with the Units, at an issue price, as
defined by the stock purchase contracts, of $42.52 per share
($1,035 million). |
|
(3) |
|
Does not reflect the common stock issuance of 86,250,000 shares
by MetLife, Inc. on October 15, 2008 at a price of $26.50
per share for total gross proceeds of $2.3 billion. Of the
shares issued, 75,000,000 shares were issued from treasury stock. |
S-27
RELATIONSHIP
OF THE COMMON EQUITY UNITS TO THE REMARKETING
In June 2005, we issued 82,800,000 Units in a registered
offering. Each Unit initially consisted of a contract to
purchase shares of MetLife, Inc.s Common Stock in
accordance with the terms of the Unit, as well as a
1/80th or 1.25% undivided beneficial interest in a
Series A Trust Preferred Security and a 1/80th or
1.25% undivided beneficial ownership interest in a Series B
Trust Preferred Security. In August 2008, MetLife Capital
Trust II was dissolved and the underlying debt securities
distributed to holders of Series A Trust Preferred
Securities were remarketed. On February 5, 2009, in
accordance with the terms of the Amended and Restated
Declaration of Trust of MetLife Capital Trust III, dated
June 21, 2005 (the Declaration), we
dissolved the Trust and distributed 4.91% Junior Subordinated
Debt Securities, Series B, due 2040 to the holders of the
Series B Trust Preferred Securities. The Series B
Trust Preferred Securities represented undivided beneficial
ownership interest in the assets of the Trust, which consisted
solely of 4.91% Junior Subordinated Debt Securities,
Series B, due 2040, which are now being remarketed as the
Debentures. MetLife, Inc. solicited and obtained the consent of
a sufficient number of holders of Units in their capacity as
beneficial owners of the Series B Trust Preferred
Securities of the Trust to effect amendments to the Indenture to
allow for a remarketing of the Debentures in two or more
tranches. On February 6, 2009, MetLife, Inc. and The Bank
of New York Mellon Trust Company, N.A. entered into the
Seventh Supplemental Indenture, implementing those and certain
additional amendments to the Indenture. Under the terms of the
Units, MetLife, Inc. engaged the Remarketing Agents to remarket
the Debentures on behalf of the holders (other than those
holders who have elected not to participate in the remarketing),
pursuant to the Remarketing Agreement.
We will not receive any of the proceeds from the remarketing.
See Use of Proceeds. Pursuant to the Remarketing
Agreement, the Remarketing Agents will retain a remarketing fee
not exceeding 35 basis points (0.35%) of the total
principal amount of the remarketing of the Debentures. A portion
of the net proceeds of the remarketing of the Debentures
comprising part of normal Units (i.e., Units
consisting, prior to the settlement of the remarketing, of a
1/80th interest in the Debentures and a stock purchase
contract) will be used to satisfy the obligation of holders of
normal Units to purchase Common Stock of MetLife, Inc. under the
stock purchase contract on the date of settlement of the
remarketing. The remaining portion, if any, of the proceeds will
be remitted for the benefit of holders of normal Units
participating in the remarketing. The net proceeds attributable
to the remarketing of separate Debentures, if any, that
participated in the remarketing, will be remitted to the holders
of separate Debentures.
S-28
DESCRIPTION
OF THE REMARKETED DEBENTURES
A description of the specific terms of the Debentures of
MetLife, Inc. being offered in this remarketing is set forth
below. The description is qualified in its entirety by reference
to the Indenture, dated as of June 21, 2005 (the Base
Indenture), between MetLife, Inc. and The Bank of New York
Mellon Trust Company, N.A. (as successor in interest to
J.P. Morgan Trust Company, National Association), as
trustee (the Trustee), as supplemented by
(i) the Second Supplemental Indenture, dated as of
June 21, 2005 (the Second Supplemental
Indenture) and (ii) the Seventh Supplemental
Indenture, dated as of February 6, 2009 (the Seventh
Supplemental Indenture and together with the Base
Indenture and the Second Supplemental Indenture, the
Indenture) between MetLife, Inc. and the Trustee,
under which the Debentures have been issued. The Indenture has
been qualified as an indenture under the Trust Indenture
Act. The terms of the Indenture are those provided in the
Indenture and those made part of the Indenture by the
Trust Indenture Act. We have filed a copy of the Indenture
with the SEC under the Securities Exchange Act of 1934, as
amended, and the Indenture is incorporated by reference as an
exhibit to the registration statement of which this prospectus
supplement forms a part. In accordance with the terms of the
Indenture, in connection with the dissolution of the Trust, we
have entered into the Seventh Supplemental Indenture with the
Trustee, making provision for the remarketing and reset
mechanics on the basis set forth in the Declaration.
The following description of certain terms of the remarketed
Debentures and certain provisions of the Indenture in this
prospectus supplement supplements the description under
Description of Debt Securities in the accompanying
prospectus. To the extent that the following description is not
consistent with that contained in the accompanying prospectus
under Description of Debt Securities you should rely
on this description. This description is only a summary of the
material terms and does not purport to be complete. We urge you
to read the Indenture in its entirety because it, and not this
description, will define your rights as a beneficial holder of
the Debentures.
Overview
The aggregate principal amount of Debentures to be remarketed
pursuant to this prospectus supplement is $1,034,999,000.
The Debentures will mature on February 15, 2019.
The Debentures have been issued as a separate series of senior
debt securities under the Indenture, limited to $1,067,010,000
in aggregate principal amount. In connection with the
dissolution of the Trust, $32.01 million in aggregate
principal amount of the Debentures held by MetLife, Inc. has
been cancelled.
The Debentures are not subject to a sinking fund provision. The
entire principal amount of the Debentures will mature and become
due and payable, together with any accrued and unpaid interest
thereon, on February 15, 2019.
Because MetLife, Inc. is principally a holding company, its
right to participate in any distribution of assets of any
subsidiary, upon the subsidiarys liquidation or
reorganization or otherwise (and thus the ability of the holders
of Debentures to benefit indirectly from any such distribution),
is subject to the prior claims of creditors of the subsidiary,
except to the extent MetLife, Inc. may be recognized as a
creditor of that subsidiary. Accordingly, MetLife, Inc.s
obligations under the Debentures will be effectively
subordinated to all existing and future liabilities of its
subsidiaries, and claimants should look only to its assets for
payment thereunder. The Indenture does not limit the incurrence
or issuance of other secured or unsecured debt by MetLife, Inc.,
including senior debt. As of September 30, 2008, MetLife,
Inc. had $7.9 billion of senior debt outstanding and our
subsidiaries had $7.6 billion of total debt outstanding
(excluding intercompany liabilities).
Under specific limited circumstances, Debentures may be issued
in certificated form in exchange for a global security. In the
case that Debentures are issued in certificated form, these
Debentures will be in minimum denominations of $1,000 or any
integral multiple thereof and may be transferred or exchanged at
the offices described below. Payments on Debentures issued as a
global security will be made to the depositary, a successor
depositary or, in the case that no depositary is used, to a
paying agent for the Debentures. In the case that Debentures are
issued in certificated form, principal and interest will be
payable, the transfer of the Debentures will be registerable and
Debentures will be exchangeable for Debentures of other
denominations of a like aggregate principal amount, at the
corporate trust office or agency of the Trustee in New York, New
York. However, at our
S-29
option, payment of interest may be made by check mailed to the
address of the entitled holder or by wire transfer to an account
appropriately designated by the entitled holder.
The Indenture does not contain provisions that afford holders of
the Debentures protection in case we are involved in a highly
leveraged transaction or other similar transaction that may
adversely affect those holders.
Interest
and Maturity
Following the remarketing, the Debentures will bear interest
from February 15, 2009 at the rate of 7.717% per year,
payable semi-annually in arrears on February 15, and August
15 of each year, commencing August 15, 2009 and ending on
February 15, 2019. The interest rate on the Debentures was
reset by the Remarketing Agents as the rate determined to be
sufficient to result in proceeds from the remarketing of the
Debentures, net of the remarketing fee described under
Plan of Distribution, of 100% of the aggregate
principal amount, plus accrued and unpaid interest, if any, to
the remarketing settlement date, of the Debentures being
remarketed. Interest is payable to the person in whose name each
Debenture, is registered, subject to certain exceptions, at the
close of business on the Business Day (as defined below) next
preceding that interest payment date. If Debentures do not
remain in book-entry only form, we will have the right to select
record dates, which shall be more than one Business Day but less
than 60 Business Days prior to the interest payment date.
The amount of interest payable for any period will be computed
on the basis of a
360-day year
consisting of twelve
30-day
months. The amount of interest payable for any period shorter
than a full semi-annual period for which interest is computed
will be computed on the basis of the actual number of days
elapsed in that
180-day
period. In the case that any date on which interest is payable
on the Debentures is not a Business Day, then payment of the
interest payable on that date will be made on the next
succeeding day that is a Business Day, and no interest or other
payment shall be paid in respect of the delay. However, if that
Business Day is in the next succeeding calendar year, then that
payment shall be made on the immediately preceding Business Day,
in each case with the same force and effect as if made on that
date.
Business Day means any day other than a day
on which federal or state banking institutions in the Borough of
Manhattan, The City of New York, are authorized or obligated by
law, executive order or regulation to close.
No Option
to Defer Interest Payments
We will not have the right to defer the payment of interest on
the Debentures.
Restrictions
on Certain Payments
If there shall have occurred and be continuing any event that,
with the giving of notice or the lapse of time, or both, would
be an event of default with respect to the Debentures of which
we have actual knowledge and which we have not taken reasonable
steps to cure, then we shall not:
|
|
|
|
|
declare or pay any dividends or distributions on, or redeem,
purchase, acquire or make a liquidation payment with respect to,
any shares of our capital stock; or
|
|
|
|
make any payment of principal of, or interest premium, if any,
on, or repay, repurchase or redeem any other debt securities
issued by us that rank equally with or junior to the Debentures.
|
The restrictions listed in the first bullet point above do not
apply to:
|
|
|
|
|
any repurchase, redemption or other acquisition of shares of our
capital stock in connection with (1) any employment
contract, benefit plan or other similar arrangement with or for
the benefit of any one or more employees, officers, directors,
consultants or independent contractors, (2) a dividend
reinvestment or stockholder purchase plan, or (3) the
issuance of our capital stock, or securities convertible into or
exercisable for such capital stock, as consideration in an
acquisition transaction entered into prior to the applicable
event of default, default or extension period, as the case may
be;
|
S-30
|
|
|
|
|
any exchange, redemption or conversion of any class or series of
our capital stock, or the capital stock of one of our
subsidiaries, for any other class or series, of our capital
stock, or of any class or series of our indebtedness for any
class or series of our capital stock;
|
|
|
|
any purchase of, or payment of cash in lieu of, fractional
interests in shares of our capital stock pursuant to the
conversion or exchange provisions of such capital stock or the
securities being converted or exchanged;
|
|
|
|
any declaration of a dividend in connection with any rights
plan, or the issuance of rights, stock or other property under
any rights plan or the redemption or repurchase of rights
pursuant thereto; or
|
|
|
|
any dividend in the form of stock, warrants, options or other
rights where the dividend stock or stock issuable upon exercise
of such warrants, options or other rights is the same stock as
that on which the dividend is being paid or ranks equally with
or junior to such stock.
|
Optional
Redemption
The Debentures will be redeemable at MetLife, Inc.s option
in whole or in part, at any time, on or after February 15,
2011 (the Redemption Date), at a
redemption price equal to the greater of 100% of the principal
amount to be redeemed plus accrued and unpaid interest to the
date of redemption and the Make-Whole
Redemption Amount (as defined below).
As used in this section:
Make-Whole Redemption Amount means the
sum, as calculated by the Premium Calculation Agent, of the
present values of the remaining scheduled payments of principal
and interest thereon for the principal amount to be redeemed
(not including any portion of those payments of interest accrued
as of the date of redemption), discounted from their respective
scheduled payment dates to the date of redemption on a
semi-annual basis (assuming a
360-day year
consisting of twelve
30-day
months) at the Treasury Rate plus 50 basis points plus, in
each case, accrued and unpaid interest thereon to the date of
redemption.
For purposes of the preceding definitions:
|
|
|
|
|
Treasury Rate means, with respect to any
Redemption Date, the rate per annum equal to the semiannual
equivalent yield to maturity of the Comparable Treasury Issue,
calculated using a price for the Comparable Treasury Issue
(expressed as a percentage of its principal amount) equal
to the Comparable Treasury Price for such Redemption Date. The
Treasury Rate will be calculated on the third Business Day
preceding the Redemption Date.
|
|
|
|
Premium Calculation Agent means an investment
banking institution of national standing appointed by MetLife,
Inc.
|
|
|
|
Comparable Treasury Issue means the
U.S. Treasury security selected by the Premium Calculation
Agent as having a maturity comparable to the term remaining from
the Redemption Date to February 15, 2019 (the
Remaining Life) that would be utilized, at
the time of selection and in accordance with customary financial
practice, in pricing new issues of corporate debt securities of
comparable term.
|
|
|
|
Comparable Treasury Price means, with respect
to a Redemption Date (1) the average of five Reference
Treasury Dealer Quotations for such Redemption Date, after
excluding the highest and lowest Reference Treasury Dealer
Quotations, or (2) if the Premium Calculation Agent obtains
fewer than five such Reference Treasury Dealer Quotations, the
average of all such quotations.
|
|
|
|
Reference Treasury Dealers means (1)
Citigroup Global Markets Inc. and Morgan Stanley & Co.
Incorporated and their successors; provided,
however, that if any of the foregoing shall cease to be a
primary U.S. government securities dealer in New York City
(a Primary Treasury Dealer) MetLife, Inc.
will substitute therefore another Primary Treasury Dealer, and
(2) any other Primary Treasury Dealers selected by the
Premium Calculation Agent after consultation with MetLife, Inc.
|
|
|
|
Reference Treasury Dealer Quotations means,
with respect to each Reference Treasury Dealer and any
redemption date, the average, as determined by the Premium
Calculation Agent of the bid and ask prices for
|
S-31
|
|
|
|
|
the Comparable Treasury Issue (expressed in each case as a
percentage of its principal amount) quoted in writing to the
Premium Calculation Agent at 5:00 p.m., New York City time,
on the third Business Day preceding such redemption date.
|
Ranking
The Debentures are unsecured and rank equally in right of
payment with all of our other senior unsecured debt to the
extent provided in the Indenture.
Events of
Default
An event of default when used in the Indenture with
respect to the Debentures, means any of the following:
|
|
|
|
|
failure to pay any installment of interest when due and payable
(including any additional interest) on the Debentures and
continuance of such default for a period of 30 days or more;
|
|
|
|
failure to pay the principal of the Debentures when due, whether
at maturity, upon redemption or otherwise; or
|
|
|
|
certain events in bankruptcy, insolvency or reorganization of
MetLife, Inc. or appointment of a receiver, liquidator or
trustee of MetLife Bank, N.A., the banking subsidiary of MetLife.
|
If an event of default under the Indenture occurs and continues
with respect to the Debentures, the Trustee or the holders of at
least 25% in aggregate principal amount of the outstanding
Debentures may declare the entire principal of and all accrued
but unpaid interest on the outstanding Debentures to be due and
payable immediately. If such declaration occurs, the holders of
a majority of the aggregate principal amount of the outstanding
Debentures can, subject to certain conditions, rescind the
declaration.
The holders of a majority in aggregate principal amount of the
outstanding Debentures may, on behalf of all holders of the
outstanding Debentures waive any past default with respect to
the Debentures except:
|
|
|
|
|
a default in payment of principal or interest; or
|
|
|
|
a default under any provision of the Indenture which itself
cannot be modified or amended without the consent of the holders
of the Debentures.
|
The holders of a majority in principal amount of the Debentures
shall have the right to direct the time, method and place of
conducting any proceeding for any remedy available to the
Trustee under the Indenture.
We are required to file an officers certificate with the
Trustee each year that states, to the knowledge of the
certifying officer, whether or not any defaults exist under the
terms of the Indenture.
Book-Entry;
Delivery and Form
Following the remarketing the Debentures will be represented by
one or more fully registered global security certificates, each
of which is referred to in this prospectus supplement as a
Global Security. Each such Global Security
will be deposited with, or on behalf of, DTC and registered in
the name of DTC or a nominee thereof. Initial settlement for the
Debentures will be made in same day funds. No assurance can be
given as to the effect, if any, of settlement in immediately
available funds on trading activity in the Debentures. Unless
and until it is exchanged in whole or in part for Debentures in
definitive form, no Global Security may be transferred except as
a whole by DTC to a nominee of DTC or by a nominee of DTC to DTC
or another nominee of DTC or by DTC or any such nominee to a
successor of DTC or a nominee of such successor.
Except under limited circumstances, Debentures represented by
the Global Security will not be exchangeable for, and will not
otherwise be issuable as, Debentures in certificated form.
Investors may elect to hold interests in the Global Securities
through either DTC (in the United States) or through Clearstream
Banking, société anonyme, Luxembourg
(Clearstream) or Euroclear Bank S.A./N.V., as
operator of the Euroclear System (Euroclear),
if they are participants in such systems, or indirectly through
organizations which are participants in such systems.
Clearstream and Euroclear will hold interests on behalf of their
participants through customers securities accounts
S-32
in Clearstreams and Euroclears names on the books of
their respective depositaries, which in turn will hold such
interests in customers securities accounts in the
depositaries names on the books of DTC. Citibank, N.A.
will act as depositary for Clearstream and JPMorgan Chase Bank
N.A. will act as depositary for Euroclear.
Beneficial interests in the Debentures will be represented
through book-entry accounts of financial institutions acting on
behalf of Beneficial Owners (as defined below) as Direct and
Indirect Participants (as defined below) in DTC. So long as DTC,
or its nominee, is a registered owner of a Global Security, DTC
or its nominee, as the case may be, will be considered the sole
owner or holder of the Debentures represented by such Global
Security for all purposes under the Indenture. Except as
provided below, the actual owners of the Debentures represented
by a Global Security (the Beneficial Owners)
will not be entitled to have the Debentures represented by such
Global Security registered in their names, will not receive or
be entitled to receive physical delivery of the Debentures in
definitive form and will not be considered the owners or holders
thereof under the Indenture.
Accordingly, each person owning a beneficial interest in a
Global Security must rely on the procedures of DTC and, if such
person is not a participant of DTC (a
Participant), on the procedures of the
Participant through which such person owns its interest, to
exercise any rights of a holder of the Debentures. Under
existing industry practices, in the event that any action is
requested of holders of the Debentures or that an owner of a
beneficial interest that a holder is entitled to give or take
under the Indenture, DTC would authorize the Participants
holding the relevant beneficial interests to give or take such
action, and such Participants would authorize Beneficial Owners
owning through such Participants to give or take such action or
would otherwise act upon the instructions of Beneficial Owners.
The following is based on information furnished by DTC:
DTC will act as securities depositary for the Debentures. The
Debentures will be in fully registered securities registered in
the name of Cede & Co. (DTCs partnership
nominee). One or more Global Securities will initially represent
the Debentures and will be deposited with DTC.
DTC is a limited-purpose trust company organized under the New
York Banking Law, a banking organization within the
meaning of the New York Banking Law, a member of the Federal
Reserve System, a clearing corporation within the
meaning of the New York Uniform Commercial Code, and a
clearing agency registered pursuant to the
provisions of Section 17A of the Exchange Act. DTC holds
securities that its Participants deposit with DTC. DTC also
facilitates the settlement among Participants of securities
transactions, such as transfers and pledges, in deposited
securities through electronic computerized book-entry changes in
Participants accounts, thereby eliminating the need for
physical movement of securities certificates. Direct
Participants of DTC (Direct Participants)
include securities brokers and dealers, banks, trust companies,
clearing corporations and certain other organizations. DTC is
owned by a number of its Direct Participants and by The New York
Stock Exchange, Inc., the American Stock Exchange, Inc., and the
Financial Industry Regulatory Authority, Inc. (FINRA). Access to
DTCs system is also available to others such as securities
brokers and dealers, banks and trust companies that clear
through or maintain a custodial relationship with a Direct
Participant, either directly or indirectly (Indirect
Participants). The rules applicable to DTC and its
Participants are on file with the SEC.
Purchases of the Debentures under DTCs system must be made
by or through Direct Participants, which will receive a credit
for the Debentures on DTCs records. The ownership interest
of each Beneficial Owner is in turn to be recorded on the
records of Direct Participants and Indirect Participants.
Beneficial Owners will not receive written confirmation from DTC
of their purchase, but Beneficial Owners are expected to receive
written confirmations providing details of the transaction, as
well as periodic statements of their holdings, from the Direct
Participants or Indirect Participants through which such
Beneficial Owner entered into the transaction. Transfers of
ownership interests the Debentures are to be accomplished by
entries made on the books of Participants acting on behalf of
Beneficial Owners. Beneficial Owners will not receive
certificates representing their ownership interests in the
Debentures, except in the limited circumstances that may be
provided in the Indenture, as the case may be.
To facilitate subsequent transfers, all Debentures deposited
with DTC are registered in the name of DTCs partnership
nominee, Cede & Co. The deposit of the Debentures with
DTC and their registration in the name of Cede & Co.
effect no change in beneficial ownership. DTC has no knowledge
of the actual Beneficial Owners of the Debentures. DTCs
records reflect only the identity of the Direct Participants to
whose accounts such securities are
S-33
credited, which may or may not be the Beneficial Owners. The
Participants will remain responsible for keeping account of
their holdings on behalf of their customers.
Conveyance of notices and other communications by DTC to Direct
Participants, by Direct Participants to Indirect Participants,
and by Direct Participants and Indirect Participants to
Beneficial Owners will be governed by arrangements among them,
subject to any statutory or regulatory requirements as may be in
effect from time to time.
Neither DTC nor Cede & Co. will consent or vote with
respect to the Debentures. Under its usual procedures, DTC mails
an Omnibus Proxy to MetLife, Inc. as soon as possible after the
applicable record date. The Omnibus Proxy assigns
Cede & Co.s consenting or voting rights to those
Direct Participants to whose accounts securities are credited on
the applicable record date (identified in a listing attached to
the Omnibus Proxy).
Payments on the Debentures will be made in immediately available
funds to DTC. DTCs practice is to credit Direct
Participants accounts on the applicable payment date in
accordance with their respective holdings shown on DTCs
records unless DTC has reason to believe that it will not
receive payment on such date. Payments by Participants to
Beneficial Owners will be governed by standing instructions and
customary practices, as is the case with securities held for the
accounts of customers in bearer form or registered in
street name, and will be the responsibility of such
Participant and not of DTC, the Trustee or MetLife, Inc.,
subject to any statutory or regulatory requirements as may be in
effect from time to time. Any payment due to DTC on behalf of
Beneficial Owners is MetLife, Inc.s responsibility or the
responsibility of the applicable agent, disbursement of such
payments to Direct Participants shall be the responsibility of
DTC, and disbursement of such payments to the Beneficial Owners
shall be the responsibility of Direct Participants and Indirect
Participants.
DTC may discontinue providing its services as securities
depositary with respect to the Debentures at any time by giving
MetLife, Inc. or the applicable agent reasonable notice. Under
such circumstances, in the event that a successor securities
depositary is not obtained, offered security certificates are
required to be printed and delivered. MetLife, Inc. may decide
to discontinue use of the system of book-entry transfers through
DTC (or a successor securities depositary). In that event,
security certificates will be printed and delivered.
Clearstream advises that it is incorporated as a limited
liability company under the laws of Luxembourg. Clearstream was
formed in January 2000 by the merger of Cedel International and
Deutsche Börse Clearing and recently fully acquired by the
Deutsche Börse Group. Clearstream holds securities for its
participating organizations (Clearstream
Participants) and facilitates the clearance and
settlement of securities transactions between Clearstream
Participants through electronic book-entry changes in accounts
of Clearstream Participants, thereby eliminating the need for
physical movement of certificates. Clearstream Participants are
recognized financial institutions around the world, including
underwriters, securities brokers and dealers, banks, trust
companies and clearing corporations. In the United States,
Clearstream Participants are limited to securities brokers and
dealers and banks, and may include the underwriters. Indirect
access to Clearstream is also available to others, such as
banks, brokers, dealers and trust companies that clear through
or maintain a custodial relationship with a Clearstream
Participant either directly or indirectly. Clearstream is an
Indirect Participant in DTC. Clearstream provides to Clearstream
Participants, among other things, services for safekeeping,
administration, clearance and settlement of internationally
traded securities and securities lending and borrowing.
Clearstream interfaces with domestic securities markets in
several countries. Clearstream has established an electronic
bridge with Euroclear Bank S.A./N.V. to facilitate settlement of
trades between Clearstream and Euroclear.
Distributions with respect to the Debentures held beneficially
through Clearstream will be credited to cash accounts of
Clearstream Participants in accordance with its rules and
procedures, to the extent received by Clearstream.
Euroclear advises that it was created in 1968 to hold securities
for participants of Euroclear (Euroclear
Participants) and to clear and settle transactions
between Euroclear Participants through simultaneous electronic
book-entry delivery against payment, thereby eliminating the
need for physical movement of certificates and any risk from
lack of simultaneous transfers of securities and cash. Euroclear
includes various other services, including securities lending
and borrowing, and interfaces with domestic markets in several
countries. The Euroclear System is owned by Euroclear plc and
operated through a license agreement by Euroclear Bank
S.A./N.V., a bank incorporated under the laws of the Kingdom of
Belgium (the Euroclear Operator), under
contract with Euroclear
S-34
Clearance Systems S.C., a Belgian cooperative corporation (the
Cooperative). All operations are conducted by
the Euroclear Operator, and all Euroclear securities clearance
accounts and Euroclear cash accounts are accounts with the
Euroclear Operator, not the Cooperative. The Cooperative
establishes policy for Euroclear on behalf of Euroclear
Participants. Euroclear Participants include banks (including
central banks), securities brokers and dealers and other
professional financial intermediaries and may include the
underwriters. Indirect access to Euroclear is also available to
other firms that clear through or maintain a custodial
relationship with a Euroclear Participant, either directly or
indirectly.
The Euroclear Operator advises that it is regulated and examined
by the Belgian Banking and Finance Commission and the National
Bank of Belgium.
Securities clearance accounts and cash accounts with the
Euroclear Operator are governed by the Terms and Conditions
Governing Use of Euroclear and the related Operating Procedures
of the Euroclear System, and applicable Belgian law
(collectively, the Terms and Conditions). The
Terms and Conditions govern transfers of securities and cash
within Euroclear, withdrawals of securities and cash from
Euroclear, and receipts of payments with respect to securities
in Euroclear. All securities in Euroclear are held on a fungible
basis without attribution of specific certificates to specific
securities clearance accounts. The Euroclear Operator acts under
the Terms and Conditions only on behalf of Euroclear
Participants, and has no record of or relationship with persons
holding through Euroclear Participants.
Distributions with respect to the Debentures held beneficially
through Euroclear will be credited to the cash accounts of
Euroclear Participants in accordance with the Terms and
Conditions, to the extent received by DTC for Euroclear.
Global
Clearance and Settlement Procedures
Secondary market trading between the DTC Participants will occur
in the ordinary way in accordance with the DTCs rules and
will be settled in immediately available funds using DTCs
Same-Day
Funds Settlement System. Secondary market trading between
Clearstream Participants
and/or
Euroclear Participants will occur in the ordinary way in
accordance with the applicable rules and operating procedures of
Clearstream and Euroclear and will be settled using the
procedures applicable to conventional Eurobonds in immediately
available funds.
Cross-market transfers between persons holding directly or
indirectly through DTC on the one hand, and directly or
indirectly through Clearstream or Euroclear Participants, on the
other, will be effected in DTC in accordance with the DTC rules
on behalf of the relevant European international clearing system
by DTC in its capacity as U.S. depositary; however, such
cross-market transactions will require delivery of instructions
to the relevant European international clearing system by the
counterparty in such system in accordance with its rules and
procedures and within its established deadlines (European time).
The relevant European international clearing system will, if the
transaction meets its settlement requirements, deliver
instructions to DTC to take action to effect final settlement on
its behalf by delivering interests in the Debentures to or
receiving interests in the Debentures from DTC, and making or
receiving payment in accordance with normal procedures for
same-day
funds settlement applicable to DTC. Clearstream Participants and
Euroclear Participants may not deliver instructions directly to
DTC.
Because of time-zone differences, credits of interests in the
Debentures received in Clearstream or Euroclear as a result of a
transaction with a DTC Participant will be made during
subsequent securities settlement processing and will be credited
the Business Day following the DTC settlement date. Such credits
or any transactions involving interests in such Debentures
settled during such processing will be reported to the relevant
Euroclear or Clearstream Participants on such Business Day. Cash
received in Clearstream or Euroclear as a result of sales of
interests in the Debentures by or through a Clearstream
Participant or a Euroclear Participant to a DTC Participant will
be received with value on the DTC settlement date but will be
available in the relevant Clearstream or Euroclear cash account
only as of the Business Day following settlement in DTC.
Although DTC, Clearstream and Euroclear have agreed to the
foregoing procedures in order to facilitate transfers of the
Debentures among participants of DTC, Clearstream and Euroclear,
they are under no obligation to perform or continue to perform
such procedures and such procedures may be discontinued at any
time.
S-35
CERTAIN
UNITED STATES FEDERAL INCOME TAX CONSEQUENCES
The following is a discussion of certain United States federal
income tax consequences of the purchase, ownership and
disposition of Debentures to Holders (as defined below) who
purchase Debentures in the remarketing at the remarketing
offering price and hold the Debentures as capital assets. This
discussion is based upon the Internal Revenue Code of 1986, as
amended (the Code), the applicable
U.S. Treasury regulations (including temporary and proposed
U.S. Treasury regulations) issued thereunder, Internal
Revenue Service (IRS) rulings and
pronouncements and judicial decisions now in effect, all of
which are subject to change, possibly with retroactive effect.
This discussion does not purport to be a complete analysis of
all of the tax considerations that may be applicable to a
decision by Holders to acquire the Debentures in the remarketing
and does not address all aspects of United States federal income
taxation that may be relevant to Holders in light of their
particular circumstances, such as Holders who are subject to
special tax treatment (for example, (1) partnerships,
banks, regulated investment companies, insurance companies,
dealers in securities or currencies, tax-exempt organizations,
or certain former citizens or residents of the United States;
(2) persons holding Debentures as part of a straddle,
hedge, conversion transaction or other integrated investment,
and (3) persons whose functional currency is not the
U.S. dollar). In addition, the discussion does not address
alternative minimum taxes, U.S. federal estate or gift tax
consequences, or U.S. state, local or foreign taxes. If a
partnership (or other entity treated as a partnership for United
States federal income tax purposes) holds Debentures, the United
States federal income tax treatment of a partner generally will
depend upon the status of the partner and the activities of the
partnership. A partner of a partnership holding Debentures
should consult its tax advisor concerning the United States
federal, state, local, and foreign income and other tax
consequences.
Prospective investors are urged to consult their own tax
advisors with respect to the United States federal income tax
consequences of the purchase, ownership and disposition of
Debentures in light of their own particular circumstances, as
well as the effect of any state, local, foreign or other tax
laws.
For purposes of this discussion, the term
U.S. holder means a beneficial owner of
the Debentures that is, for United States federal income tax
purposes, (1) an individual citizen or resident of the
United States, (2) a corporation, or other entity treated
as a corporation for United States federal income tax purposes,
created or organized in or under the laws of the United States
or any state thereof or the District of Columbia, (3) an
estate, the income of which is subject to United States federal
income tax regardless of its source, or (4) a trust, if
(a) a court within the United States is able to exercise
primary supervision over its administration, and one or more
United States persons (as determined for United States federal
income tax purposes) have the authority to control all of its
substantial decisions or (b) the trust has a valid election
in effect under applicable U.S. Treasury regulations to be
treated as a U.S. person. For purposes of this discussion,
the term
Non-U.S. holder
means a beneficial owner of the Debentures that is not a
U.S. holder and U.S. holders and
Non-U.S. holders
shall be referred to collectively as Holders.
By purchasing the Debentures, Holders have agreed to treat the
Debenture as indebtedness for United States federal income tax
purposes. We expect to treat, and will report accordingly, the
Debentures in the same manner.
The purchase price of the Debentures sold in the remarketing
will include an amount of interest attributable to interest
accrued for the period prior to the remarketing. We believe that
the portion of the first interest payment received on the
Debentures that is equal to such amount should be treated as a
return of such pre-acquisition accrued interest, rather than as
interest payable on the Debentures as described below. If this
position is respected, as will be assumed for purposes of the
remainder of this discussion, our payment of such amounts would
not be treated as taxable income to you. You should consult your
own tax advisor concerning the tax treatment of any
pre-acquisition accrued interest on Debentures.
Tax
Consequences to U.S. Holders
Interest Income. Interest paid on the
Debentures will be taxable to U.S. holders as ordinary
interest income at the time it is received or accrued, depending
upon the method of tax accounting applicable to such
U.S. holder.
S-36
Sale, Exchange or Other Taxable Disposition of the
Debentures. U.S. holders of the Debentures
will generally recognize capital gain or loss upon the sale or
other taxable disposition of such indebtedness (except to the
extent such amount is attributable to accrued interest, which
will be taxable as ordinary interest income to the extent such
interest has not been previously included in income). The gain
or loss recognized by a U.S. holder will be equal to the
difference between the proceeds received in exchange for such
U.S. holders Debentures and such
U.S. holders adjusted United States federal income
tax basis in such Debentures. A U.S. holders adjusted
tax basis in the Debentures acquired in the remarketing will
equal the amount that such U.S. holder paid for the
Debentures (excluding amounts attributable to pre-acquisition
accrued interest). The gain or loss recognized on the sale or
other taxable disposition of the Debentures will be long-term
capital gain or loss if such debentures were held for more than
one year immediately prior to such disposition. Subject to
certain exceptions, long-term capital gains of individuals are
generally eligible for reduced rates of taxation. The
deductibility of capital losses is subject to limitations.
Tax
Consequences to
Non-U.S.
holders
Interest Income. Generally, payments of
interest on the Debentures to a
Non-U.S. holder
will be considered portfolio interest and will not
be subject to United States federal income or withholding tax,
provided that:
|
|
|
|
|
Such
Non-U.S. holder
does not actually (or constructively) own 10% or more of the
total combined voting power of all classes of our voting stock
within the meaning of the Code and the Treasury regulations, and
such holder is not a controlled foreign corporation that is
related to us through stock ownership;
|
|
|
|
Such
Non-U.S. holder
is not a bank for United States federal income tax purposes
whose receipt of interest is described in
Section 881(c)(3)(A) of the Code;
|
|
|
|
Interest on the Debentures is not contingent interest within the
meaning of Section 871(h)(4) (A) of the Code; and
|
|
|
|
Such
Non-U.S. holder
provides either (a) their name, address and certain other
information on an IRS
Form W-8BEN
(or a suitable substitute form), and certifies, under penalties
of perjury, that such holder is not a U.S. person or
(b) holds its Debentures through certain foreign
intermediaries or certain foreign partnerships and certain
special certification requirements are satisfied.
|
If a
Non-U.S. holder
cannot satisfy the requirements described above, payments of
interest will be subject to a 30% United States federal income
withholding tax unless a tax treaty applies or the interest
payments are effectively connected with the
Non-U.S. holders
conduct of a U.S. trade or business. If a tax treaty
applies to a
Non-U.S. holder
under these circumstances, such holder may be eligible for a
reduced rate of withholding. In order to claim any exemption
from or reduction in the 30% withholding tax under an applicable
treaty, such holder will need to provide a properly executed IRS
Form W-8BEN
(or suitable substitute form) claiming a reduction of or an
exemption from withholding under an applicable tax treaty.
Interest payments made on the Debentures that are effectively
connected with the
Non-U.S. holders
conduct of a U.S. trade or business (and where a tax treaty
applies, are attributable to a U.S. permanent establishment
of the
Non-U.S. holder)
are not subject to the 30% United States federal income
withholding tax, so long as such
Non-U.S. holder
provides a valid IRS
Form W-8ECI
(or an acceptable substitute form) certifying, under penalties
of perjury, that the holder is a
non-U.S. person
and the interest is effectively connected with the holders
conduct of a U.S. trade or business and is includable in
the holders gross income. Instead, such
Non-U.S. holder
will be subject to United States federal income tax on such
payment on a net income basis in the same manner as if such
holder were a U.S. holder. In addition, in certain
circumstances, if such
Non-U.S. holder
is a foreign corporation, such holder may be subject to a 30%
(or, if a tax treaty applies, such lower rate as may be
provided) branch profits tax on its effectively connected
earnings and profits for the taxable year, subject to certain
adjustments.
Sale, Exchange or Other Taxable Disposition of the
Debentures. Any gain realized on the sale or
other disposition of the Debentures by a
Non-U.S. holder
will generally not be subject to United States federal income
tax unless
S-37
|
|
|
|
|
Such gain or income is effectively connected with such
holders conduct of a trade or business in the United
States (and, where an applicable tax treaty so provides, is also
attributable to a U.S. permanent establishment maintained
by the holder); or
|
|
|
|
Such holder is an individual who is present in the United States
for 183 days or more in the taxable year of the disposition
and certain other conditions are met.
|
If the first bullet point above applies, the
Non-U.S. Holder
will generally be taxed on its net gain derived from the sale or
other disposition of the Debentures at the regular graduated
rates and in the manner applicable to U.S. holders and, if
the
Non-U.S. holder
is a foreign corporation, a 30% branch profits tax may also
apply (or, if a tax treaty applies, such lower rate as may be
provided thereunder).
If the second bullet point above applies, the
Non-U.S. Holder
will be subject to a 30% tax on gain derived from the sale or
disposition of the Debentures.
Backup
Withholding and Information Reporting
Unless a U.S. holder is an exempt recipient, such as a
corporation, payments made with respect to the Debentures may be
subject to information reporting and may also be subject to
United States federal backup withholding at the applicable rate
if a holder of the Debentures fails to comply with applicable
United States information reporting and certification
requirements.
Non-U.S. holders
may be required to comply with certain certification procedures
to establish that the holder is not a U.S. person in order
to avoid information reporting and backup withholding tax.
Backup withholding is not an additional tax. Any amounts so
withheld under the backup withholding rules may be allowed as a
credit against a Holders United States federal income tax
liability provided such Holder furnishes the required
information to the IRS.
THE PRECEDING DISCUSSION OF CERTAIN MATERIAL UNITED STATES
FEDERAL INCOME TAX CONSEQUENCES IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT BEING PROVIDED AS, OR INTENDED TO
CONSTITUTE, TAX ADVICE. ACCORDINGLY, YOU SHOULD CONSULT YOUR OWN
TAX ADVISOR AS TO THE PARTICULAR TAX CONSEQUENCES TO YOU OF
PURCHASING, HOLDING OR DISPOSING OF THE DEBENTURES, INCLUDING
THE APPLICABILITY AND EFFECT OF ANY STATE, LOCAL, FOREIGN OR
OTHER TAX LAWS, AND OF ANY CHANGES OR PROPOSED CHANGES IN
APPLICABLE LAW.
S-38
PLAN OF
DISTRIBUTION
The remarketing is being conducted pursuant to the Remarketing
Agreement. Under the Remarketing Agreement, the Remarketing
Agents have agreed to use their commercially reasonable efforts
to remarket the Debentures at a price which results in proceeds,
net of the remarketing fees described below, of at least 100% of
the aggregate principal amount of the Debentures being
remarketed, plus accrued and unpaid interest, if any, to the
remarketing settlement date.
The Remarketing Agents will use a portion of the net proceeds of
the remarketing of Debentures comprising a part of
normal units (i.e., Units consisting, prior
to the settlement of the remarketing, of a 1/80th interest
in the Debentures and a stock purchase contract):
|
|
|
|
|
to pay the Remarketing Agents a remarketing fee not exceeding
35 basis points (0.35%) of the total principal of the sale
of the Debentures, that are part of normal Units that
participated in the remarketing;
|
|
|
|
to satisfy the obligation of holders of normal Units to purchase
common stock of MetLife, Inc. under the stock purchase contract
on the date of settlement of the remarketing; and
|
|
|
|
any remaining portion, if any, of the proceeds will be remitted
for the benefit of holders of normal Units participating in the
remarketing.
|
The Remarketing Agents will retain a total remarketing fee not
exceeding 35 basis points (0.35%) of the total principal of
the sale of the Debentures. Neither we nor the holders of
Debentures participating in this remarketing will otherwise be
responsible for any remarketing fee or commission in connection
with this remarketing.
We have been advised by the Remarketing Agents that they propose
initially to remarket the Debentures to investors at the price
to the public set forth on the cover page of this prospectus
supplement.
The Debentures have no established trading market. The
Remarketing Agents have advised us that they intend to make a
market for the Debentures, but they have no obligation to do so
and may discontinue market making at any time without providing
any notice. No assurance can be given as to the liquidity of any
trading market for the Debentures.
To facilitate the remarketing of the Debentures, the Remarketing
Agents may engage in transactions that stabilize, maintain or
otherwise affect the price of the Debentures. These transactions
consist of bids or purchases for the purpose of pegging, fixing
or maintaining the price of the Debentures. In general,
purchases of a security for the purpose of stabilization could
cause the price of the security to be higher than it might be in
the absence of these purchases. We and the Remarketing Agents
make no representation or prediction as to the direction or
magnitude of any effect that the transactions described above
may have on the price of the debentures. In addition, we and the
Remarketing Agents make no representation that the Remarketing
Agents will engage in these transactions or that these
transactions, once commenced, will not be discontinued without
notice.
We have agreed to indemnify the Remarketing Agents against, or
to contribute to payments that the Remarketing Agents may be
required to make in respect of, certain liabilities, including
liabilities under the Securities Act of 1933, as amended.
Each of the Remarketing Agents has in the past provided, and may
in the future provide, investment banking and underwriting
services to us and our affiliates for which it has received, or
will receive, customary compensation.
Standard Chartered Bank is not a U.S. registered
broker-dealer and, therefore, does not intend to effect any
sales of the Debentures in the United States.
OFFERING
RESTRICTIONS
The Debentures are offered for sale in those jurisdictions in
the United States, Asia, Europe and elsewhere where it is lawful
to make such offers. No action has been taken, or will be taken,
which would permit a public offering of the Debentures in any
jurisdiction outside the United States.
S-39
Each of the Remarketing Agents has severally represented and
agreed that it has not offered, sold or delivered and it will
not offer, sell or deliver or indirectly, any of the Debentures,
in or from any jurisdiction except under circumstances that are
reasonably designed to result in compliance with the applicable
laws and regulations thereof.
United
States of America
The Debentures may not be acquired or held by any person who is
an employee benefit plan or other plan or arrangement subject to
Title I of the Employee Retirement Income Security Act of
1974, as amended (ERISA), or
Section 4975 of the Code, or who is acting on behalf of or
investing the assets of any such plan or arrangement, unless the
acquisition and holding of the Debentures by such person will
not result in a non-exempt prohibited transaction under
Section 406 of ERISA or Section 4975 of the Code.
European
Economic Area
In relation to each member state of the European Economic Area
which has implemented the Prospectus Directive (each, a
relevant member state), each Remarketing
Agent represents that it has not made and will not make an offer
of the Debentures to the public in that relevant member state,
except that it may make an offer of the Debentures to the public
in that relevant member state at any time under the following
exemptions under the Prospectus Directive (as defined below), if
they have been implemented in that relevant member state:
(i) to legal entities which are authorized or regulated to
operate in the financial markets or, if not so authorized or
regulated, whose corporate purpose is solely to invest in
securities; (ii) to any legal entity which has two or more
of (1) an average of at least 250 employees during the
last financial year; (2) a total balance sheet of more than
43,000,000 and (3) an annual net turnover of more
than 50,000,000, as shown in its last annual or
consolidated accounts; (iii) to fewer than 100 natural or
legal persons (other than qualified investors as defined in the
Prospectus Directive) subject to obtaining the prior consent of
the joint book-running managers for any such offer; or
(iv) in any other circumstances falling within
Article 3(2) of the Prospectus Directive, provided that no
such offer of Debentures shall result in a requirement for the
publication by us or any Remarketing Agent of a prospectus
pursuant to Article 3 of the Prospectus Directive.
For the purposes of this section, the expression an offer
of the Debentures to the public in relation to any
Debentures in any relevant member state means the communication
in any form and by any means of sufficient information on the
terms of the offer and the Debentures to be offered so as to
enable an investor to decide to purchase or subscribe to
purchase the Debentures, as the same may be varied in that
member state by any measure implementing the Prospectus
Directive in that member state, and references to the
Prospectus Directive means Directive 2003/71/EC and
includes any relevant implementing measure in each relevant
member state.
United
Kingdom
Each Remarketing Agent represents that, in connection with the
distribution of the Debentures, it has only communicated or
caused to be communicated and will only communicate or cause to
be communicated any invitation or inducement to engage in
investment activity (within the meaning of section 21 of
the Financial Services and Markets Act 2000, or the FSMA, of the
United Kingdom) received by it in connection with the issue or
sale of such Debentures or any investments representing the
Debentures in circumstances in which section 21(1) of the
FSMA does not apply to us and that it has complied and will
comply with all the applicable provisions of the FSMA with
respect to anything done by it in relation to any Debentures in,
from or otherwise involving the United Kingdom.
Hong
Kong
The Debentures may not be offered or sold by means of any
document other than (i) in circumstances which do not
constitute an offer to the public within the meaning of the
Companies Ordinance (Cap.32, Laws of Hong Kong), (ii) to
professional investors within the meaning of the
Securities and Futures Ordinance (Cap.571, Laws of Hong Kong)
and any rules made thereunder or (iii) in other
circumstances which do not result in the document being a
prospectus within the meaning of the Companies
Ordinance (Cap.32, Laws of Hong Kong), and no advertisement,
invitation or document relating to the Debentures may be issued
or may be in the possession of any person for
S-40
the purpose of issue (in each case whether in Hong Kong or
elsewhere), which is directed at, or the contents of which are
likely to be accessed or read by, the public in Hong Kong
(except if permitted to do so under the laws of Hong Kong) other
than with respect to Debentures which are or are intended to be
disposed of only to persons outside Hong Kong or only to
professional investors within the meaning of the
Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong)
and any rules made thereunder.
Japan
The Debentures have not been and will not be registered under
the Financial Instruments and Exchange Law of Japan (the
Securities and Exchange Law) and each Remarketing Agent has
agreed that it will not offer or sell any Debentures, directly
or indirectly, in Japan or to, or for the benefit of, any
resident of Japan (which term as used herein means any person
resident in Japan, including any corporation or other entity
organized under the laws of Japan), or to others for re-offering
or resale, directly or indirectly, in Japan or to a resident of
Japan, except pursuant to an exemption from the registration
requirements of, and otherwise in compliance with, the Financial
Instruments and Exchange Law and any other applicable laws,
regulations and ministerial guidelines of Japan.
Singapore
This prospectus supplement and the accompanying prospectus have
not been registered as a prospectus with the Monetary Authority
of Singapore. Accordingly, this prospectus supplement, the
accompanying prospectus and any other document or material in
connection with the offer or sale, or invitation for
subscription or purchase, of the Debentures may not be
circulated or distributed, nor may the Debentures be offered or
sold, or be made the subject of an invitation for subscription
or purchase, whether directly or indirectly, to persons in
Singapore other than (i) to an institutional investor under
Section 274 of the Securities and Futures Act,
Chapter 289 of Singapore, or the SFA, (ii) to a
relevant person, or any person pursuant to Section 275(1A),
and in accordance with the conditions, specified in
Section 275 of the SFA or (iii) otherwise pursuant to,
and in accordance with the conditions of, any other applicable
provision of the SFA.
Where the Debentures are subscribed or purchased under
Section 275 by a relevant person which is: (a) a
corporation (which is not an accredited investor) the sole
business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of
whom is an accredited investor; or (b) a trust (where the
trustee is not an accredited investor) whose sole purpose is to
hold investments and each beneficiary is an accredited investor,
shares, debentures and units of shares and debentures of that
corporation or the beneficiaries rights and interest in
that trust shall not be transferable for 6 months after
that corporation or that trust has acquired the Debentures under
Section 275 except: (1) to an institutional investor
under Section 274 of the SFA or to a relevant person, or
any person pursuant to Section 275(1A), and in accordance
with the conditions, specified in Section 275 of the SFA;
(2) where no consideration is given for the transfer; or
(3) by operation of law.
S-41
LEGAL
OPINIONS
Unless otherwise indicated in this prospectus supplement, the
validity of the Debentures remarketed hereby will be passed upon
for MetLife, Inc. by Matthew M. Ricciardi, Chief Counsel, Public
Company and Corporate Law Section, of MetLife Group, Inc., an
affiliate of MetLife, Inc. and by Dewey & LeBoeuf LLP.
Mr. Ricciardi is paid a salary by MetLife, is a participant
in various employee benefit plans offered by MetLife to
employees generally, holds MetLife, Inc. common stock and has
options to purchase shares of MetLife, Inc. common stock.
Dewey & LeBoeuf LLP maintains various group and other
insurance policies with Metropolitan Life Insurance Company.
Dewey & LeBoeuf LLP has, from time to time,
represented, currently represents, and may continue to
represent, some or all of the Remarketing Agents in connection
with various legal matters. Skadden, Arps, Slate,
Meagher & Flom LLP will pass upon certain legal
matters for the Remarketing Agents. Skadden, Arps, Slate,
Meagher & Flom LLP has, from time to time,
represented, currently represents, and may continue to
represent, MetLife, Inc. and its affiliates in connection with
various legal matters. Skadden, Arps, Slate, Meagher &
Flom LLP maintains a group life insurance policy and short- and
long-term disability insurance policies with Metropolitan Life
Insurance Company.
EXPERTS
The consolidated financial statements and financial statement
schedules, incorporated by reference in this prospectus
supplement from MetLife, Inc. and subsidiaries Current
Report on
Form 8-K
dated November 14, 2008, and the effectiveness of MetLife,
Inc. and subsidiaries internal control over financial
reporting for the year ended December 31, 2007, have been
audited by Deloitte & Touche LLP, an independent
registered public accounting firm, as stated in their reports
(which (1) express an unqualified opinion on the
consolidated financial statements and financial statement
schedules and include an explanatory paragraph regarding changes
in MetLife, Inc.s method of accounting for deferred
acquisition costs and for income taxes as required by accounting
guidance adopted on January 1, 2007, and its method of
accounting for defined benefit pension and other postretirement
plans as required by accounting guidance adopted on
December 31, 2006, and (2) express an unqualified
opinion on MetLife and subsidiaries effectiveness of
internal control over financial reporting), which are
incorporated herein by reference. Such consolidated financial
statements and financial statement schedules have been so
incorporated in reliance upon the reports of such firm given
upon their authority as experts in accounting and auditing.
S-42
PROSPECTUS
METLIFE, INC.
DEBT SECURITIES, PREFERRED
STOCK, DEPOSITARY SHARES,
COMMON STOCK, WARRANTS,
PURCHASE CONTRACTS AND UNITS
METLIFE CAPITAL
TRUST V
METLIFE CAPITAL
TRUST VI
METLIFE CAPITAL
TRUST VII
METLIFE CAPITAL
TRUST VIII
METLIFE CAPITAL
TRUST IX
TRUST PREFERRED
SECURITIES
Fully and Unconditionally
Guaranteed by MetLife, Inc.,
As Described in this Prospectus
and the Accompanying Prospectus Supplement
MetLife, Inc., or any of the trusts named above, may offer these
securities, or any combination thereof, from time to time in
amounts, at prices and on other terms to be determined at the
time of the offering. MetLife, Inc., or any of the trusts named
above, will provide the specific terms of these securities in
supplements to this prospectus. You should read this prospectus
and the accompanying prospectus supplement carefully before you
make your investment decision.
THIS PROSPECTUS MAY NOT BE USED TO SELL SECURITIES UNLESS
ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.
MetLife, Inc., or any of the trusts named above, may offer
securities through underwriting syndicates managed or co-managed
by one or more underwriters, through agents, or directly to
purchasers. The prospectus supplement for each offering of
securities will describe in detail the plan of distribution for
that offering. For general information about the distribution of
securities offered, please see Plan of Distribution
in this prospectus.
MetLife, Inc.s common stock is listed on the New York
Stock Exchange under the trading symbol MET. Unless
otherwise stated in this prospectus or an accompanying
prospectus supplement, none of these securities will be listed
on a securities exchange, other than MetLife, Inc.s common
stock.
MetLife, Inc., or any of the trusts named above, or any of their
respective affiliates may use this prospectus and the applicable
prospectus supplement in a remarketing or other resale
transaction involving the securities after their initial sale.
These transactions may be executed at negotiated prices that are
related to market prices at the time of purchase or sale, or at
other prices, as determined from time to time.
Investing in our securities or the securities of the trusts
involves risk. See Risk Factors on page 1 of this
prospectus.
None of the Securities and Exchange Commission, any state
securities commission, the New York Superintendent of Insurance
or any other regulatory body has approved or disapproved of
these securities or determined if this prospectus or the
accompanying prospectus supplement is truthful or complete. They
have not made, nor will they make, any determination as to
whether anyone should buy these securities. Any representation
to the contrary is a criminal offense.
The date of this prospectus is November 6, 2007
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
5
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
15
|
|
|
|
|
21
|
|
|
|
|
23
|
|
|
|
|
24
|
|
|
|
|
25
|
|
|
|
|
26
|
|
|
|
|
28
|
|
|
|
|
31
|
|
|
|
|
32
|
|
|
|
|
32
|
|
ABOUT
THIS PROSPECTUS
Unless otherwise stated or the context otherwise requires,
references in this prospectus to MetLife,
we, our, or us refer to
MetLife, Inc., and its direct and indirect subsidiaries, while
references to MetLife, Inc. refer only to MetLife,
Inc. on an unconsolidated basis. References in this prospectus
to the trusts refer to MetLife Capital Trust V,
MetLife Capital Trust VI, MetLife Capital Trust VII,
MetLife Capital Trust VIII and MetLife Capital
Trust IX.
This prospectus is part of a registration statement that
MetLife, Inc. and the trusts filed with the U.S. Securities
and Exchange Commission (the SEC) using a
shelf registration process. Under this shelf
process, MetLife, Inc. may, from time to time, sell any
combination of debt securities, preferred stock, depositary
shares, common stock, warrants, purchase contracts and units and
the trusts may, from time to time, sell trust preferred
securities guaranteed by MetLife, Inc., as described in this
prospectus, in one or more offerings in one or more foreign
currencies, foreign currency units or composite currencies. This
prospectus provides you with a general description of the
securities MetLife, Inc. and the trusts may offer. Each time
that securities are sold, a prospectus supplement that will
contain specific information about the terms of that offering
will be provided. The prospectus supplement may also add, update
or change information contained in this prospectus. You should
read both this prospectus and any prospectus supplement together
with additional information described under the heading
Where You Can Find More Information.
You should rely on the information contained or incorporated by
reference in this prospectus. Neither MetLife, Inc. nor the
trusts have authorized anyone to provide you with different
information. If anyone provides you with different or
inconsistent information, you should not rely on it. Neither
MetLife, Inc. nor the trusts are making an offer to sell these
securities in any jurisdiction where the offer or sale is not
permitted.
You should assume that the information in this prospectus is
accurate as of the date of the prospectus. Our business,
financial condition, results of operations and prospects may
have changed since that date.
RISK
FACTORS
Investing in MetLife, Inc. securities or the securities of the
trusts involve risks. You should carefully consider the risks
described in our filings with the SEC referred to under the
heading Where You Can Find More Information,
referenced in Special Note Regarding Forward-Looking
Statements below, as well as those included in any
prospectus supplement hereto. For example, MetLife, Inc.s
Annual Report on
Form 10-K
for the year ended December 31, 2006 contains a discussion
of significant risks under the heading Risk Factors
which could be relevant to your investment in the securities.
Subsequent filings with the SEC may contain amended and updated
discussions of significant risks.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the accompanying prospectus supplement may
contain or incorporate by reference information that includes or
is based upon forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements give expectations or forecasts of
future events. You can identify these statements by the fact
that they do not relate strictly to historical or current facts.
They use words such as anticipate,
estimate, expect, project,
intend, plan, believe, and
other words and terms of similar meaning in connection with a
discussion of future operating or financial performance. In
particular, these include statements relating to future actions,
prospective services or products, future performance or results
of current and anticipated services or products, sales efforts,
expenses, the outcome of contingencies such as legal
proceedings, trends in operations and financial results.
Any or all forward-looking statements may turn out to be wrong.
They can be affected by inaccurate assumptions or by known or
unknown risks and uncertainties. Many such factors will be
important in determining MetLifes actual future results.
These statements are based on current expectations and the
current economic environment. They involve a number of risks and
uncertainties that are difficult to predict. These statements
are not guarantees of future performance, and there are no
guarantees about the performance of any securities offered by
1
this prospectus. Actual results could differ materially from
those expressed or implied in the forward-looking statements.
Risks, uncertainties and other factors that might cause such
differences include the risks, uncertainties and other factors
identified in our filings with the SEC referred to under the
heading Where You Can Find More Information,
including those identified under Risk Factors above.
These factors include:
|
|
|
|
|
changes in general economic conditions, including the
performance of financial markets and interest rates;
|
|
|
|
heightened competition, including with respect to pricing, entry
of new competitors, the development of new products by new and
existing competitors and for personnel;
|
|
|
|
investment losses and defaults;
|
|
|
|
unanticipated changes in industry trends;
|
|
|
|
catastrophe losses;
|
|
|
|
ineffectiveness of risk management policies and procedures;
|
|
|
|
changes in accounting standards, practices and/or policies;
|
|
|
|
changes in assumptions related to deferred policy acquisition
costs (DAC), value of business acquired or goodwill;
|
|
|
|
discrepancies between actual claims experience and assumptions
used in setting prices for our products and establishing the
liabilities for our obligations for future policy benefits and
claims;
|
|
|
|
discrepancies between actual experience and assumptions used in
establishing liabilities related to other contingencies or
obligations;
|
|
|
|
adverse results or other consequences from litigation,
arbitration or regulatory investigations;
|
|
|
|
downgrades in our and our affiliates claims paying
ability, financial strength or credit ratings;
|
|
|
|
regulatory, legislative or tax changes that may affect the cost
of, or demand for, our products or services;
|
|
|
|
MetLife, Inc.s primary reliance, as a holding company, on
dividends from its subsidiaries to meet debt payment obligations
and the applicable regulatory restrictions on the ability of the
subsidiaries to pay such dividends;
|
|
|
|
deterioration in the experience of the closed block
established in connection with the reorganization of
Metropolitan Life Insurance Company;
|
|
|
|
economic, political, currency and other risks relating to our
international operations;
|
|
|
|
the effects of business disruption or economic contraction due
to terrorism or other hostilities;
|
|
|
|
our ability to identify and consummate on successful terms any
future acquisitions, and to successfully integrate acquired
businesses with minimal disruption;
|
|
|
|
other risks and uncertainties described from time to time in
MetLife, Inc.s or the trusts filings with the SEC;
|
|
|
|
the risk factors or uncertainties set forth herein or listed
from time to time in prospectus supplements or any document
incorporated by reference herein; and
|
|
|
|
other risks and uncertainties that have not been identified at
this time.
|
Neither MetLife, Inc. nor the trusts undertake any obligation to
publicly correct or update any forward-looking statement if any
of MetLife, Inc. or the trusts later become aware that it is not
likely to be achieved. You are advised, however, to consult any
further disclosures MetLife, Inc. or the trusts make on related
subjects in reports to the SEC.
WHERE YOU
CAN FIND MORE INFORMATION
MetLife, Inc. files reports, proxy statements and other
information with the SEC. These reports, proxy statements and
other information, including the registration statement of which
this prospectus is a part, can be read and copied at the
SECs public reference room at 100 F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at
2
1-800-SEC-0330
for further information on the operation of the public reference
room. The SEC maintains an internet site at www.sec.gov that
contains reports, proxy and information statements and other
information regarding companies that file electronically with
the SEC, including MetLife, Inc. MetLife, Inc.s common
stock is listed and traded on the New York Stock Exchange under
the symbol MET. These reports, proxy statements and
other information can also be read at the offices of the New
York Stock Exchange, 11 Wall Street, New York, New York
10005.
The SEC allows incorporation by reference into this
prospectus of information that MetLife, Inc. files with the SEC.
This permits MetLife, Inc. to disclose important information to
you by referencing these filed documents. Any information
referenced this way is considered part of this prospectus, and
any information filed with the SEC subsequent to the date of
this prospectus will automatically be deemed to update and
supersede this information. Information furnished under
Item 2.02 and Item 7.01 of MetLife, Inc.s
Current Reports on
Form 8-K
is not incorporated by reference in this registration statement
and prospectus. MetLife, Inc. incorporates by reference the
following documents which have been filed with the SEC:
|
|
|
|
|
Registration Statement on
Form 8-A,
dated March 31, 2000, relating to registration of shares of
MetLife, Inc.s common stock and Registration Statement on
Form 8-A, dated March 31, 2000, relating to
registration of MetLife, Inc.s Series A Junior
Participating Preferred Stock purchase rights;
|
|
|
|
Annual Report on
Form 10-K
for the year ended December 31, 2006;
|
|
|
|
Quarterly Reports on
Form 10-Q
for the quarters ended March 31, 2007, June 30, 2007
and September 30, 2007; and
|
|
|
|
Current Reports on
Form 8-K
filed January 22, 2007, February 16, 2007,
March 5, 2007, May 15, 2007, May 25, 2007,
June 25, 2007, August 15, 2007, August 28, 2007,
September 26, 2007 and October 24, 2007.
|
MetLife, Inc. incorporates by reference the documents listed
above and any future filings made with the SEC in accordance
with Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934 until MetLife, Inc. and the trusts file a
post-effective amendment which indicates the termination of the
offering of the securities made by this prospectus. Any reports
filed by us with the SEC after the date of this prospectus and
before the date that the offering of the securities by means of
this prospectus is terminated will automatically update and,
where applicable, supersede any information contained in this
prospectus or incorporated by reference in this prospectus.
MetLife, Inc. will provide without charge upon written or oral
request, a copy of any or all of the documents which are
incorporated by reference into this prospectus, other than
exhibits to those documents, unless those exhibits are
specifically incorporated by reference into those documents.
Requests should be directed to Investor Relations, MetLife,
Inc., 1 MetLife Plaza, Long Island City, New York 11101 by
electronic mail (metir@metlife.com) or by telephone
(212-578-2211).
You may also obtain some of the documents incorporated by
reference into this document at MetLifes website,
www.metlife.com. You should be aware that all other information
contained on MetLifes website is not a part of this
document.
METLIFE,
INC.
We are a leading provider of insurance and other financial
services with operations throughout the United States and the
regions of Latin America, Europe and Asia Pacific. Through our
domestic and international subsidiaries and affiliates, we offer
life insurance, annuities, automobile and homeowners insurance,
retail banking and other financial services to individuals, as
well as group insurance, reinsurance, and retirement &
savings products and services to corporations and other
institutions.
We are one of the largest insurance and financial services
companies in the Unites States. Our franchises and brand names
uniquely position us to be the preeminent provider of protection
and savings and investment products in the Unites States. In
addition, our international operations are focused on markets
where the demand for insurance and savings and investment
products is expected to grow rapidly in the future.
As a holding company, the primary source of MetLife, Inc.s
liquidity is dividends it receives from its insurance
subsidiaries. MetLife, Inc.s insurance subsidiaries are
subject to regulatory restrictions on the payment of dividends
3
imposed by the regulators of their respective domiciles. The
dividend limitation for U.S. insurance subsidiaries is based on
the surplus to policyholders as of the immediately preceding
calendar year and statutory net gain from operations of the
immediately preceding calendar year. Statutory accounting
practices, as prescribed by insurance regulators of various
states in which we conduct business, differ in certain respects
from accounting principles used in financial statements prepared
in conformity with GAAP. The significant differences related to
the treatment of DAC, certain deferred income tax, required
investment reserves, reserve calculation assumptions, goodwill
and surplus notes.
MetLife, Inc. is incorporated under the laws of the State of
Delaware. MetLife, Inc.s principal executive offices are
located at 200 Park Avenue, New York, New York 10166-0188,
and its telephone number is
212-578-2211.
THE
TRUSTS
MetLife Capital Trust V, MetLife Capital Trust VI,
MetLife Capital Trust VII, MetLife Capital Trust VIII
and MetLife Capital Trust IX are statutory trusts formed on
October 31, 2007 under Delaware law pursuant to
declarations of trust between the trustees named therein and
MetLife, Inc. and the filing of certificates of trust with the
Secretary of State of the State of Delaware. MetLife, Inc., as
sponsor of the trusts, and the trustees named in the
declarations of trust will amend and restate the declarations of
trust in their entirety substantially in the forms which are
incorporated by reference as exhibits to the registration
statement of which this prospectus forms a part, as of or prior
to the date the trusts issue any trust preferred securities. The
declarations of trust will be qualified as indentures under the
Trust Indenture Act of 1939, as amended (the Trust
Indenture Act).
The trusts exist for the exclusive purposes of:
|
|
|
|
|
issuing preferred securities offered by this prospectus and
common securities to MetLife, Inc.;
|
|
|
|
investing the gross proceeds of the preferred securities and
common securities in related series of debt securities, which
may be senior or subordinated, issued by MetLife, Inc.; and
|
|
|
|
engaging in only those other activities which are necessary,
appropriate, convenient or incidental to the purposes set forth
above.
|
The payment of periodic cash distributions on the trust
preferred securities and payments on liquidation and redemption
with respect to the trust preferred securities, in each case to
the extent the trusts have funds legally and immediately
available, will be guaranteed by MetLife, Inc. to the extent set
forth under Description of Guarantees.
MetLife, Inc. will own, directly or indirectly, all of the
common securities of the trusts. The common securities will
represent an aggregate liquidation amount equal to at least 3%
of each trusts total capitalization. The preferred
securities of each trust will represent the remaining 97% of
each trusts total capitalization. The common securities
will have terms substantially identical to, and will rank equal
in priority of payment with, the preferred securities. However,
if MetLife, Inc. defaults on the related series of debt
securities, then cash distributions and liquidation, redemption
and other amounts payable on the common securities will be
subordinate to the trust preferred securities in priority of
payment.
The trusts each have a term of approximately 55 years, but
may dissolve earlier as provided in their respective
declarations of trust. The trusts activities will be
conducted by the trustees appointed by MetLife, Inc., as the
direct or indirect holder of all of the common securities. The
holder of the common securities of each trust will be entitled
to appoint, remove or replace any of, or increase or reduce the
number of, the trustees of the trust. However, the number of
trustees shall be at least three, at least one of which shall be
an administrative trustee. The duties and obligations of the
trustees will be governed by the declaration of trust for each
trust. A majority of the trustees of each trust will be persons
who are employees or officers of or affiliated with MetLife,
Inc. One trustee of each trust will be a financial institution
which will be unaffiliated with MetLife, Inc. and which will act
as property trustee and as indenture trustee for purposes of the
Trust Indenture Act, pursuant to the terms set forth in a
prospectus supplement. In addition, unless the property trustee
maintains a principal place of business in the State of
Delaware,
4
and otherwise meets the requirements of applicable law, one
trustee of each trust will have its principal place of business
or reside in the State of Delaware.
The property trustee will hold title to the debt securities for
the benefit of the holders of the trust securities and the
property trustee will have the power to exercise all rights,
powers and privileges under the indenture as the holder of the
debt securities. In addition, the property trustee will maintain
exclusive control of a segregated non-interest bearing bank
account to hold all payments made in respect of the debt
securities for the benefit of the holders of the trust
securities. The property trustee will make payments of
distributions and payments on liquidation, redemption and
otherwise to the holders of the trust securities out of funds
from this property account.
The rights of the holders of the trust preferred securities,
including economic rights, rights to information and voting
rights, are provided in the declarations of trust of MetLife
Capital Trust V, MetLife Capital Trust VI, MetLife
Capital Trust VII, MetLife Capital Trust VIII and
MetLife Capital Trust IX, including any amendments thereto,
the trust preferred securities, the Delaware Statutory
Trust Act and the Trust Indenture Act.
MetLife, Inc. will pay all fees and expenses related to the
trusts and the offering of trust preferred securities. The
principal offices of each trust is: The Bank of New York
(Delaware), 100 White Clay Center, Route 273, Newark,
Delaware 19711, Attention: Corporate Trust Administration. The
telephone number of each trust is:
302-283-8905.
Please read the prospectus supplement relating to the trust
preferred securities for further information concerning the
trusts and the trust preferred securities.
USE OF
PROCEEDS
We may use the proceeds of securities sold or re-sold under this
registration statement for, among other things, general
corporate purposes. The prospectus supplement for each offering
of securities will specify the intended use of the proceeds of
that offering. Unless otherwise indicated in an accompanying
prospectus supplement, the trusts will use all of the proceeds
they receive from the sale of trust preferred securities to
purchase debt securities issued by MetLife, Inc.
RATIO OF
EARNINGS TO FIXED CHARGES
AND RATIO OF EARNINGS TO FIXED CHARGES AND PREFERRED STOCK
DIVIDENDS
The following table sets forth our historical ratio of earnings
to fixed
charges(1)
for the periods indicated:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
2002
|
|
|
Ratio of Earnings to Fixed Charges
|
|
|
1.80
|
|
|
|
1.72
|
|
|
|
1.67
|
|
|
|
1.92
|
|
|
|
2.03
|
|
|
|
1.73
|
|
|
|
1.47
|
|
Ratio of Earnings to Fixed Charges and Preferred Stock Dividends
|
|
|
1.78
|
|
|
|
1.70
|
|
|
|
1.65
|
|
|
|
1.90
|
|
|
|
2.03
|
|
|
|
1.73
|
|
|
|
1.47
|
|
|
|
(1) |
For purposes of this computation, earnings are defined as income
before provision for income tax and discontinued operations and
excluding undistributed income and losses from equity method
investments, minority interest and fixed charges, excluding
capitalized interest. Fixed charges are the sum of interest and
debt issue costs, interest credited to policyholder account
balances, and an estimated interest component of rent expense.
We did not have any preferred stock outstanding prior to the
initial issuances of our (i) Floating Rate Non-Cumulative
Preferred Stock, Series A, issued on June 13, 2005;
and (ii) 6.50% Non-Cumulative Preferred Stock,
Series B, issued on June 16, 2005. The preferred stock
dividends are included within the total fixed charges to
calculate the ratio of earnings to fixed charges and preferred
stock dividends.
|
DESCRIPTION
OF SECURITIES
This prospectus contains summary descriptions of the debt
securities, preferred stock, depositary shares, common stock,
warrants, purchase contracts and units that MetLife, Inc. may
sell from time to time, and the trust
5
preferred securities guaranteed by MetLife, Inc. that the trusts
may sell from time to time. These summary descriptions are not
meant to be complete descriptions of each security. However,
this prospectus and the accompanying prospectus supplement
contain the material terms of the securities being offered.
DESCRIPTION
OF DEBT SECURITIES
As used in this prospectus, debt securities means the
debentures, notes, bonds and other evidences of indebtedness
that MetLife, Inc. may issue from time to time. The debt
securities will either be senior debt securities or subordinated
debt securities. Unless the applicable prospectus supplement
states otherwise, senior debt securities will be issued under
the Senior Indenture dated as of November 9, 2001 between
MetLife, Inc, and Bank One Trust Company, N.A. (predecessor to
The Bank of New York Trust Company, N.A.) (the Senior
Indenture) and subordinated debt securities will be issued
under the Subordinated Indenture dated as of June 21, 2005
between MetLife, Inc. and J.P. Morgan Trust Company, National
Association (predecessor to The Bank of New York Trust Company,
N.A.) (the Subordinated Indenture). This prospectus
sometimes refers to the Senior Indenture and the Subordinated
Indenture collectively as the Indentures.
The Senior Indenture and the Subordinated Indenture are
incorporated by reference as exhibits to the registration
statement of which this prospectus forms a part. The statements
and descriptions in this prospectus or in any prospectus
supplement regarding provisions of the Indentures and debt
securities are summaries thereof, do not purport to be complete
and are subject to, and are qualified in their entirety by
reference to, all of the provisions of the Indentures and the
debt securities, including the definitions therein of certain
terms.
General
The debt securities will be direct unsecured obligations of
MetLife, Inc. The senior debt securities will rank equally with
all of MetLife, Inc.s other senior and unsubordinated
debt. The subordinated debt securities will be subordinate and
junior in right of payment to all of MetLife, Inc.s
present and future senior indebtedness.
Because MetLife, Inc. is principally a holding company, its
right to participate in any distribution of assets of any
subsidiary, including Metropolitan Life Insurance Company, upon
the subsidiarys liquidation or reorganization or
otherwise, is subject to the prior claims of creditors of the
subsidiary, except to the extent MetLife, Inc. may be recognized
as a creditor of that subsidiary. Accordingly, MetLife,
Inc.s obligations under the debt securities will be
effectively subordinated to all existing and future indebtedness
and liabilities of its subsidiaries, including liabilities under
contracts of insurance and annuities written by MetLife,
Inc.s insurance subsidiaries, and holders of debt
securities should look only to MetLife, Inc.s assets for
payment thereunder.
The Indentures do not limit the aggregate principal amount of
debt securities that MetLife, Inc. may issue and provide that
MetLife, Inc. may issue debt securities from time to time in one
or more series, in each case with the same or various
maturities, at par or at a discount. MetLife, Inc. may issue
additional debt securities of a particular series without the
consent of the holders of the debt securities of such series
outstanding at the time of the issuance. Any such additional
debt securities, together with all other outstanding debt
securities of that series, will constitute a single series of
debt securities under the applicable Indenture. The Indentures
also do not limit our ability to incur other debt.
Each prospectus supplement will describe the terms relating to
the specific series of debt securities being offered. These
terms will include some or all of the following:
|
|
|
|
|
the title of debt securities and whether they are subordinated
debt securities or senior debt securities;
|
|
|
|
any limit on the aggregate principal amount of the debt
securities;
|
|
|
|
the price or prices at which MetLife, Inc. will sell the debt
securities;
|
|
|
|
the maturity date or dates of the debt securities;
|
|
|
|
the rate or rates of interest, if any, which may be fixed or
variable, per annum at which the debt securities will bear
interest, or the method of determining such rate or rates, if
any;
|
6
|
|
|
|
|
the date or dates from which any interest will accrue, the dates
on which interest will be payable, or the method by which such
date or dates will be determined;
|
|
|
|
the right, if any, to extend the interest payment periods and
the duration of any such deferral period, including the maximum
consecutive period during which interest payment periods may be
extended;
|
|
|
|
whether the amount of payments of principal of (and premium, if
any) or interest on the debt securities may be determined with
reference to any index, formula or other method, such as one or
more currencies, commodities, equity indices or other indices,
and the manner of determining the amount of such payments;
|
|
|
|
the dates on which MetLife, Inc. will pay interest on the debt
securities and the regular record date for determining who is
entitled to the interest payable on any interest payment date;
|
|
|
|
the place or places where the principal of (and premium, if any)
and interest on the debt securities will be payable;
|
|
|
|
if MetLife, Inc. possesses the option to do so, the periods
within which and the prices at which MetLife, Inc. may redeem
the debt securities, in whole or in part, pursuant to optional
redemption provisions, and the other terms and conditions of any
such provisions;
|
|
|
|
MetLife, Inc.s obligation, if any, to redeem, repay or
purchase debt securities by making periodic payments to a
sinking fund or through an analogous provision or at the option
of holders of the debt securities, and the period or periods
within which and the price or prices at which MetLife, Inc. will
redeem, repay or purchase the debt securities, in whole or in
part, pursuant to such obligation, and the other terms and
conditions of such obligation;
|
|
|
|
the denominations in which the debt securities will be issued,
if other than denominations of $1,000 and integral multiples of
$1,000;
|
|
|
|
the portion, or methods of determining the portion, of the
principal amount of the debt securities which MetLife, Inc. must
pay upon the acceleration of the maturity of the debt securities
in connection with an Event of Default (as described below), if
other than the full principal amount;
|
|
|
|
the currency, currencies or currency unit in which MetLife, Inc.
will pay the principal of (and premium, if any) or interest, if
any, on the debt securities, if not United States dollars and
the manner of determining the equivalent thereof in United
States dollars;
|
|
|
|
provisions, if any, granting special rights to holders of the
debt securities upon the occurrence of specified events;
|
|
|
|
any deletions from, modifications of or additions to the Events
of Default or MetLife, Inc.s covenants with respect to the
applicable series of debt securities, and whether or not such
Events of Default or covenants are consistent with those
contained in the applicable Indenture;
|
|
|
|
the application, if any, of the terms of the Indenture relating
to defeasance and covenant defeasance (which terms are described
below) to the debt securities;
|
|
|
|
whether the subordination provisions summarized below or
different subordination provisions will apply to the debt
securities;
|
|
|
|
the terms, if any, upon which the holders may or are required to
convert or exchange such debt securities into or for MetLife,
Inc.s common stock or other securities or property or into
securities of a third party, including conversion price (which
may be adjusted), the method of calculating the conversion
price, or the conversion period;
|
|
|
|
whether any of the debt securities will be issued in global or
certificated form and, if so, the terms and conditions upon
which global debt securities may be exchanged for certificated
debt securities;
|
|
|
|
any change in the right of the trustee or the requisite holders
of debt securities to declare the principal amount thereof due
and payable because of an Event of Default;
|
7
|
|
|
|
|
the depositary for global or certificated debt securities;
|
|
|
|
if applicable, a discussion of the U.S. federal income tax
considerations applicable to specific debt securities;
|
|
|
|
any trustees, authenticating or paying agents, transfer agents
or registrars or other agents with respect to the debt
securities; and
|
|
|
|
any other terms of the debt securities not inconsistent with the
provisions of the Indentures, as amended or supplemented.
|
Unless otherwise specified in the applicable prospectus
supplement, the debt securities will not be listed on any
securities exchange.
Unless otherwise specified in the applicable prospectus
supplement, the debt securities will be issued in fully
registered form without coupons.
Debt securities may be sold at a substantial discount below
their stated principal amount, bearing no interest or interest
at a rate which at the time of issuance is below market rates.
The applicable prospectus supplement will describe the federal
income tax consequences and special considerations applicable to
any such debt securities. The debt securities may also be issued
as indexed securities or securities denominated in foreign
currencies or currency units, as described in more detail in the
prospectus supplement relating to any of the particular debt
securities. The prospectus supplement relating to specific debt
securities will also describe any special considerations and
certain additional tax considerations applicable to such debt
securities.
Subordination
The prospectus supplement relating to any offering of
subordinated debt securities will describe the specific
subordination provisions. However, unless otherwise noted in the
prospectus supplement, subordinated debt securities will be
subordinate and junior in right of payment to all of MetLife,
Inc.s Senior Indebtedness (as described below).
Under the Subordinated Indenture, Senior
Indebtedness means all amounts due on obligations in
connection with any of the following, whether outstanding at the
date of execution of the Subordinated Indenture or thereafter
incurred or created:
|
|
|
|
|
the principal of (and premium, if any) and interest in respect
of indebtedness of MetLife, Inc. for borrowed money and
indebtedness evidenced by securities, debentures, bonds or other
similar instruments issued by MetLife, Inc.;
|
|
|
|
all capital lease obligations of MetLife, Inc.;
|
|
|
|
all obligations of MetLife, Inc. issued or assumed as the
deferred purchase price of property, all conditional sale
obligations of MetLife, Inc. and all obligations of MetLife,
Inc. under any title retention agreement (but excluding trade
accounts payable in the ordinary course of business);
|
|
|
|
all obligations of MetLife, Inc. for the reimbursement on any
letter of credit, bankers acceptance, security purchase
facility or similar credit transaction;
|
|
|
|
all obligations of MetLife, Inc. in respect of interest rate
swap, cap or other agreements, interest rate future or options
contracts, currency swap agreements, currency future or option
contracts and other similar agreements;
|
|
|
|
all obligations of the types referred to above of other persons
for the payment of which MetLife, Inc. is responsible or liable
as obligor, guarantor or otherwise; and
|
|
|
|
all obligations of the types referred to above of other persons
secured by any lien on any property or asset of MetLife, Inc.
whether or not such obligation is assumed by MetLife, Inc.
|
8
Senior Indebtedness does not include:
|
|
|
|
|
indebtedness or monetary obligations to trade creditors created
or assumed by MetLife, Inc. in the ordinary course of business
in connection with the obtaining of materials or services;
|
|
|
|
indebtedness that is, by its terms, subordinated to, or ranks
equal with, the subordinated debt securities; and
|
|
|
|
any indebtedness of MetLife, Inc. to its affiliates (including
all debt securities and guarantees in respect of those debt
securities issued to any trust, partnership or other entity
affiliated with MetLife, Inc. that is a financing vehicle of
MetLife, Inc. in connection with the issuance by such financing
entity of preferred securities or other securities guaranteed by
MetLife, Inc.) unless otherwise expressly provided in the terms
of any such indebtedness.
|
At both September 30, 2007 and December 31, 2006,
Senior Indebtedness aggregated approximately $7.0 billion.
The amount of Senior Indebtedness which MetLife, Inc. may issue
is subject to limitations imposed by its board of directors.
Senior Indebtedness shall continue to be Senior Indebtedness and
be entitled to the benefits of the subordination provisions
irrespective of any amendment, modification or waiver of any
term of such Senior Indebtedness.
Unless otherwise noted in the accompanying prospectus
supplement, if MetLife, Inc. defaults in the payment of any
principal of (or premium, if any) or interest on any Senior
Indebtedness when it becomes due and payable, whether at
maturity or at a date fixed for prepayment or by declaration or
otherwise, then, unless and until such default is cured or
waived or ceases to exist, MetLife, Inc. will make no direct or
indirect payment (in cash, property, securities, by set-off or
otherwise) in respect of the principal of or interest on the
subordinated debt securities or in respect of any redemption,
retirement, purchase or other requisition of any of the
subordinated debt securities.
In the event of the acceleration of the maturity of any
subordinated debt securities, the holders of all senior debt
securities outstanding at the time of such acceleration will
first be entitled to receive payment in full of all amounts due
on the senior debt securities before the holders of the
subordinated debt securities will be entitled to receive any
payment of principal (and premium, if any) or interest on the
subordinated debt securities.
If any of the following events occurs, MetLife, Inc. will pay in
full all Senior Indebtedness before it makes any payment or
distribution under the subordinated debt securities, whether in
cash, securities or other property, to any holder of
subordinated debt securities:
|
|
|
|
|
any dissolution or winding-up or liquidation or reorganization
of MetLife, Inc., whether voluntary or involuntary or in
bankruptcy, insolvency or receivership;
|
|
|
|
any general assignment by MetLife, Inc. for the benefit of
creditors; or
|
|
|
|
any other marshaling of MetLife, Inc.s assets or
liabilities.
|
In such event, any payment or distribution under the
subordinated debt securities, whether in cash, securities or
other property, which would otherwise (but for the subordination
provisions) be payable or deliverable in respect of the
subordinated debt securities, will be paid or delivered directly
to the holders of Senior Indebtedness in accordance with the
priorities then existing among such holders until all Senior
Indebtedness has been paid in full. If any payment or
distribution under the subordinated debt securities is received
by the trustee of any subordinated debt securities in
contravention of any of the terms of the Subordinated Indenture
and before all the Senior Indebtedness has been paid in full,
such payment or distribution or security will be received in
trust for the benefit of, and paid over or delivered and
transferred to, the holders of the Senior Indebtedness at the
time outstanding in accordance with the priorities then existing
among such holders for application to the payment of all Senior
Indebtedness remaining unpaid to the extent necessary to pay all
such Senior Indebtedness in full.
The Subordinated Indenture does not limit the issuance of
additional Senior Indebtedness.
If debt securities are issued to a trust in connection with the
issuance of trust preferred securities, such debt securities may
thereafter be distributed pro rata to the holders of such trust
securities in connection with the dissolution of such trust upon
the occurrence of certain events described in the applicable
prospectus supplement.
9
Restrictive
Covenants
Unless an accompanying prospectus supplement states otherwise,
the following restrictive covenants shall apply to each series
of senior debt securities:
Limitation on Liens. So long as any senior
debt securities are outstanding, neither MetLife, Inc. nor any
of its subsidiaries will create, assume, incur or guarantee any
debt which is secured by any mortgage, pledge, lien, security
interest or other encumbrance on any capital stock of:
|
|
|
|
|
Metropolitan Life Insurance Company;
|
|
|
|
any successor to substantially all of the business of
Metropolitan Life Insurance Company which is also a subsidiary
of MetLife, Inc.; or
|
|
|
|
any corporation (other than MetLife, Inc.) having direct or
indirect control of Metropolitan Life Insurance Company or any
such successor.
|
However, this restriction will not apply if the debt securities
then outstanding are secured at least equally and ratably with
the otherwise prohibited secured debt so long as it is
outstanding.
Limitations on Dispositions of Stock of Certain
Subsidiaries. So long as any senior debt
securities are outstanding and subject to the provisions of the
Senior Indenture regarding mergers, consolidations and sales of
assets, neither MetLife, Inc. nor any of its subsidiaries will
sell or otherwise dispose of any shares of capital stock (other
than preferred stock having no voting rights of any kind) of:
|
|
|
|
|
Metropolitan Life Insurance Company;
|
|
|
|
any successor to substantially all of the business of
Metropolitan Life Insurance Company which is also a subsidiary
of MetLife, Inc.; or
|
|
|
|
any corporation (other than MetLife, Inc.) having direct or
indirect control of Metropolitan Life Insurance Company or any
such successor;
|
except for, in each case:
|
|
|
|
|
a sale or other disposition of any of such stock to a
wholly-owned subsidiary of MetLife, Inc. or of such subsidiary;
or
|
|
|
|
a sale or other disposition of all of such stock for at least
fair value (as determined by MetLife, Inc.s board of
directors acting in good faith); or a sale or other disposition
required to comply with an order of a court or regulatory
authority of competent jurisdiction, other than an order issued
at MetLife, Inc.s request or the request of any of
MetLife, Inc.s subsidiaries.
|
Consolidation,
Merger, Sale of Assets and Other Transactions
(i) MetLife, Inc. may not merge with or into or consolidate
with another corporation or sell, assign, transfer, lease or
convey all or substantially all of its properties and assets to,
any other corporation other than a direct or indirect
wholly-owned subsidiary of MetLife, Inc., and (ii) no
corporation may merge with or into or consolidate with MetLife,
Inc. or, except for any direct or indirect wholly-owned
subsidiary of MetLife, Inc., sell, assign, transfer, lease or
convey all or substantially all of its properties and assets to
MetLife, Inc., unless:
|
|
|
|
|
MetLife, Inc. is the surviving corporation or the corporation
formed by or surviving such merger or consolidation or to which
such sale, assignment, transfer, lease or conveyance has been
made, if other than MetLife, Inc., has expressly assumed by
supplemental indenture all the obligations of MetLife, Inc.
under the debt securities, the Indentures, and any guarantees of
preferred securities or common securities issued by the trusts;
|
|
|
|
immediately after giving effect to such transaction, no default
or Event of Default has occurred and is continuing;
|
10
|
|
|
|
|
if at the time any preferred securities of the trusts are
outstanding, such transaction is not prohibited under the
applicable declaration of trust and the applicable preferred
securities guarantee of each trust; and
|
|
|
|
MetLife, Inc. delivers to the trustee an officers
certificate and an opinion of counsel, each stating that the
supplemental indenture complies with the applicable Indenture.
|
Events
of Default, Notice and Waiver
Unless an accompanying prospectus supplement states otherwise,
the following shall constitute Events of Default
under the Indentures with respect to each series of debt
securities:
|
|
|
|
|
MetLife, Inc.s failure to pay any interest on any debt
security of such series when due and payable, continued for
30 days;
|
|
|
|
MetLife, Inc.s failure to pay principal (or premium, if
any) on any debt security of such series when due, regardless of
whether such payment became due because of maturity, redemption,
acceleration or otherwise, or is required by any sinking fund
established with respect to such series;
|
|
|
|
MetLife, Inc.s failure to observe or perform any other of
its covenants or agreements with respect to such series for
90 days after MetLife, Inc. receives notice of such failure;
|
|
|
|
certain defaults with respect to MetLife, Inc.s debt which
result in a principal amount in excess of $100,000,000 becoming
or being declared due and payable prior to the date on which it
would otherwise have become due and payable (other than the debt
securities or non-recourse debt);
|
|
|
|
certain events of bankruptcy, insolvency or reorganization of
MetLife, Inc.; and
|
|
|
|
certain events of dissolution or winding-up of the trusts in the
event that debt securities are issued to the trusts or a trustee
of the trusts in connection with the issuance of securities by
the trusts.
|
If an Event of Default with respect to any debt securities of
any series outstanding under either of the Indentures shall
occur and be continuing, the trustee under such Indenture or the
holders of at least 25% in aggregate principal amount of the
debt securities of that series outstanding may declare, by
notice as provided in the applicable Indenture, the principal
amount (or such lesser amount as may be provided for in the debt
securities of that series) of all the debt securities of that
series outstanding to be due and payable immediately; provided
that, in the case of an Event of Default involving certain
events in bankruptcy, insolvency or reorganization, acceleration
is automatic; and, provided further, that after such
acceleration, but before a judgment or decree based on
acceleration, the holders of a majority in aggregate principal
amount of the outstanding debt securities of that series may,
under certain circumstances, rescind and annul such acceleration
if all Events of Default, other than the nonpayment of
accelerated principal, have been cured or waived. Upon the
acceleration of the maturity of original issue discount
securities, an amount less than the principal amount thereof
will become due and payable. Reference is made to the prospectus
supplement relating to any original issue discount securities
for the particular provisions relating to acceleration of
maturity thereof.
Any past default under either Indenture with respect to debt
securities of any series, and any Event of Default arising
therefrom, may be waived by the holders of a majority in
principal amount of all debt securities of such series
outstanding under such Indenture, except in the case of
(i) default in the payment of the principal of (or premium,
if any) or interest on any debt securities of such series, or
(ii) default in respect of a covenant or provision which
may not be amended or modified without the consent of the holder
of each outstanding debt security of such series affected.
The trustee is required, within 90 days after the
occurrence of a default (which is known to the trustee and is
continuing), with respect to the debt securities of any series
(without regard to any grace period or notice requirements), to
give to the holders of the debt securities of such series notice
of such default; provided, however, that, except in the case of
a default in the payment of the principal of (and premium, if
any) or interest, or in the payment of any sinking fund
installment, on any debt securities of such series, the trustee
shall be protected in withholding such notice if it in good
faith determines that the withholding of such notice is in the
interests of the holders of the debt securities of such series.
11
The trustee, subject to its duties during default to act with
the required standard of care, may require indemnification by
the holders of the debt securities of any series with respect to
which a default has occurred before proceeding to exercise any
right or power under the Indentures at the request of the
holders of the debt securities of such series. Subject to such
right of indemnification and to certain other limitations, the
holders of a majority in aggregate principal amount of the
outstanding debt securities of any series under either Indenture
may direct the time, method and place of conducting any
proceeding for any remedy available to the trustee, or
exercising any trust or power conferred on the trustee with
respect to the debt securities of such series.
No holder of a debt security of any series may institute any
action against MetLife, Inc. under either of the Indentures
(except actions for payment of overdue principal of (and
premium, if any) or interest on such debt security or for the
conversion or exchange of such debt security in accordance with
its terms) unless (i) the holder has given to the trustee
written notice of an Event of Default and of the continuance
thereof with respect to the debt securities of such series
specifying an Event of Default, as required under the applicable
Indenture, (ii) the holders of at least 25% in aggregate
principal amount of the debt securities of that series then
outstanding under such Indenture shall have requested the
trustee to institute such action and offered to the trustee
reasonable indemnity against the costs, expenses and liabilities
to be incurred in compliance with such request, and
(iii) the trustee shall not have instituted such action
within 60 days of such request.
MetLife, Inc. is required to furnish annually to the trustee
statements as to MetLife, Inc.s compliance with all
conditions and covenants under each Indenture.
Discharge,
Defeasance and Covenant Defeasance
If indicated in the applicable prospectus supplement, MetLife,
Inc. may discharge or defease its obligations under each
Indenture as set forth below.
MetLife, Inc. may discharge certain obligations to holders of
any series of debt securities issued under either the Senior
Indenture or the Subordinated Indenture which have not already
been delivered to the trustee for cancellation and which have
either become due and payable or are by their terms due and
payable within one year (or scheduled for redemption within one
year) by irrevocably depositing with the trustee cash or, in the
case of debt securities payable only in U.S. dollars,
U.S. government obligations (as defined in either
Indenture), as trust funds in an amount certified to be
sufficient to pay when due, whether at maturity, upon redemption
or otherwise, the principal of (and premium, if any) and
interest on such debt securities.
If indicated in the applicable prospectus supplement, MetLife,
Inc. may elect either (i) to defease and be discharged from
any and all obligations with respect to the debt securities of
or within any series (except as otherwise provided in the
relevant Indenture) (defeasance) or (ii) to be
released from its obligations with respect to certain covenants
applicable to the debt securities of or within any series
(covenant defeasance), upon the deposit with the
relevant Indenture trustee, in trust for such purpose, of money
and/or government obligations which, through the payment of
principal and interest in accordance with their terms, will
provide money in an amount sufficient, without reinvestment, to
pay the principal of (and premium, if any) or interest on such
debt securities to maturity or redemption, as the case may be,
and any mandatory sinking fund or analogous payments thereon. As
a condition to defeasance or covenant defeasance, MetLife, Inc.
must deliver to the trustee an opinion of counsel to the effect
that the holders of such debt securities will not recognize
income, gain or loss for federal income tax purposes as a result
of such defeasance or covenant defeasance and will be subject to
federal income tax on the same amounts and in the same manner
and at the same times as would have been the case if such
defeasance or covenant defeasance had not occurred. Such opinion
of counsel, in the case of defeasance under clause (i)
above, must refer to and be based upon a ruling of the Internal
Revenue Service or a change in applicable federal income tax law
occurring after the date of the relevant Indenture. In addition,
in the case of either defeasance or covenant defeasance,
MetLife, Inc. shall have delivered to the trustee (i) an
officers certificate to the effect that the relevant debt
securities exchange(s) have informed it that neither such debt
securities nor any other debt securities of the same series, if
then listed on any securities exchange, will be delisted as a
result of such deposit, and (ii) an officers
certificate and an opinion of counsel, each stating that all
conditions precedent with respect to such defeasance or covenant
defeasance have been complied with.
12
MetLife, Inc. may exercise its defeasance option with respect to
such debt securities notwithstanding its prior exercise of its
covenant defeasance option.
Modification
and Waiver
Under the Indentures, MetLife, Inc. and the applicable trustee
may supplement the Indentures for certain purposes which would
not materially adversely affect the interests or rights of the
holders of debt securities of a series without the consent of
those holders. MetLife, Inc. and the applicable trustee may also
modify the Indentures or any supplemental indenture in a manner
that affects the interests or rights of the holders of debt
securities with the consent of the holders of at least a
majority in aggregate principal amount of the outstanding debt
securities of each affected series issued under the Indenture.
However, the Indentures require the consent of each holder of
debt securities that would be affected by any modification which
would:
|
|
|
|
|
extend the fixed maturity of any debt securities of any series,
or reduce the principal amount thereof, or reduce the rate or
extend the time of payment of interest thereon, or reduce any
premium payable upon the redemption thereof;
|
|
|
|
reduce the amount of principal of an original issue discount
debt security or any other debt security payable upon
acceleration of the maturity thereof;
|
|
|
|
change the currency in which any debt security or any premium or
interest is payable;
|
|
|
|
impair the right to enforce any payment on or with respect to
any debt security;
|
|
|
|
adversely change the right to convert or exchange, including
decreasing the conversion rate or increasing the conversion
price of, any debt security (if applicable);
|
|
|
|
reduce the percentage in principal amount of outstanding debt
securities of any series, the consent of whose holders is
required for modification or amendment of the Indentures or for
waiver of compliance with certain provisions of the Indentures
or for waiver of certain defaults;
|
|
|
|
reduce the requirements contained in the Indentures for quorum
or voting; or
|
|
|
|
modify any of the above provisions.
|
If debt securities are held by a trust or a trustee of a trust,
a supplemental indenture that affects the interests or rights of
the holders of debt securities will not be effective until the
holders of not less than a majority in liquidation preference of
the preferred securities and common securities of the applicable
trust, collectively, have consented to the supplemental
indenture; provided, further, that if the consent of the holder
of each outstanding debt security is required, the supplemental
indenture will not be effective until each holder of the
preferred securities and the common securities of the applicable
trust has consented to the supplemental indenture.
The Indentures permit the holders of at least a majority in
aggregate principal amount of the outstanding debt securities of
any series issued under the Indenture which is affected by the
modification or amendment to waive MetLife, Inc.s
compliance with certain covenants contained in the Indentures.
Payment
and Paying Agents
Unless otherwise indicated in the applicable prospectus
supplement, payment of interest on a debt security on any
interest payment date will be made to the person in whose name a
debt security is registered at the close of business on the
record date for the interest.
Unless otherwise indicated in the applicable prospectus
supplement, principal, interest and premium on the debt
securities of a particular series will be payable at the office
of such paying agent or paying agents as MetLife, Inc. may
designate for such purpose from time to time. Notwithstanding
the foregoing, at MetLife, Inc.s option, payment of any
interest may be made by check mailed to the address of the
person entitled thereto as such address appears in the security
register.
Unless otherwise indicated in the applicable prospectus
supplement, a paying agent designated by MetLife, Inc. and
located in the Borough of Manhattan, The City of New York, will
act as paying agent for payments with
13
respect to debt securities of each series. All paying agents
initially designated by MetLife, Inc. for the debt securities of
a particular series will be named in the applicable prospectus
supplement. MetLife, Inc. may at any time designate additional
paying agents or rescind the designation of any paying agent or
approve a change in the office through which any paying agent
acts, except that MetLife, Inc. will be required to maintain a
paying agent in each place of payment for the debt securities of
a particular series.
All moneys paid by MetLife, Inc. to a paying agent for the
payment of the principal, interest or premium on any debt
security which remain unclaimed at the end of two years after
such principal, interest or premium has become due and payable
will be repaid to MetLife, Inc. upon request, and the holder of
such debt security thereafter may look only to MetLife, Inc. for
payment thereof.
Denominations,
Registrations and Transfer
Unless an accompanying prospectus supplement states otherwise,
debt securities will be represented by one or more global
certificates registered in the name of a nominee for The
Depository Trust Company (DTC). In such case, each
holders beneficial interest in the global securities will
be shown on the records of DTC and transfers of beneficial
interests will only be effected through DTCs records.
A holder of debt securities may only exchange a beneficial
interest in a global security for certificated securities
registered in the holders name if:
|
|
|
|
|
DTC notifies MetLife, Inc. that it is unwilling or unable to
continue serving as the depositary for the relevant global
securities or DTC ceases to maintain certain qualifications
under the Securities Exchange Act of 1934 and no successor
depositary has been appointed for 90 days; or
|
|
|
|
MetLife, Inc. determines, in its sole discretion and subject to
the procedures of DTC, that the global security shall be
exchangeable.
|
If debt securities are issued in certificated form, they will
only be issued in the minimum denomination specified in the
accompanying prospectus supplement and integral multiples of
such denomination. Transfers and exchanges of such debt
securities will only be permitted in such minimum denomination.
Transfers of debt securities in certificated form may be
registered at the trustees corporate office or at the
offices of any paying agent or trustee appointed by MetLife,
Inc. under the Indentures. Exchanges of debt securities for an
equal aggregate principal amount of debt securities in different
denominations may also be made at such locations.
Governing
Law
The Indentures and debt securities will be governed by, and
construed in accordance with, the internal laws of the State of
New York, without regard to its principles of conflicts of laws.
Relationship
with the Trustees
The trustee under the Indentures is The Bank of New York Trust
Company, N.A. (in the case of the Senior Indenture, as successor
to Bank One Trust Company, N.A., and in the case of the
Subordinated Indenture, as successor to J.P. Morgan Trust
Company, National Association). MetLife, Inc. and its
subsidiaries maintain ordinary banking and trust relationships
with a number of banks and trust companies, including the
trustee under the Indentures.
Conversion
or Exchange Rights
The prospectus supplement will describe the terms, if any, on
which a series of debt securities may be convertible into or
exchangeable for securities described in this prospectus. These
terms will include provisions as to whether conversion or
exchange is mandatory, at the option of the holder or at
MetLife, Inc.s option. These provisions may allow or
require the number of shares of MetLife, Inc.s common
stock or other securities to be received by the holders of such
series of debt securities to be adjusted.
14
DESCRIPTION
OF CAPITAL STOCK
MetLife, Inc.s authorized capital stock consists of:
|
|
|
|
|
200,000,000 shares of preferred stock, par value
$0.01 per share, of which 84,000,000 shares were
issued and outstanding as of September 30, 2007:
|
|
|
|
|
|
27,600,000 shares of Floating Rate Non-Cumulative Preferred
Stock, Series A (the Series A Preferred
Stock), of which 24,000,000 shares were issued and
outstanding as of September 30, 2007;
|
|
|
|
69,000,000 shares of 6.500% Non-Cumulative Preferred Stock,
Series B (the Series B Preferred Stock) of
which 60,000,000 shares were issued and outstanding as of
September 30, 2007; and
|
|
|
|
10,000,000 shares of Series A Junior Participating
Preferred Stock, par value $0.01 per share, of which no
shares were issued or outstanding as of the date of this
prospectus; and
|
|
|
|
|
|
3,000,000,000 shares of common stock, par value
$0.01 per share, of which 740,286,838 shares, as well
as the same number of rights to purchase shares of Series A
Junior Participating Preferred Stock pursuant to the stockholder
rights plan adopted by MetLife, Inc.s board of directors
on September 29, 1999, were outstanding as of
September 30, 2007. See Stockholder
Rights Plan for a description of the Series A Junior
Participating Preferred Stock. The remaining shares of
authorized and unissued common stock will be available for
future issuance without additional stockholder approval.
|
Common
Stock
Dividends. The holders of common stock, after
any preferences of holders of any preferred stock, are entitled
to receive dividends as determined by the board of directors.
The issuance of dividends will depend upon, among other factors
deemed relevant by MetLife, Inc.s board of directors,
MetLifes financial condition, results of operations, cash
requirements, future prospects and regulatory restrictions on
the payment of dividends by Metropolitan Life Insurance Company
and MetLife, Inc.s other subsidiaries. There is no
requirement or assurance that MetLife, Inc. will declare and pay
any dividends. In addition, (i) the certificates of
designation for the Series A Preferred Stock and the
Series B Preferred Stock, (ii) MetLife, Inc.s
6.40% Fixed-to-Floating Rate Junior Subordinated Debentures due
2066, and (iii) both series of junior subordinated debt
securities underlying MetLife, Inc.s common equity units,
all prohibit the declaration or payment of dividends or
distributions on common stock under certain circumstances. Under
the certificates of designation for the Series A Preferred
Stock and the Series B Preferred Stock, if dividends on
such securities are not paid, no dividends may be paid on the
common stock. Similarly, under the the 6.40% Fixed-to-Floating
Rate Junior Subordinated Debentures due 2066, under certain
circumstances, if interest is not paid in full on such
securities, whether because of an optional deferral or a trigger
event, subject to certain exceptions, than no dividends may be
paid on the common stock. The indenture governing the terms of
the junior subordinated debt securities underlying the common
equity units prohibits, during any period in which the payment
of interest on either series is deferred, or certain other
events have occurred, among other things, the declaration or
payment of any dividends or distributions on, the redemption,
purchase, acquisition of or making a liquidation payment with
respect to, any shares of capital stock.
Voting Rights. The holders of common stock are
entitled to one vote per share on all matters on which the
holders of common stock are entitled to vote and do not have any
cumulative voting rights.
Liquidation and Dissolution. In the event of
MetLife, Inc.s liquidation, dissolution or winding-up, the
holders of common stock are entitled to share equally and
ratably in MetLife, Inc.s assets, if any, remaining after
the payment of all of MetLife, Inc.s liabilities and the
liquidation preference of any outstanding class or series of
preferred stock.
Other Rights. The holders of common stock have
no preemptive, conversion, redemption or sinking fund rights.
The holders of shares of MetLife, Inc.s common stock are
not required to make additional capital contributions.
Transfer Agent and Registrar. The transfer
agent and registrar for MetLife, Inc.s common stock is
Mellon Investor Services LLC, successor to ChaseMellon
Shareholder Services, L.L.C.
15
Preferred
Stock
General. MetLife, Inc.s board of
directors has the authority to issue preferred stock in one or
more series and to fix the title and number of shares
constituting any such series and the designations, powers,
preferences, limitations and relative rights including offering
price, any dividend rights (including whether dividends will be
cumulative or non-cumulative), dividend rate, voting rights,
terms of any redemption, any redemption price or prices,
conversion or exchange rights and any liquidation preferences of
the shares constituting any series, without any further vote or
action by stockholders. The specific terms of the preferred
stock will be described in the prospectus supplement.
MetLife, Inc. has authorized 10,000,000 shares of
Series A Junior Participating Preferred Stock for issuance
in connection with its stockholder rights plan. See
Stockholder Rights Plan for a
description of the Series A Junior Participating Preferred
Stock.
Voting Rights. The Delaware General
Corporation Law provides that the holders of preferred stock
will have the right to vote separately as a class on any
proposal involving fundamental changes in the rights of holders
of such preferred stock. The prospectus supplement will describe
the voting rights, if any, of the preferred stock.
Conversion or Exchange. The prospectus
supplement will describe the terms, if any, on which the
preferred stock may be convertible into or exchangeable for
securities described in this prospectus. These terms will
include provisions as to whether conversion or exchange is
mandatory, at the option of the holder or at MetLife,
Inc.s option. These provisions may set forth the
conversion price, the method of determining the conversion price
and the conversion period and may allow or require the number of
shares of MetLife, Inc.s common stock or other securities
to be received by the holders of preferred stock to be adjusted.
Redemption. The prospectus supplement will
describe the obligation, if any, to redeem the preferred stock
in whole or in part at the times and at the redemption prices
set forth in the applicable prospectus supplement.
Unless otherwise indicated in the applicable prospectus
supplement, MetLife, Inc. may not purchase or redeem any of the
outstanding shares or any series of preferred stock unless full
cumulative dividends, if any, have been paid or declared and set
apart for payment upon all outstanding shares of any series of
preferred stock for all past dividend periods, and unless all of
MetLife, Inc.s matured obligations with respect to all
sinking funds, retirement funds or purchase funds for all series
of preferred stock then outstanding have been met.
Certain
Provisions in MetLife, Inc.s Certificate of Incorporation
and By-Laws and in Delaware and New York Law
A number of provisions of MetLife, Inc.s certificate of
incorporation and by-laws deal with matters of corporate
governance and rights of stockholders. The following discussion
is a general summary of selected provisions of MetLife,
Inc.s certificate of incorporation and by-laws and
regulatory provisions that might be deemed to have a potential
anti-takeover effect. These provisions may have the
effect of discouraging a future takeover attempt which is not
approved by MetLife, Inc.s board of directors but which
individual stockholders may deem to be in their best interests
or in which stockholders may receive a substantial premium for
their shares over then current market prices. As a result,
stockholders who might desire to participate in such a
transaction may not have an opportunity to do so. Such
provisions will also render the removal of the incumbent board
of directors or management more difficult. Some provisions of
the Delaware General Corporation Law and the New York Insurance
Law may also have an anti-takeover effect. The following
description of selected provisions of MetLife, Inc.s
certificate of incorporation and by-laws and selected provisions
of the Delaware General Corporation Law and the New York
Insurance Law is necessarily general and reference should be
made in each case to MetLife, Inc.s certificate of
incorporation and by-laws, which are incorporated by reference
as exhibits to the registration statement of which this
prospectus forms a part, and to the provisions of those laws.
Classified
Board of Directors and Removal of Directors
Pursuant to MetLife, Inc.s certificate of incorporation,
the directors are divided into three classes, as nearly equal in
number as possible, with each class having a term of three
years. The classes serve staggered terms, such that the term of
one class of directors expires each year. Any effort to obtain
control of MetLife, Inc.s board of
16
directors by causing the election of a majority of the board may
require more time than would be required without a staggered
election structure. MetLife, Inc.s certificate of
incorporation also provides that, subject to the rights of the
holders of any class of preferred stock, directors may be
removed only for cause at a meeting of stockholders by a vote of
a majority of the shares then entitled to vote. This provision
may have the effect of slowing or impeding a change in
membership of MetLife, Inc.s board of directors that would
effect a change of control.
Exercise
of Duties by Board of Directors
MetLife, Inc.s certificate of incorporation provides that
while the MetLife Policyholder Trust (as described below) is in
existence, each MetLife, Inc. director is required, in
exercising his or her duties as a director, to take the
interests of the trust beneficiaries into account as if they
were holders of the shares of common stock held in the trust,
except to the extent that any such director determines, based on
advice of counsel, that to do so would violate his or her duties
as a director under Delaware law.
Restriction
on Maximum Number of Directors and Filling of Vacancies on
MetLife, Inc.s Board of Directors
Pursuant to MetLife, Inc.s by-laws and subject to the
rights of the holders of any class of preferred stock, the
number of directors may be fixed and increased or decreased from
time to time by resolution of the board of directors, but the
board of directors will at no time consist of fewer than three
directors. Subject to the rights of the holders of any class of
preferred stock, stockholders can only remove a director for
cause by a vote of a majority of the shares entitled to vote, in
which case the vacancy caused by such removal may be filled at
such meeting by the stockholders entitled to vote for the
election of the director so removed. Any vacancy on the board of
directors, including a vacancy resulting from an increase in the
number of directors or resulting from a removal for cause where
the stockholders have not filled the vacancy, subject to the
rights of the holders of any class of preferred stock, may be
filled by a majority of the directors then in office, although
less than a quorum. If the vacancy is not so filled it will be
filled by the stockholders at the next annual meeting of
stockholders. The stockholders are not permitted to fill
vacancies between annual meetings, except where the vacancy
resulted from a removal for cause. These provisions give
incumbent directors significant authority that may have the
effect of limiting the ability of stockholders to effect a
change in management.
Advance
Notice Requirements for Nomination of Directors and Presentation
of New Business at Meetings of Stockholders; Action by Written
Consent
MetLife, Inc.s by-laws provide for advance notice
requirements for stockholder proposals and nominations for
director. In addition, pursuant to the provisions of both the
certificate of incorporation and the by-laws, action may not be
taken by written consent of stockholder. Rather, any action
taken by the stockholders must be effected at a duly called
meeting. Moreover, the stockholders do not have the power to
call a special meeting. Only the chief executive officer or the
secretary pursuant to a board resolution or, under some
circumstances, the president or a director who also is an
officer, may call a special meeting. These provisions make it
more difficult for a stockholder to place a proposal or
nomination on the meeting agenda and prohibit a stockholder from
taking action without a meeting, and therefore may reduce the
likelihood that a stockholder will seek to take independent
action to replace directors or with respect to other matters
that are not supported by management for stockholder vote.
Limitations
on Director Liability
MetLife, Inc.s certificate of incorporation contains a
provision that is designed to limit the directors
liability to the extent permitted by the Delaware General
Corporation Law and any amendments to that law. Specifically,
directors will not be held liable to MetLife, Inc. or its
stockholders for an act or omission in their capacity as a
director, except for liability as a result of:
|
|
|
|
|
a breach of the duty of loyalty to MetLife, Inc. or its
stockholders;
|
|
|
|
acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law;
|
17
|
|
|
|
|
payment of an improper dividend or improper repurchase of
MetLife, Inc.s stock under Section 174 of the
Delaware General Corporation Law; or
|
|
|
|
actions or omissions pursuant to which the director received an
improper personal benefit.
|
The principal effect of the limitation on liability provision is
that a stockholder is unable to prosecute an action for monetary
damages against a director of MetLife, Inc. unless the
stockholder can demonstrate one of the specified bases for
liability. This provision, however, does not eliminate or limit
director liability arising in connection with causes of action
brought under the federal securities laws. MetLife, Inc.s
certificate of incorporation also does not eliminate the
directors duty of care. The inclusion of the limitation on
liability provision in the certificate may, however, discourage
or deter stockholders or management from bringing a lawsuit
against directors for a breach of their fiduciary duties, even
though such an action, if successful, might otherwise have
benefited MetLife, Inc. and its stockholders. This provision
should not affect the availability of equitable remedies such as
injunction or rescission based upon a directors breach of
the duty of care.
MetLife, Inc.s by-laws also provide that MetLife, Inc.
indemnify its directors and officers to the fullest extent
permitted by Delaware law. MetLife, Inc. is required to
indemnify its directors and officers for all judgments, fines,
settlements, legal fees and other expenses reasonably incurred
in connection with pending or threatened legal proceedings
because of the directors or officers position with
MetLife, Inc. or another entity, including Metropolitan Life
Insurance Company, that the director or officer serves at
MetLife, Inc.s request, subject to certain conditions, and
to advance funds to MetLife, Inc.s directors and officers
to enable them to defend against such proceedings. To receive
indemnification, the director or officer must succeed in the
legal proceeding or act in good faith and in a manner reasonably
believed to be in or not opposed to the best interests of
MetLife, Inc. and with respect to any criminal action or
proceeding, in a manner he or she reasonably believed to be
lawful.
Supermajority
Voting Requirement for Amendment of Certain Provisions of the
Certificate of Incorporation and By-Laws
Some of the provisions of MetLife, Inc.s certificate of
incorporation, including those that authorize the board of
directors to create stockholder rights plans, that set forth the
duties, election and exculpation from liability of directors and
that prohibit stockholders from taking actions by written
consent, may not be amended, altered, changed or repealed unless
the amendment is approved by the vote of holders of 75% of the
then outstanding shares entitled to vote at an election of
directors. This requirement exceeds the majority vote of the
outstanding stock that would otherwise be required by the
Delaware General Corporation Law for the repeal or amendment of
such provisions of the certificate of incorporation. MetLife,
Inc.s by-laws may be amended, altered or repealed by the
board of directors or by the vote of holders of 75% of the then
outstanding shares entitled to vote in the election of
directors. These provisions make it more difficult for any
person to remove or amend any provisions that have an
anti-takeover effect.
Business
Combination Statute
In addition, as a Delaware corporation, MetLife, Inc. is subject
to Section 203 of the Delaware General Corporation Law,
unless it elects in its certificate of incorporation not to be
governed by the provisions of Section 203. MetLife, Inc.
has not made that election. Section 203 can affect the
ability of an interested stockholder of MetLife,
Inc. to engage in certain business combinations, including
mergers, consolidations or acquisitions of additional shares of
MetLife, Inc. for a period of three years following the time
that the stockholder becomes an interested
stockholder. An interested stockholder is
defined to include any person owning, directly or indirectly,
15% or more of the outstanding voting stock of a corporation.
The provisions of Section 203 are not applicable in some
circumstances, including those in which (1) the business
combination or transaction which results in the stockholder
becoming an interested stockholder is approved by
the corporations board of directors prior to the time the
stockholder becomes an interested stockholder or
(2) the interested stockholder, upon
consummation of such transaction, owns at least 85% of the
voting stock of the corporation outstanding prior to such
transaction.
18
Restrictions
on Acquisitions of Securities
The insurance laws and regulations of New York, the jurisdiction
in which MetLife, Inc.s principal insurance subsidiary,
Metropolitan Life Insurance Company, is organized, may delay or
impede a business combination involving MetLife, Inc. In
addition to the limitations described in the immediately
preceding paragraph, the New York Insurance Law prohibits any
person from acquiring control of Metropolitan Life Insurance
Company, either directly or indirectly through any acquisition
of control of MetLife, Inc., without the prior approval of
the New York Superintendent of Insurance. That law presumes that
control exists where any person, directly or indirectly, owns,
controls, holds the power to vote or holds proxies representing
10% or more of MetLife, Inc.s outstanding voting stock,
unless the New York Superintendent, upon application, determines
otherwise. Even persons who do not acquire beneficial ownership
of more than 10% of the outstanding shares of MetLife,
Inc.s common stock may be deemed to have acquired such
control, if the New York Superintendent determines that such
persons, directly or indirectly, exercise a controlling
influence over MetLife, Inc.s management or policies.
Therefore, any person seeking to acquire a controlling interest
in MetLife, Inc. would face regulatory obstacles which may
delay, deter or prevent an acquisition.
The insurance holding company law and other insurance laws of
many other states also regulate changes of control (generally
presumed upon acquisitions of 10% or more of voting securities)
of domestic insurers (including insurers owned by MetLife, Inc.)
and insurance holding companies such as MetLife, Inc.
Stockholder
Rights Plan
MetLife, Inc.s board of directors has adopted a
stockholder rights plan under which each outstanding share of
MetLife, Inc.s common stock issued between April 4,
2000 and the earlier of the distribution date (as described
below) and the expiration of the rights (as described below)
will be coupled with a stockholder right. Initially, the
stockholder rights will be attached to the certificates
representing outstanding shares of common stock, and no separate
rights certificates will be distributed. Each right will entitle
the holder to purchase one one-hundredth of a share of MetLife,
Inc.s Series A Junior Participating Preferred Stock.
Each one one-hundredth of a share of Series A Junior
Participating Preferred Stock will have economic and voting
terms equivalent to one share of MetLife, Inc.s common
stock. Until it is exercised, the right itself will not entitle
the holder thereof to any rights as a stockholder, including the
right to receive dividends or to vote at stockholder meetings.
The description and terms of the rights are set forth in a
rights agreement entered into between MetLife, Inc. and Mellon
Investor Services LLC, successor to ChaseMellon Shareholder
Services, L.L.C., as rights agent. Although the material
provisions of the rights agreement have been accurately
summarized, the statements below concerning the rights agreement
are not necessarily complete and in each instance reference is
made to the rights agreement itself, which is incorporated by
reference into this prospectus in its entirety. Each statement
is qualified in its entirety by such reference.
Stockholder rights are not exercisable until the distribution
date and will expire at the close of business on April 4,
2010, unless earlier redeemed or exchanged by MetLife, Inc. A
distribution date would occur upon the earlier of:
|
|
|
|
|
the tenth day after the first public announcement or
communication to MetLife, Inc. that a person or group of
affiliated or associated persons (referred to as an
acquiring person) has acquired beneficial ownership
of 10% or more of MetLife, Inc.s outstanding common stock
(the date of such announcement or communication is referred to
as the stock acquisition time); or
|
|
|
|
the tenth business day after the commencement or announcement of
the intention to commence a tender offer or exchange offer that
would result in a person or group becoming an acquiring person.
|
If any person becomes an acquiring person, each holder of a
stockholder right will be entitled to exercise the right and
receive, instead of Series A Junior Participating Preferred
Stock, common stock (or, in certain circumstances, cash, a
reduction in purchase price, property or other securities of
MetLife, Inc.) having a value equal to two times the purchase
price of the stockholder right. All stockholder rights that are
beneficially owned by an acquiring person or its transferee will
become null and void.
If at any time after a public announcement has been made or
MetLife, Inc. has received notice that a person has become an
acquiring person, (1) MetLife, Inc. is acquired in a merger
or other business combination, or (2) 50% or
19
more of MetLife, Inc.s and its subsidiaries assets,
cash flow or earning power is sold or transferred, each holder
of a stockholder right (except rights which previously have been
voided as set forth above) will have the right to receive, upon
exercise, common stock of the acquiring company having a value
equal to two times the purchase price of the right.
The purchase price payable, the number of one one-hundredths of
a share of Series A Junior Participating Preferred Stock or
other securities or property issuable upon exercise of rights
and the number of rights outstanding, are subject to adjustment
from time to time to prevent dilution. With certain exceptions,
no adjustment in the purchase price or the number of shares of
Series A Junior Participating Preferred Stock issuable upon
exercise of a stockholder right will be required until the
cumulative adjustment would require an increase or decrease of
at least one percent in the purchase price or number of shares
for which a right is exercisable.
At any time until the earlier of (1) the stock acquisition
time, or (2) the final expiration date of the rights
agreement, MetLife, Inc. may redeem all the stockholder rights
at a price of $0.01 per right. At any time after a person
has become an acquiring person and prior to the acquisition of
beneficial ownership by such person of 50% or more of the
outstanding shares of MetLife, Inc.s common stock,
MetLife, Inc. may exchange the stockholder rights, in whole or
in part, at an exchange ratio of one share of common stock, or
one one-hundredth of a share of Series A Junior
Participating Preferred Stock (or of a share of a class or
series of preferred stock having equivalent rights, preferences
and privileges), per right.
The stockholder rights plan is designed to protect stockholders
in the event of unsolicited offers to acquire MetLife, Inc. and
other coercive takeover tactics which, in the opinion of its
board of directors, could impair its ability to represent
stockholder interests. The provisions of the stockholder rights
plan may render an unsolicited takeover more difficult or less
likely to occur or may prevent such a takeover, even though such
takeover may offer MetLife, Inc.s stockholders the
opportunity to sell their stock at a price above the prevailing
market rate and may be favored by a majority of MetLife,
Inc.s stockholders.
MetLife
Policyholder Trust
Under a plan of reorganization adopted in September 1999,
Metropolitan Life Insurance Company converted from a mutual life
insurance company to a stock life insurance company subsidiary
of MetLife, Inc. MetLife established the MetLife Policyholder
Trust to hold the shares of common stock allocated to eligible
policyholders. A total of 494,466,664 shares of common
stock were distributed to the MetLife Policyholder Trust on the
effective date of the plan of reorganization. As of
October 31, 2007, the trust held 262,431,955 shares of
MetLife, Inc.s common stock. Because of the number of
shares held by the trust and the voting provisions of the trust,
the trust may affect the outcome of matters brought to a
stockholder vote.
The trustee will generally vote all of the shares of common
stock held in the trust in accordance with the recommendations
given by MetLife, Inc.s board of directors to its
stockholders or, if the board gives no such recommendation, as
directed by the board, except on votes regarding certain
fundamental corporate actions. As a result of the voting
provisions of the trust, MetLife, Inc.s board of directors
will effectively be able to control votes on all matters
submitted to a vote of stockholders, excluding those fundamental
corporate actions described below, so long as the trust holds a
substantial number of shares of MetLife, Inc.s common
stock.
If the vote relates to fundamental corporate actions specified
in the trust, the trustee will solicit instructions from the
beneficiaries and vote all shares held in the trust in
proportion to the instructions it receives, which would give
disproportionate weight to the instructions actually given by
trust beneficiaries. These actions include:
|
|
|
|
|
an election or removal of directors in which a stockholder has
properly nominated one or more candidates in opposition to a
nominee or nominees of MetLife, Inc.s board of directors
or a vote on a stockholders proposal to oppose a board
nominee for director, remove a director for cause or fill a
vacancy caused by the removal of a director by stockholders,
subject to certain conditions;
|
|
|
|
a merger or consolidation, a sale, lease or exchange of all or
substantially all of the assets, or a recapitalization or
dissolution of MetLife, Inc., in each case requiring a vote of
MetLife, Inc.s stockholders under applicable Delaware law;
|
20
|
|
|
|
|
any transaction that would result in an exchange or conversion
of shares of common stock held by the trust for cash, securities
or other property; and
|
|
|
|
any proposal requiring MetLife, Inc.s board of directors
to amend or redeem the rights under the stockholder rights plan,
other than a proposal with respect to which MetLife, Inc. has
received advice of nationally-recognized legal counsel to the
effect that the proposal is not a proper subject for stockholder
action under Delaware law.
|
DESCRIPTION
OF DEPOSITARY SHARES
The following outlines some of the general terms and provisions
of the depositary shares. Further terms of the depositary shares
and the applicable deposit agreement will be stated in the
applicable prospectus supplement. The following description and
any description of the depositary shares in a prospectus
supplement may not be complete and is subject to and qualified
in its entirety by reference to the terms and provisions of the
deposit agreement, a form of which has been or will be filed as
an exhibit to the registration statement of which this
prospectus forms a part.
The particular terms of the depositary shares offered by any
prospectus supplement and the extent to which the general
provisions described below may apply to such depositary shares
will be outlined in the applicable prospectus supplement.
General
MetLife, Inc. may choose to offer fractional interests in debt
securities or fractional shares of common stock or preferred
stock. MetLife, Inc. may issue fractional interests in debt
securities, common stock or preferred stock, as the case may be,
in the form of depositary shares. Each depositary share would
represent a fractional interest in a security of a particular
series of debt securities or a fraction of a share of common
stock or of a particular series of preferred stock, as the case
may be, and would be evidenced by a depositary receipt.
MetLife, Inc. will deposit the debt securities or shares of
common stock or preferred stock represented by depositary shares
under a deposit agreement between MetLife, Inc. and a depositary
which will be named in the applicable prospectus supplement.
Subject to the terms of the deposit agreement, as an owner of a
depositary share, you will be entitled, in proportion to the
applicable fraction of a debt security or share of common stock
or preferred stock represented by the depositary share, to all
the rights and preferences of the debt security, common stock or
preferred stock, as the case may be, represented by the
depositary share, including, as the case may be, interest,
dividend, voting, conversion, redemption, sinking fund,
repayment at maturity, subscription and liquidation rights.
Interest,
Dividends and Other Distributions
The depositary will distribute all payments of interest, cash
dividends or other cash distributions received on the debt
securities, common stock or preferred stock, as the case may be,
to you in proportion to the number of depositary shares that you
own. In the event of a distribution other than in cash, the
depositary will distribute property received by it to you in an
equitable manner, unless the depositary determines that it is
not feasible to make a distribution. In that case, the
depositary may sell the property and distribute the net proceeds
from the sale to you.
Redemption
of Depositary Shares
If a debt security, common stock or series of preferred stock
represented by depositary shares is redeemed, the depositary
will redeem your depositary shares from the proceeds received by
the depositary resulting from the redemption. The redemption
price per depositary share will be equal to the applicable
fraction of the redemption price per debt security or share of
common stock or preferred stock, as the case may be, payable in
relation to the redeemed series of debt securities, common stock
or preferred stock. Whenever MetLife, Inc. redeems debt
securities or shares of common stock or preferred stock held by
the depositary, the depositary will redeem, as of the same
redemption date, the number of depositary shares representing,
as the case may be, fractional interests in the debt securities
or shares of common stock or preferred stock redeemed. If fewer
than all the depositary shares are to
21
be redeemed, the depositary shares to be redeemed will be
selected by lot, proportionately or by any other equitable
method as the depositary may determine.
Exercise
of Rights under the Indentures or Voting the Common Stock or
Preferred
Upon receipt of notice of any meeting at which you are entitled
to vote, or of any request for instructions or directions from
you as holder of fractional interests in debt securities, common
stock or preferred stock, the depositary will mail to you the
information contained in that notice. Each record holder of the
depositary shares on the record date will be entitled to
instruct the depositary how to give instructions or directions
with respect to the debt securities represented by that
holders depositary shares or how to vote the amount of the
common stock or preferred stock represented by that
holders depositary shares. The record date for the
depositary shares will be the same date as the record date for
the debt securities, common stock or preferred stock, as the
case may be. The depositary will endeavor, to the extent
practicable, to give instructions or directions with respect to
the debt securities or to vote the amount of the common stock or
preferred stock, as the case may be, represented by the
depositary shares in accordance with those instructions.
MetLife, Inc. will agree to take all reasonable action which the
depositary may deem necessary to enable the depositary to do so.
The depositary will abstain from giving instructions or
directions with respect to your fractional interests in the debt
securities or voting shares of the common stock or preferred
stock, as the case may be, if it does not receive specific
instructions from you.
Amendment
and Termination of the Deposit Agreement
MetLife, Inc. and the depositary may amend the form of
depositary receipt evidencing the depositary shares and any
provision of the deposit agreement at any time. However, any
amendment which materially and adversely affects the rights of
the holders of the depositary shares will not be effective
unless the amendment has been approved by the holders of at
least a majority of the depositary shares then outstanding.
The deposit agreement will terminate if:
|
|
|
|
|
all outstanding depositary shares have been redeemed;
|
|
|
|
if applicable, the debt securities and the preferred stock
represented by depositary shares have been converted into or
exchanged for common stock or, in the case of debt securities,
repaid in full; or
|
|
|
|
there has been a final distribution in respect of the common
stock or preferred stock, including in connection with the
liquidation, dissolution or winding-up of MetLife, Inc., and the
distribution proceeds have been distributed to you.
|
Resignation
and Removal of Depositary
The depositary may resign at any time by delivering to MetLife,
Inc. notice of its election to do so. MetLife, Inc. also may, at
any time, remove the depositary. Any resignation or removal will
take effect upon the appointment of a successor depositary and
its acceptance of such appointment. MetLife, Inc. must appoint
the successor depositary within 60 days after delivery of
the notice of resignation or removal. The successor depositary
must be a bank or trust company having its principal office in
the United States and having total assets of not less than
$1,000,000,000.
Charges
of Depositary
MetLife, Inc. will pay all transfer and other taxes and
governmental charges arising solely from the existence of the
depositary arrangements. MetLife, Inc. will pay charges of the
depositary in connection with the initial deposit of the debt
securities or common stock or preferred stock, as the case may
be, and issuance of depositary receipts, all withdrawals of
depositary shares of debt securities or common stock or
preferred stock, as the case may be, by you and any repayment or
redemption of the debt securities or preferred stock, as the
case may be. You will pay other transfer and other taxes and
governmental charges, as well as the other charges that are
expressly provided in the deposit agreement to be for your
account.
22
Miscellaneous
The depositary will forward all reports and communications from
MetLife, Inc. which are delivered to the depositary and which
MetLife, Inc. is required or otherwise determines to furnish to
holders of debt securities, common stock or preferred stock, as
the case may be. Neither MetLife, Inc. nor the depositary will
be liable under the deposit agreement to you other than for its
gross negligence, willful misconduct or bad faith. Neither
MetLife, Inc. nor the depositary will be obligated to prosecute
or defend any legal proceedings relating to any depositary
shares, debt securities, common stock or preferred stock unless
satisfactory indemnity is furnished. MetLife, Inc. and the
depositary may rely upon written advice of counsel or
accountants, or upon information provided by persons presenting
debt securities or shares of common stock or preferred stock for
deposit, you or other persons believed to be competent and on
documents which MetLife, Inc. and the depositary believe to be
genuine.
DESCRIPTION
OF WARRANTS
MetLife, Inc. may issue warrants to purchase debt securities,
preferred stock, common stock or other securities described in
this prospectus, or any combination of these securities, and
these warrants may be issued independently or together with any
underlying securities and may be attached or separate from the
underlying securities. MetLife, Inc. will issue each series of
warrants under a separate warrant agreement to be entered into
between MetLife, Inc. and a warrant agent. The warrant agent
will act solely as MetLife, Inc.s agent in connection with
the warrants of such series and will not assume any obligation
or relationship of agency for or with holders or beneficial
owners of warrants.
The following outlines some of the general terms and provisions
of the warrants. Further terms of the warrants and the
applicable warrant agreement will be stated in the applicable
prospectus supplement. The following description and any
description of the warrants in a prospectus supplement may not
be complete and is subject to and qualified in its entirety by
reference to the terms and provisions of the warrant agreement,
a form of which has been or will be filed as an exhibit to the
registration statement of which this prospectus forms a part.
The applicable prospectus supplement will describe the terms of
any warrants that MetLife, Inc. may offer, including the
following:
|
|
|
|
|
the title of the warrants;
|
|
|
|
the total number of warrants;
|
|
|
|
the price or prices at which the warrants will be issued;
|
|
|
|
the currency or currencies investors may use to pay for the
warrants;
|
|
|
|
the designation and terms of the underlying securities
purchasable upon exercise of the warrants;
|
|
|
|
the price at which and the currency, currencies, or currency
units in which investors may purchase the underlying securities
purchasable upon exercise of the warrants;
|
|
|
|
the date on which the right to exercise the warrants will
commence and the date on which the right will expire;
|
|
|
|
whether the warrants will be issued in registered form or bearer
form;
|
|
|
|
information with respect to book-entry procedures, if any;
|
|
|
|
if applicable, the minimum or maximum amount of warrants which
may be exercised at any one time;
|
|
|
|
if applicable, the designation and terms of the underlying
securities with which the warrants are issued and the number of
warrants issued with each underlying security;
|
|
|
|
if applicable, the date on and after which the warrants and the
related underlying securities will be separately transferable;
|
|
|
|
if applicable, a discussion of material United States federal
income tax considerations;
|
23
|
|
|
|
|
the identity of the warrant agent;
|
|
|
|
the procedures and conditions relating to the exercise of the
warrants; and
|
|
|
|
any other terms of the warrants, including terms, procedures and
limitations relating to the exchange and exercise of the
warrants.
|
Warrant certificates may be exchanged for new warrant
certificates of different denominations, and warrants may be
exercised at the warrant agents corporate trust office or
any other office indicated in the applicable prospectus
supplement. Prior to the exercise of their warrants, holders of
warrants exercisable for debt securities will not have any of
the rights of holders of the debt securities purchasable upon
such exercise and will not be entitled to payments of principal
(or premium, if any) or interest, if any, on the debt securities
purchasable upon such exercise. Prior to the exercise of their
warrants, holders of warrants exercisable for shares of
preferred stock or common stock will not have any rights of
holders of the preferred stock or common stock purchasable upon
such exercise and will not be entitled to dividend payments, if
any, or voting rights of the preferred stock or common stock
purchasable upon such exercise. Prior to the exercise of their
warrants, holders of warrants exercisable for other securities
described in this prospectus will not have any rights of holders
of such securities purchasable upon such exercise.
Exercise
of Warrants
A warrant will entitle the holder to purchase for cash an amount
of securities at an exercise price that will be stated in, or
that will be determinable as described in, the applicable
prospectus supplement. Warrants may be exercised at any time up
to the close of business on the expiration date set forth in the
applicable prospectus supplement. After the close of business on
the expiration date, unexercised warrants will become void.
Warrants may be exercised as set forth in the applicable
prospectus supplement. Upon receipt of payment and the warrant
certificate properly completed and duly executed at the
corporate trust office of the warrant agent or any other office
indicated in the prospectus supplement, MetLife, Inc. will, as
soon as practicable, forward the securities purchasable upon
such exercise. If less than all of the warrants represented by
such warrant certificate is exercised, a new warrant certificate
will be issued for the remaining warrants.
Enforceability
of Rights; Governing Law
The holders of warrants, without the consent of the warrant
agent, may, on their own behalf and for their own benefit,
enforce, and may institute and maintain any suit, action or
proceeding against MetLife, Inc. to enforce their rights to
exercise and receive the securities purchasable upon exercise of
their warrants. Unless otherwise stated in the prospectus
supplement, each issue of warrants and the applicable warrant
agreement will be governed by, and construed in accordance with,
the internal laws of the State of New York, without regard to
its principles of conflicts of laws.
DESCRIPTION
OF PURCHASE CONTRACTS
As may be specified in a prospectus supplement, MetLife, Inc.
may issue purchase contracts obligating holders to purchase from
MetLife, Inc., and MetLife, Inc. to sell to the holders, a
number of debt securities, shares of common stock or preferred
stock, or other securities described in this prospectus or the
applicable prospectus supplement at a future date or dates. The
purchase contracts may require MetLife, Inc. to make periodic
payments to the holders of the purchase contracts. These
payments may be unsecured or prefunded on some basis to be
specified in the applicable prospectus supplement.
The prospectus supplement relating to any purchase contracts
will specify the material terms of the purchase contracts and
any applicable pledge or depositary arrangements, including one
or more of the following:
|
|
|
|
|
The stated amount that a holder will be obligated to pay under
the purchase contract in order to purchase debt securities,
common stock, preferred stock, or other securities described in
this prospectus or the formula by which such amount shall be
determined.
|
24
|
|
|
|
|
The settlement date or dates on which the holder will be
obligated to purchase such securities. The prospectus supplement
will specify whether the occurrence of any events may cause the
settlement date to occur on an earlier date and the terms on
which an early settlement would occur.
|
|
|
|
The events, if any, that will cause MetLife, Inc.s
obligations and the obligations of the holder under the purchase
contract to terminate.
|
|
|
|
The settlement rate, which is a number that, when multiplied by
the stated amount of a purchase contract, determines the number
of securities that MetLife, Inc. or a trust will be obligated to
sell and a holder will be obligated to purchase under that
purchase contract upon payment of the stated amount of that
purchase contract. The settlement rate may be determined by the
application of a formula specified in the prospectus supplement.
If a formula is specified, it may be based on the market price
of such securities over a specified period or it may be based on
some other reference statistic.
|
|
|
|
Whether the purchase contracts will be issued separately or as
part of units consisting of a purchase contract and an
underlying security with an aggregate principal amount equal to
the stated amount. Any underlying securities will be pledged by
the holder to secure its obligations under a purchase contract.
|
|
|
|
The type of underlying security, if any, that is pledged by the
holder to secure its obligations under a purchase contract.
Underlying securities may be debt securities, common stock,
preferred stock, or other securities described in this
prospectus or the applicable prospectus supplement.
|
|
|
|
The terms of the pledge arrangement relating to any underlying
securities, including the terms on which distributions or
payments of interest and principal on any underlying securities
will be retained by a collateral agent, delivered to MetLife,
Inc. or be distributed to the holder.
|
|
|
|
The amount of the contract fee, if any, that may be payable by
MetLife, Inc. to the holder or by the holder to MetLife, Inc.,
the date or dates on which the contract fee will be payable and
the extent to which MetLife, Inc. or the holder, as applicable,
may defer payment of the contract fee on those payment dates.
The contract fee may be calculated as a percentage of the stated
amount of the purchase contract or otherwise.
|
The descriptions of the purchase contracts and any applicable
underlying security or pledge or depository arrangements in this
prospectus and in any prospectus supplement are summaries of the
material provisions of the applicable agreements and are subject
to and qualified in their entirety by reference to the terms and
provisions of the purchase contract agreement, pledge agreement
and deposit agreement, forms of which have been or will be filed
as exhibits to the registration statement of which this
prospectus forms a part.
DESCRIPTION
OF UNITS
As specified in the applicable prospectus supplement, MetLife,
Inc. may issue units comprised of one or more of the other
securities described in this prospectus in any combination. Each
unit may also include debt obligations of third parties, such as
U.S. Treasury securities. Each unit will be issued so that
the holder of the unit is also the holder of each security
included in the unit. Thus, the holder of a unit will have the
rights and obligations of a holder of each included security.
The prospectus supplement will describe:
|
|
|
|
|
the designation and terms of the units and of the securities
comprising the units, including whether and under what
circumstances the securities comprising the units may be held or
transferred separately;
|
|
|
|
a description of the terms of any unit agreement governing the
units;
|
|
|
|
a description of the provisions for the payment, settlement,
transfer or exchange of the units; and
|
|
|
|
whether the units will be issued in fully registered or global
form.
|
The descriptions of the units and any applicable underlying
security or pledge or depositary arrangements in this prospectus
and in any prospectus supplement are summaries of the material
provisions of the applicable agreements and are subject to, and
qualified in their entirety by reference to, the terms and
provisions of the applicable agreements, forms of which have
been or will be filed as exhibits to the registration statement
of which this prospectus forms a part.
25
DESCRIPTION
OF TRUST PREFERRED SECURITIES
The following outlines some of the general terms and provisions
of the trust preferred securities. Further terms of the trust
preferred securities and the amended and restated declarations
of trust will be stated in the applicable prospectus supplement.
The prospectus supplement will also indicate whether the general
terms described in this section apply to that particular series
of trust preferred securities. The following description and any
description of the trust preferred securities and amended and
restated declarations of trust in a prospectus supplement may
not be complete and are subject to and qualified in their
entirety by reference to the terms and provisions of the amended
and restated declarations of trust, forms of which have been or
will be filed as exhibits to the registration statement of which
this prospectus forms a part.
General
Each trust may issue only one series of trust preferred
securities having terms described in the prospectus supplement.
The declaration of trust of each trust will authorize the
administrative trustees, on behalf of the trust, to issue the
trust preferred securities of the trust. The trusts will use all
of the proceeds they receive from the sale of trust preferred
securities and common securities to purchase debt securities
issued by MetLife, Inc. The debt securities will be held in
trust by the trusts property trustee for the benefit of
the holders of the trust preferred securities and common
securities.
The trust preferred securities of each trust will have such
terms as are set forth in the trusts declaration of trust,
including as relates to distributions, redemption, voting,
liquidation rights and the other preferred, deferral and special
rights and restrictions. A prospectus supplement relating to the
trust preferred securities being offered will include specific
terms relating to the offering. These terms will include some or
all of the following:
|
|
|
|
|
the distinctive designation of the trust preferred securities;
|
|
|
|
the number of trust preferred securities issued by the trust;
|
|
|
|
the total and per-security liquidation amount of the trust
preferred securities;
|
|
|
|
the annual distribution rate, or method of determining such
rate, for trust preferred securities of the trust;
|
|
|
|
the date or dates on which distributions will be payable and any
corresponding record dates;
|
|
|
|
whether distributions on the trust preferred securities will be
cumulative;
|
|
|
|
if the trust preferred securities have cumulative distribution
rights, the date or dates, or method of determining the date or
dates, from which distributions on the trust preferred
securities will be cumulative;
|
|
|
|
the amount or amounts that will be paid out of the assets of the
trust to the holders of the trust preferred securities of the
trust upon voluntary or involuntary dissolution, winding-up or
termination of the trust;
|
|
|
|
the obligation, if any, of the trust to purchase or redeem the
trust preferred securities;
|
|
|
|
if the trust is to purchase or redeem the trust preferred
securities:
|
|
|
|
the price or prices at which the trust preferred securities will
be purchased or redeemed in whole or in part;
|
|
|
|
the period or periods within which the trust preferred
securities will be purchased or redeemed, in whole or in part;
|
|
|
|
the terms and conditions upon which the trust preferred
securities will be purchased or redeemed, in whole or in part;
|
|
|
|
the voting rights, if any, of the trust preferred securities in
addition to those required by law, including:
|
|
|
|
|
|
the number of votes per trust preferred security; and
|
|
|
|
any requirement for the approval by the holders of trust
preferred securities as a condition to specified action or
amendments to the trusts declaration of trust;
|
26
|
|
|
|
|
the rights, if any, to defer distributions on the trust
preferred securities by extending the interest payment period on
the related debt securities;
|
|
|
|
if the trust preferred securities may be converted into or
exercised or exchanged for MetLifes common stock or
preferred stock or any other securities, the terms on which
conversion, exercise or exchange is mandatory, at the option of
the holder or at the option of each trust, the date on or the
period during which conversion, exercise or exchange may occur,
the initial conversion, exercise or exchange price or rate and
the circumstances or manner in which the amount of common stock
or preferred stock or other securities issuable upon conversion,
exercise or exchange may be adjusted;
|
|
|
|
the terms upon which the debt securities may be distributed to
holders of trust preferred securities;
|
|
|
|
whether the preferred securities are to be issued in book-entry
form and represented by one or more global certificates;
|
|
|
|
certain U.S. federal income tax considerations;
|
|
|
|
if applicable, any securities exchange upon which the trust
preferred securities shall be listed;
|
|
|
|
provisions relating to events of default and the rights of
holders of trust preferred securities in the event of default;
|
|
|
|
other agreements or other rights including upon the
consolidation or merger of the trust; and
|
|
|
|
any other relative rights, preferences, privileges, limitations
or restrictions of the trust preferred securities not
inconsistent with the trusts declaration of trust or
applicable law.
|
All trust preferred securities offered will be guaranteed by
MetLife, Inc. to the extent set forth under Description of
Guarantees. Any material United States federal income tax
considerations applicable to an offering of trust preferred
securities will be described in the applicable prospectus
supplement.
In connection with the issuance of preferred securities, each
trust will issue one series of common securities. The
declaration of each trust authorizes the administrative trustees
to issue on behalf of such trust one series of common securities
having such terms including distributions, redemption, voting,
liquidation rights or such restrictions as shall be set forth
therein. The terms of the common securities issued by the trust
will be substantially identical to the terms of the preferred
securities issued by such trust and the common securities will
rank equally, and payments will be made thereon pro rata, with
the preferred securities. However, upon an event of default
under the declaration of trust, the rights of the holders of the
common securities to payment in respect of distributions and
payments upon liquidation, redemption and otherwise will be
subordinated to the rights of the holders of the preferred
securities. Except in certain limited circumstances, the common
securities will also carry the right to vote, and appoint,
remove or replace any of the trustees of a trust. MetLife, Inc.
will own, directly or indirectly, all of the common securities
of each trust.
Enforcement
of Certain Rights by Holders of Trust Preferred
Securities
If an event of default occurs, and is continuing, under the
declaration of trust of any of the trusts, the holders of the
preferred securities of that trust would typically rely on the
property trustee to enforce its rights as a holder of the
related debt securities against MetLife, Inc. Additionally,
those who together hold a majority of the liquidation amount of
the trusts preferred securities will have the right to:
|
|
|
|
|
direct the time, method and place of conducting any proceeding
for any remedy available to the property trustee; or
|
|
|
|
direct the exercise of any trust or power that the property
trustee holds under the declaration of trust, including the
right to direct the property trustee to exercise the remedies
available to it as a holder of MetLife, Inc.s debt
securities.
|
If the property trustee fails to enforce its rights under the
applicable series of debt securities, to the fullest extent
permitted by law, a holder of trust preferred securities of such
trust may institute a legal proceeding directly against
27
MetLife, Inc. to enforce the property trustees rights
under the applicable series of debt securities without first
instituting any legal proceeding against the property trustee or
any other person or entity.
Notwithstanding the foregoing, if an event of default occurs and
the event is attributable to MetLife, Inc.s failure to pay
interest or principal on the debt securities when due, including
any payment on redemption, and this debt payment failure is
continuing, a preferred securities holder of the trust may
directly institute a proceeding for the enforcement of this
payment. Such a proceeding will be limited, however, to
enforcing the payment of this principal or interest only up to
the value of the aggregate liquidation amount of the
holders preferred securities as determined after the due
date specified in the applicable series of debt securities.
DESCRIPTION
OF GUARANTEES
The following outlines some of the general terms and provisions
of the guarantees. Further terms of the guarantees will be
stated in the applicable prospectus supplement. The prospectus
supplement will also indicate whether the general terms
described in this section apply to those guarantees. The
following description and any description of the guarantees in a
prospectus supplement may not be complete and is subject to and
qualified in its entirety by reference to the terms and
provisions of the guarantee agreements, forms of which have been
or will be filed as exhibits to the registration statement of
which this prospectus forms a part, and the Trust Indenture Act.
MetLife, Inc. will execute and deliver the guarantees for the
benefit of the holders of the trust preferred securities. Each
guarantee will be held by the guarantee trustee for the benefit
of holders of the trust preferred securities to which it relates.
Each guarantee will be qualified as an indenture under the Trust
Indenture Act. The Bank of New York Trust Company, N.A. will act
as indenture trustee under each guarantee for purposes of the
Trust Indenture Act.
General
Pursuant to each guarantee, MetLife, Inc. will irrevocably and
unconditionally agree, to the extent set forth in the guarantee,
to pay in full, to the holders of the related trust preferred
securities, the following guarantee payments, to the extent
these guarantee payments are not paid by, or on behalf of, the
related trust, regardless of any defense, right of set-off or
counterclaim that MetLife, Inc. may have or assert against any
person:
|
|
|
|
|
any accrued and unpaid distributions required to be paid on the
trust preferred securities of the trust, but if and only if and
to the extent that the trust has funds legally and immediately
available to make those payments;
|
|
|
|
any distributions of MetLifes common stock or preferred
stock or any of its other securities, in the event that the
trust preferred securities may be converted into or exercised
for common stock or preferred stock, to the extent the
conditions of such conversion or exercise have occurred or have
been satisfied and the trust does not distribute such shares or
other securities but has received such shares or other
securities;
|
|
|
|
the redemption price, including all accrued and unpaid
distributions to the date of redemption, with respect to any
trust preferred securities called for redemption by the trust,
but if and only to the extent the trust has funds legally and
immediately available to make that payment; and
|
|
|
|
upon a dissolution, winding-up or termination of the trust,
other than in connection with the distribution of debt
securities to the holders of trust preferred securities of the
trust, the lesser of:
|
|
|
|
|
|
the total of the liquidation amount and all accrued and unpaid
distributions on the trust preferred securities of the trust to
the date of payment, to the extent the trust has funds legally
and immediately available to make that payment; and
|
|
|
|
the amount of assets of the trust remaining available for
distribution to holders of trust preferred securities of the
trust in liquidation of the trust.
|
28
MetLife, Inc. may satisfy its obligation to make a guarantee
payment by directly paying the required amounts to the holders
of the related trust preferred securities or by causing the
related trust to pay such amounts to such holders.
Each guarantee will constitute a guarantee of payments with
respect to the related trust preferred securities from the time
of issuance of the trust preferred securities. The guarantees
will not apply to the payment of distributions and other
payments on the trust preferred securities when the related
trust does not have sufficient funds legally and immediately
available to make the distributions or other payments. If
MetLife, Inc. does not make interest payments on the debt
securities purchased by a trust, such trust will not pay
distributions on the preferred securities issued by such trust
and will not have funds available therefor. The guarantee, when
taken together with MetLife, Inc.s obligations under the
debt securities, the Indentures and the declarations of trust,
will provide a full and unconditional guarantee by MetLife, Inc.
of payments due on the trust preferred securities.
MetLife, Inc. will also agree separately, through guarantees of
the common securities, to irrevocably and unconditionally
guarantee the obligations of the trusts with respect to the
common securities to the same extent as the guarantees of the
preferred securities. However, upon an event of default under
the Indentures, holders of preferred securities shall have
priority over holders of common securities with respect to
distributions and payments on liquidation, redemption or
otherwise.
Subordination
MetLife, Inc.s obligation under each guarantee to make the
guarantee payments will be an unsecured obligation of MetLife,
Inc. and, if subordinated debt securities are issued to the
applicable trust and unless otherwise noted in the prospectus
supplement, will rank:
|
|
|
|
|
subordinate and junior in right of payment to all of MetLife,
Inc.s other liabilities, including the subordinated debt
securities, except those obligations or liabilities ranking
equal or subordinate to the guarantees by their terms;
|
|
|
|
equally with any other securities, liabilities or obligations
that may have equal ranking by their terms; and
|
|
|
|
senior to all of MetLife, Inc.s common stock.
|
If subordinated debt securities are issued to the applicable
trust, the terms of the trust preferred securities will provide
that each holder of trust preferred securities, by accepting the
trust preferred securities, agrees to the subordination
provisions and other terms of the guarantee related to
subordination.
Each guarantee will constitute a guarantee of payment and not of
collection. This means that the holder of trust preferred
securities may institute a legal proceeding directly against
MetLife, Inc. to enforce its rights under the guarantee without
first instituting a legal proceeding against any other person or
entity.
Each guarantee will be unsecured and, because MetLife, Inc. is
principally a holding company, will be effectively subordinated
to all existing and future liabilities of MetLife, Inc.s
subsidiaries, including liabilities under contracts of insurance
and annuities written by MetLife, Inc.s insurance
subsidiaries. The guarantee does not limit the incurrence or
issuance of other secured or unsecured debt by MetLife, Inc.
Amendments
and Assignment
For any changes that materially and adversely affect the rights
of holders of the related trust preferred securities, each
guarantee may be amended only if there is prior approval of the
holders of more than 50% in liquidation amount of the
outstanding trust preferred securities issued by the applicable
trust. All guarantees and agreements contained in each guarantee
will bind the successors, assigns, receivers, trustees and
representatives of MetLife, Inc. and will inure to the benefit
of the holders of the related trust preferred securities of the
applicable trust then outstanding.
29
Termination
Each guarantee will terminate and will have no further force and
effect as to the related trust preferred securities upon:
|
|
|
|
|
distribution of debt securities to the holders of all trust
preferred securities of the applicable trust; or
|
|
|
|
full payment of the amounts payable upon liquidation of the
applicable trust.
|
Each guarantee will continue to be effective or will be
reinstated, as the case may be, if at any time any holder of the
related trust preferred securities must restore payment of any
sums paid with respect to the trust preferred securities or
under the guarantee.
Events
of Default
Each guarantee provides that an event of default under a
guarantee occurs upon MetLife, Inc.s failure to perform
any of its obligations under the applicable guarantee.
The holders of a majority or more in liquidation amount of the
trust preferred securities to which any guarantee relates may
direct the time, method and place of conducting any proceeding
for any remedy available to the guarantee trustee with respect
to the guarantee or may direct the exercise of any trust or
power conferred upon the guarantee trustee in respect of the
guarantee.
If the guarantee trustee fails to enforce the guarantee, any
holder of the related trust preferred securities may institute a
legal proceeding directly against MetLife, Inc. to enforce the
holders rights under such guarantee without first
instituting a legal proceeding against the trust, the guarantee
trustee or any other person or entity.
Furthermore, if MetLife, Inc. fails to make a guarantee payment,
a holder of trust preferred securities may directly institute a
proceeding against MetLife, Inc. for enforcement of the trust
preferred securities guarantee for such payment.
The holders of a majority or more in liquidation amount of trust
preferred securities of any series may, by vote, on behalf of
the holders of all the trust preferred securities of the series,
waive any past event of default and its consequences.
Information
Concerning the Guarantee Trustee
Prior to an event of default with respect to any guarantee and
after the curing or waiving of all events of default with
respect to the guarantee, the guarantee trustee may perform only
the duties that are specifically set forth in the guarantee.
Once a guarantee event of default has occurred and is
continuing, the guarantee trustee is to exercise, with respect
to the holder of the trust preferred securities of the series,
the same degree of care as a prudent individual would exercise
in the conduct of his or her own affairs. Unless the guarantee
trustee is offered reasonable indemnity against the costs,
expenses and liabilities which may be incurred by the guarantee
trustee by a holder of the related trust preferred securities,
the guarantee trustee is not required to exercise any of its
powers under any guarantee at the request of the holder.
Additionally, the guarantee trustee is not required to expend or
risk its own funds or otherwise incur any financial liability in
the performance of its duties if the guarantee trustee
reasonably believes that it is not assured repayment or adequate
indemnity.
The guarantee trustee is The Bank of New York Trust Company,
N.A., which is one of a number of banks and trust companies with
which MetLife, Inc. and its subsidiaries maintain ordinary
banking and trust relationships.
Governing
Law
Each guarantee will be governed by, and construed in accordance
with, the internal laws of the State of New York, without regard
to its principles of conflicts of laws.
30
PLAN OF
DISTRIBUTION
MetLife, Inc. may sell the securities being offered hereby in
one or more of the following ways from time to time:
|
|
|
|
|
to underwriters or dealers for resale to the public or to
institutional investors;
|
|
|
|
directly to institutional investors; or
|
|
|
|
through agents to the public or to institutional investors.
|
The prospectus supplement with respect to each series of
securities will state the terms of the offering of the
securities, including:
|
|
|
|
|
the name or names of any underwriters or agents;
|
|
|
|
the purchase price of the securities and the proceeds to be
received by MetLife, Inc. or the applicable trust from the sale;
|
|
|
|
any underwriting discounts or agency fees and other items
constituting underwriters or agents compensation;
|
|
|
|
any initial public offering price;
|
|
|
|
any discounts or concessions allowed or reallowed or paid to
dealers; and
|
|
|
|
any securities exchange on which the securities may be listed.
|
If MetLife, Inc. or the trusts use underwriters in the sale, the
securities will be acquired by the underwriters for their own
account and may be resold from time to time in one or more
transactions, including:
|
|
|
|
|
negotiated transactions;
|
|
|
|
at a fixed public offering price or prices, which may be changed;
|
|
|
|
at market prices prevailing at the time of sale;
|
|
|
|
at prices related to prevailing market prices; or
|
|
|
|
at negotiated prices.
|
The securities may also be offered and sold, if so indicated in
the prospectus supplement, in connection with a remarketing upon
their purchase, in accordance with a redemption or repayment
pursuant to their terms, or otherwise, by one or more
remarketing firms, acting as principals for their own accounts
or as agents for MetLife, Inc. or the trusts. The prospectus
supplement will identify any remarketing firm and will describe
the terms of its agreement, if any, with MetLife, Inc. or the
trusts and its compensation.
Unless otherwise stated in a prospectus supplement, the
obligations of the underwriters to purchase any securities will
be conditioned on customary closing conditions and the
underwriters will be obligated to purchase all of such series of
securities, if any are purchased.
If MetLife, Inc. sells the securities directly or through agents
designated by it, MetLife, Inc. will identify any agent involved
in the offering and sale of the securities and will list any
commissions payable by MetLife, Inc. to the agent in the
accompanying prospectus supplement. Unless indicated otherwise
in the prospectus supplement, any such agent will be acting on a
best efforts basis to solicit purchases for the period of its
appointment.
MetLife, Inc. may authorize agents, underwriters or dealers to
solicit offers by certain institutional investors to purchase
securities and provide for payment and delivery on a future date
specified in an accompanying prospectus supplement. MetLife,
Inc. will describe any such arrangement in the prospectus
supplement. Any such institutional investor may be subject to
limitations on the minimum amount of securities that it may
purchase or on the portion of the aggregate principal amount of
such securities that it may sell under such arrangements.
Institutional investors from which such authorized offers may be
solicited include:
|
|
|
|
|
commercial and savings banks;
|
31
|
|
|
|
|
insurance companies;
|
|
|
|
pension funds;
|
|
|
|
investment companies;
|
|
|
|
educational and charitable institutions; and
|
|
|
|
such other institutions as MetLife, Inc. may approve.
|
Underwriters, dealers, agents and remarketing firms may be
entitled under agreements entered into with MetLife, Inc. and/or
the applicable trust, or both, to indemnification by MetLife,
Inc. against certain civil liabilities, including liabilities
under the Securities Act, or to contribution with respect to
payments which the underwriters, dealers, agents and remarketing
firms may be required to make. Underwriters, dealers, agents and
remarketing agents may be customers of, engage in transactions
with, or perform services for MetLife, Inc., any trust, and/or
MetLife, Inc.s affiliates in the ordinary course of
business.
Each series of securities will be a new issue of securities and
will have no established trading market other than the common
stock which is listed on the New York Stock Exchange. Any common
stock sold will be listed on the New York Stock Exchange, upon
official notice of issuance. The securities, other than the
common stock, may or may not be listed on a national securities
exchange. Any underwriters to whom securities are sold by
MetLife, Inc. or any trust for public offering and sale may make
a market in the securities, but such underwriters will not be
obligated to do so and may discontinue any market making at any
time without notice.
Any offering of trust preferred securities will be made in
compliance with Rule 2810 of the Conduct Rules of the
National Association of Securities Dealers, Inc.
LEGAL
OPINIONS
Unless otherwise indicated in the applicable prospectus
supplement, the validity of the securities offered hereby will
be passed upon for MetLife, Inc. by Richard S. Collins,
Senior Chief Counsel General Corporate, of
Metropolitan Life Insurance Company and for any underwriters or
agents by counsel named in the applicable prospectus supplement.
Mr. Collins is paid a salary by MetLife, is a participant
in various employee benefit plans offered by MetLife to
employees generally and has options to purchase shares of
MetLife, Inc. common stock. Certain matters of Delaware law
relating to the validity of the trust preferred securities of
MetLife Capital Trust V, MetLife Capital Trust VI,
MetLife Capital Trust VII, MetLife Capital Trust VIII
and MetLife Capital Trust IX will be passed upon for the
trust by Richards, Layton & Finger, P.A., Wilmington,
Delaware, special Delaware counsel for the trusts.
EXPERTS
The consolidated financial statements, consolidated financial
statement schedules, and managements report on the
effectiveness of internal control over financial reporting,
incorporated in this Prospectus by reference from MetLifes
Annual Report on
Form 10-K
for the year ended December 31, 2006, have been audited by
Deloitte & Touche LLP, an independent registered
public accounting firm, as stated in their reports which are
incorporated herein by reference, (which (1) express an
unqualified opinion on the consolidated financial statements and
consolidated financial statement schedules and include an
explanatory paragraph referring to MetLifes change of its
method of accounting for defined benefit pension and other
postretirement plans, and for certain non-traditional long
duration contracts and separate accounts as required by
accounting guidance which MetLife adopted on December 31,
2006 and January 1, 2004, respectively, (2) express an
unqualified opinion on managements assessment regarding
the effectiveness of internal control over financial reporting,
and (3) express an unqualified opinion on the effectiveness
of internal control over financial reporting), and have been so
incorporated in reliance upon the reports of such firm given
upon their authority as experts in accounting and auditing.
32